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ABSTRACT
Both acute and chronic steroidogenesis are regulated by adrenocorticotropic
hormone (ACTH), a principal regulator of the adrenal cortex. A number of studies
have demonstrated that Steroidogenic Acute Regulatory (StAR) protein plays a
crucial role in facilitating cholesterol transfer from the outer to the inner
mitochondrial membrane, where the first step of cholesterol conversion to steroid
hormones occurs. This work has evaluated the relationships between the
expression of StAR protein and signalling pathways of ACTH-induced
steroidogenesis in primary cultures of bovine adrenal zona fasciculata (ZF) cells.
A novel sheep anti-bovine peptide StAR polyclonal antibody has been
characterised and optimised for Western immunoblotting. A newly formulated
protocol based on enhanced chemiluminescence methodology provided a linear,
reproducible and sensitive approach to detect and quantify StAR protein by
molecular image analysis.
The expression level of StAR protein after ACTH treatment of adrenal ZF cells
showed that levels of StAR were insensitive to ACTH in freshly isolated cells due to
the high initial levels of the protein. The cell responsiveness to ACTH was
remarkable, however, after the basal levels of StAR protein diminished to a
relatively lower levels after 2 days of culture. Concentration-response curves
demonstrated that, in general, increasing concentrations of ACTH resulted in
increasing in Cortisol output in parallel with increases of cyclic adenosine 3', 5'-
monophosphate (cAMP) production; the maximal effects of ACTH on Cortisol and
cAMP levels exhibited with 10~8 M ACTH treatment after both 1 and 6 hr. Marked
changes in StAR protein occurred at 6 hr, attaining a maximal level with 10"8 M
ACTH. Interestingly, at 1 and 6 hr the elevation of Cortisol levels were significantly
altered at 10"12 M ACTH without any notable increase in cAMP levels. The time
courses for ACTH treatment showed that at 10"8 M ACTH (a supraphysiological
concentration) there was a strong positive correlation between Cortisol and StAR
protein induction, suggesting that newly synthesised StAR protein may be a major
mediator for steroidogenesis. On the other hand, at 10"12 M ACTH (a physiological
concentration) Cortisol secretion rose apparently prior to the measurable changes in
total StAR protein, and the Cortisol changes were poorly correlated with StAR
protein. All these profiles clearly suggested that steroidogenesis may at least
partially rely on pre-existing StAR protein and a cAMP-independent signalling
pathway may also participate in steroidogenesis, particularly for physiologically
relevant doses of ACTH.
The roles of phospholipase A2 (PLA2) and arachidonic acid (AA) signalling
pathways in ACTH-stimulated Cortisol secretion were evaluated using various
selective inhibitors, including 4-bromophenacyl bromide for PLA2,
nordihydroguaiaretic acid for lipoxygenase and indomethacin for cyclooxygenase.
The results suggested that Cortisol induction by 10~8 M ACTH is also mediated by
PLA2-AA and/or AA metabolites in addition to the cAMP pathway. More importantly,
the PLA2-AA signalling system seemed potentially a key second messenger system
in response to 10"12 M ACTH. Meanwhile, the total StAR protein levels exhibited no
significant alteration in the presence of the various inhibitors.
Further investigation showed that phorbol-12-myristate 13-acetate (PMA), a
protein kinase C activator, significantly increased the expression of StAR protein
(P<0.05). However, it poorly promoted Cortisol output, possibly due to a lack of
appropriate Ca2+ mobilisation. Chronically (24 hr), PMA increased StAR protein
levels (P<0.01) but attenuated Cortisol production in the presence of ACTH (10 8 M),
implying that an inhibitory effect of PMA on other components of steroidogenic
pathways was likely. Furthermore, bisindolylmaleimide I, a highly selective protein
kinase C inhibitor, resulted in significant inhibitory effect on Cortisol levels induced
by 10"12 M and 10"8 M ACTH, especially at 1 hr, and appeared not to affect the level
of StAR protein.
In summary, very acute increases in Cortisol may well be independent of the
changes in total StAR protein levels. The de novo synthesis of StAR protein
provides, however, a continuous source of the labile protein that promotes further
elevated levels of Cortisol output. cAMP and AA cascades are dual signalling
pathways mediating ACTH-stimulated Cortisol output. Overall, it is suggestive that
there are at least two fundamental mechanisms for steroidogenesis, i.e. the
activation of second messenger networks and the regulation of the protein(s) for
initiating steroidogenesis via a rapid non-genomic response (post-translational
modification).
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1.1 THE ADRENAL GLAND
1.1.1 Functional anatomy of the adrenal gland
The main steroidogenic glands of mammals are the adrenal gland and gonads (testis
and ovary). Fig. 1-1-1 illustrates that the adrenal gland consists of two
embryologically and functionally distinct tissues: the cortex and the medulla.
Conventionally, the adrenal cortex is further divided into three concentric zones,
varying in both their morphological features and the steroid hormones which they
secrete. The zona glomerulosa (ZG) cells produce the mineralocorticoid aldosterone,
zonae fasciculata (ZF) and reticularis (ZR) secrete the glucocorticoids (Cortisol and
corticosterone) and 19-carbon steroids (Orth et al., 1992). Recent studies have
shown a novel layer between ZG and ZF in the rat (Mitani et al., 1994), which was
proposed as a undifferentiated zone containing stem cells (Mitani et al., 1999). The
adrenal medulla is the central part of the adrenal gland, comprising almost entirely
chromaffin cells. They secrete catecholamines including adrenaline (epinephrine),
noradrenaline (norepinephrine), and small amounts of dopamine (Landsberg and
Young, 1992).
1.1.2 Control of the adrenal cortex
Fig. 1-1-2 shows that the secretion of glucocorticoids is principally regulated by the
hypothalamus-pituitary-adrenal (HPA) axis and its negative feedback loop. In
response to stress the hypothalamus secretes corticotrophin-releasing hormone
(CRH) which stimulates the release of adenocorticotrophic hormone (ACTH) from the
adrenohypophysis (anterior pituitary). Subsequently, ACTH circulates to the adrenal
cortex, stimulating glucocorticoids secretion (Orth et al., 1992). The major circulating
mineralocorticoid, aldosterone, is produced by the adrenal ZG which is controlled by
multiple factors that have complex regulatory interactions (Quinn and Williams,
1988), of which the renin-angiotensin system and potassium ions are of key





















Fig. 1-1-2 Hormonal regulation of adrenal glucocorticoid via HPA axis and
the feedback of loop. ©: Positive control; ©: Negative control.
1.2 BIOSYNTHESIS OF STEROID HORMONES
1.2.1 Cholesterol translocation
Unlike polypeptide hormone-secreting cells such as pituitary cells, steroidogenic cells
do not tend to store steroid hormones. This is because lipophilic steroids can diffuse
more or less freely across organellar and cellular membranes. Thus, instead of
accumulating the end products, steroidogenic cells accumulate large amounts of
steroid precursor, cholesterol. These cells are able to use one or more of three
sources of cholesterol, i.e. intracellular stores, circulating lipoproteins (LDL and HDL)
and de novo synthesis (Cherradi et al., 1998a; Jefcoate et al., 1992; Kovanen et al.,
1979).
In mammals steroids are synthesised from a common substrate, cholesterol. The
initial phase of steroid synthesis is the mobilisation of cholesterol from cellular
compartments such as lipid droplets to the outer mitochondrial membrane (i. e.
transfer step 1), which may be via a process involving cytoskeletal components (e.g.
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microfilaments and microtubules), calmodulin-Ca2+, and perhaps also a sterol-binding
protein (Crivello and Jefcoate, 1980; Simpson and Waterman, 1983).
Subsequently, cholesterol is transferred from the outer to the inner mitochondrial
membrane (i. e. transfer step 2) where the cytochrome P450 side chain cleavage
enzyme (CYP11A) resides (Cherradi et al., 1998a; Jefcoate et al., 1992). CYP11A
has been observed at the matrix side of the inner mitochondrial membrane by
immunochemical staining together with electron microscopic analysis (Mitani et al.,
1982). On the other hand, the synthesis of the first product of steroidogenesis,
pregnenolone (Stone and Hechter, 1954), is independent of prior hormonal
stimulation when adrenal mitochondria are incubated with 25-hydroxycholesterol
which readily passes through mitochondria membranes (Jefcoate et al., 1974;
Simpson and Waterman, 1983). This result is indicative that CYP11A activity per se
is not the limiting factor for pregnenolone formation, but rather the availability of
cholesterol to CYP11A is what determines the rate of steroidogenesis.
Fig 1-2-1 illustrates ACTH causes the increase in intracellular cAMP which activates
protein kinase, resulting in phosphorylation of a labile protein to act on cholesterol
transportation (see details in section 1-3-1 & 1-4-1). In addition, ACTH also
stimulates cholesterol ester hydrolysis in cytoplasmic lipid droplets, ensuring a
continuous supply of substrate to activate steroidogenesis. Cycloheximide (CHX), a
protein synthesis inhibitor, blocks the transfer of cholesterol to CYP11A without
affecting transfer step 1 (DiBartolomeis and Jefcoate, 1984; Garren et al., 1971).
Since cholesterol accumulates in the outer mitochondrial membrane, transfer step 2
is apparently prevented rather than transfer step 1 (Privalle et al., 1983), implying
that the second step is more critical for steroidogenesis.
1.2.2 Biosynthetic pathways for steroid hormones
The biosynthesis of steroid hormones begins from the conversion of cholesterol to
pregnenolone which is catalysed by CYP11A (Simpson and Boyd, 1967). The side-
chain cleavage system consists of three components: a cytochrome P450
haemoprotein, a flavin adenine dinucleotide (FAD)-NADPH: adrenodoxin reductase,
and an iron-sulphur protein (Simpson and Waterman, 1983). The steroidogenic
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process is through a series of oxidation and reduction reactions catalysed by steroid
dehydrogenases by several mitochondrial and microsomal steroid hydroxylases.
Based on sequence homology between the various steroidogenic forms of
cytochrome P450, CYP11A, cytochrome P450 17a-hydroxylase (CYP17) and
cytochrome P450 21-hydroxylase (CYP21) are members of different gene families
within the overall cytochrome P450 gene superfamily (Simpson and Waterman,
1988).
As shown in Fig. 1-2-1 and Fig. 1-2-2, in adrenal ZFR the conversion of cholesterol to
pregnenolone occurs in the mitochondria. The major mechanism of this step is via an
initial hydroxylation at the 22-position of cholesterol to yield (22R)-22-
dihydroxycholesterol, then to pregnenolone. Pregenolone diffuses from mitochondria
to endoplasmic reticulum/microsome and metabolised to 17a-hydroxypregneolone or
alternatively to progesterone, then 17a-hydroxyprogesterone which is further
metabolised to 11-deoxycortisol. The latter product is delivered back to mitochondria,
subsequently for conversion to the end product, Cortisol.
1.3 HORMONAL REGULATION OF STEROIDOGENESIS
Steroid hormone production in the adrenal gland is mainly regulated by trophic
peptide hormones that stimulate steroidogenesis in their corresponding target
tissues.
1.3.11ntracelluar response to ACTH
1.3.1.1 The action of ACTH
ACTH, a principal regulatory factor of steroidogenesis (Haynes, 1958), is a major
trophic hormone for the adrenocortical cells both in vitro and in vivo. ACTH regulates
cholesterol metabolism through the control of cholesterol availability to CYP11A










































Fig. 1-2-2 Pathways for steroid hormone biosynthesis in bovine adrenal cortex
and in gonads. CYP11A (P450scc): Cytochrome P450 side-chain cleavage enzyme;
3p-HSD: 3p-Hydroxysteroid dehydrogenease; CYP17: Cytochrome P450 17a-
hydroxylase; CYP21: Cytochrome P450 21-hydroxylase; CYP11B: Aldosterone
synthase (in adrenal ZG) or Cytochrome P450 11|3-hydroxylase (in adrenal ZFR);
17p-HSD: 17p-hydroxysteroid dehydrogenase; CYP19: Cytochrome P450
aromatase. Modified from Brook and Marshall (Brook and Marshall, 1996).
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ACTH is a 39-amino-acid peptide that stimulates secretion of glucocorticoids
(corticosterone and Cortisol), androgenic steroids and, to a lesser extent,
mineralocorticoids. The first 24 NH2-terminal amino acids of ACTH are the same in all
species studied (Orth et al., 1992) and possess full biological activity in terms of
corticosterone and cAMP production (Seelig and Sayers, 1973). On a molar basis,
ACTHt-24 and ACTHi-39 are equipotent to replace bound [125I]-ACTH and to stimulate
cAMP and steroid production (Penhoat et al., 1989a). Synthetic ACTH^ is therefore
widely used for research and clinical purposes.
Fig. 1-3-1-1 illustrates that ACTH stimulates adrenal steroidogenesis by interacting
with specific receptors (Schulster and Schwyzer, 1980) at the cell surface. ACTH
receptors act through GTP-binding regulatory protein (Gs protein) to activate
adenylate cyclase (Rodbell, 1980) and the further action of ACTH is mediated at
least in part by protein kinase A (PKA) (Krueger and Orme-Johnson, 1983) which
phosphorylates serine / threonine residues of proteins.
The acute effect of ACTH is to increase the conversion of cholesterol to
pregnenolone. ACTH can maximally activate steroidogenesis with 5 min (Kim et al.,
1997). The chronic effects of ACTH involve progressively increased synthesis of
most enzymes of the steroidogenic pathway and more general actions on
adrenocortical cell protein, RNA and DNA synthesis, and cell growth (Simpson and
Waterman, 1983; Simpson and Waterman, 1988). Under chronic ACTH stimulation,
the elevations of corticosteroids (corticosterone and aldosterone) and changes in
mRNA and protein levels of steroidogenic enzymes in both adrenal ZG and ZFR
were observed in rat adrenal in vivo (LeHoux et al., 1998).
1.3.1.2 ACTH receptor
ACTH receptor (ACTH-R) has a small number of high affinity sites for ACTH and a
much larger number of low affinity sites. The existence of high- and low-affinity sites
for ACTH in mouse adrenal tumour cells was proposed by Lefkowitz et al on the basis
of [125I]-ACTH binding studies. The data in Table 1-3-1 are a hypothetical projection of
the number of receptors of each order occupied at various concentrations of ACTH
(Lefkowitz et al., 1971).
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Table 1-3-1 Relation of ACTH concentration to the number of receptors
occupied
Sites occupied per cell










Some investigators suggested that there may be two classes of ACTH receptors on
adrenocortical cells (Mcllhinney and Schulster, 1975). Two receptors or at least two
different affinity sites may involved in the interaction of ACTH with rat adrenal cells
(Moyle et al., 1973). Moreover, ACTH receptors on adrenocortical cells are much in
excess of the those necessary for maximal steroidogenesis. The stimulation of a
small fraction of receptors (<3%) is sufficient for maximal steroidogenesis (Buckley
and Ramachandran, 1981).
Five transcripts of ACTH-R mRNA, two major of 1.8 and 3.4 kb and three minor of 4,
7 and 11 kb were found in the human adrenal (Lebrethon et al., 1994). Bovine
adrenal ZFR cells express at least four ACTH-R transcripts, one major of 3.6 kb and
three minor ones of 4.2, 1.8 and 1.3 kb. ACTH treatment increased the levels of
ACTH-R mRNA in a time- and dose-dependent manner, i. e. ACTH has a positive
effect on its own receptor, which is another important regulatory mechanism involved
in the responsiveness of adrenocortical cells (Penhoat et al., 1994).
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1.3.1.3 G-proteins and adenylate cyclases
The G-proteins, an extensive family, are the critical mediators between the receptors
and a variety of effectors in the plasma membrane, consisting of three subunits. The
largest one (39-46 kDa) has the a subunit which contains the binding site for guanine
nucleotides. The second ((3, 35-36 kDa) and third (y, approx. 8 kDa) subunits form
stable noncovalent complex, tightly coupling with the membrane. An interaction
among multiple components allows a dynamic range of response to stimuli. The (3y
subunits are associated with a number of activities such as the activation of
adenylate cyclase (AC) isoenzymes (Sternweis, 1996).
ACs are responsible for the conversion ATP to cyclic AMP. At least nine isoforms of
AC have been identified and are classified into three groups: (i) Ca27calmodulin-
activated isoforms (type I, III and VIII); (ii) Ca2+-inhibited (type V, VI and possibly IX)
isoforms; (iii) Ca2+-insensitive (type II, IV and VII) isoforms (Burnay et al, 1998;
Taussig and Gilman, 1995) and more recently another isoform (sAC) was found in
brain. The G-protein-coupled receptors can be differently integrated with AC
depending on the properties and the level of isoforms in various tissues or cells
(Defer et al., 2000).
1.3.2 Intracelluar response to angiotensin II (Ang II)
Ang II is a principal regulator of steroidogenesis in adrenal ZG, modulating
aldosterone production. As shown in Fig. 1-3-1-1, Ang II binds angiotensin type 1
(AT1) receptors (Balla et al., 1991; Sasaki et al., 1991), which couple with
phospholipase C (PLC) through Gq/11 protein. This action results in the hydrolysis of a
plasma membrane lipid, phosphatidylinositol 4,5-bisphosphate (PIP2) generating
diacylglycerol (DAG), an activator of protein kinase C (Hunyady et al., 1990; Lang
and Vallotton, 1987) and inositol 1,4, 5-triphosphate (IP3), which is responsible for
calcium release from intracellular pools (Kojima et al., 1984; Rossier et al., 1987;
Rossier, 1997).
Submitochondrial membrane analysis showed Ang ll-stimulated exogenous
cholesterol mobilisation to the mitochondria and a concomitant transport of
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endogenous cholesterol to contact sites (Cherradi et at., 1996). Although well known
as a major activator of aldosterone secretion by adrenal ZG cells, Ang II is also a
potent effector of glucocorticoid secretion in bovine adrenal ZF cells via a distinct
class of receptors (Hadjian et al., 1984). Several types of Ang II receptors have been
identified in adrenal ZG and ZFR cells (Enyeart et al., 1996).
In addition to the PLC-DAG/IP3 second messenger system, Peytremann and co¬
workers firstly demonstrated that Ang II stimulated cAMP accumulation and
subsequently increased steroidogenesis in bovine adrenal ZF cells (Peytremann et
al., 1973). Ang II (10 7 M) caused a time-dependent increase in cAMP, reaching a 8-
fold increase at 3 hr in fetal bovine adrenocortical cells (Bird et al., 1993).
Ang II has a potentiating effects on ACTH-stimulated cAMP in cultured bovine
adrenal ZG cells (Baukal et al., 1994). There are at least two concepts with regard to
the mechanism of Ang ll-stimulated cAMP formation: (1) The mechanism of the
combined effect of Ang II and ACTH may be that calcium entry into the cell plays an
important role in the activation of adenylate cyclase (probably type III) by Ang II
(Burnay et al., 1998); (2) the action of Ang II on cAMP formation may be through the
cross-talk via PKC rather than that direct coupling with adenylate cyclase (Bird et al.,
1993).
Apart from ACTH and Ang II, some other agents are also able to modulate the
growth and function of the adrenal cortex, including insulin-like growth factor I (IGF-I)
(Louveau et al., 1989; Penhoat et al., 1989b), atrial natriuretic factor (ANF) (Nawata
et al., 1991), fibroblast growth factor (FGF) (Ehrhart-Bornstein et al., 1998), tumour
necrosis factor-a (TNF-a) (Natarajan et al., 1989) and transforming growth factor-[3
(TGF-P) (Brand et al., 1998; Naville et al., 1991; Roy et al., 2000).
1.4 INTRACELLULAR SIGNALLING SYSTEMS RESPONDING TO
TROPHIC HORMONES
Different intracellular signalling systems mediate the hormonal actions on steroid
biosynthesis, depending on the type and intensity of the stimuli. Several major factors
1-12
Chapter 1
have been proved to play a role in these signalling pathways. Amplification of the
action of an initial stimulus is the central theme to signal transduction.
1.4.1 Cyclic adenosine 3', 5'-monophosphate (cAMP)
The role of cAMP as a second messenger was first revealed by Sutherland and co¬
workers in 1960s (Sutherland and Rail, 1960). cAMP is the primary intracellular
mediator of ACTH-stimulated steroidogenesis in the adrenal gland (Mackie et al.,
1972) and plays a key role in steroid synthesis in both the acute and chronic phase. It
activates the hydrolysis of cholesterol esters in lipid droplets within seconds or
minutes. In the chronic phase, cAMP regulates the transcriptional activation of genes
encoding steroid hydroxylase and accessory proteins (Waterman, 1995).
ACTH induces an increase in intracellular cAMP via the activation of a Gs-protein-
coupled to AC and consequently activates PKA and ultimately elevates steroid
production.
Ang II can cause a small but significant increase in cAMP production via the AT1
receptors in bovine adrenal ZF cells. This result was demonstrated using four
different radioimmunoassays for cAMP and three commercial sources of human
synthetic Ang II. The cAMP production was specific and was both concentration- and
time-dependent with a significant increase in the presence of 10"9 M Ang II and a
maximal response at 10~7 M Ang II (Rainey et al., 1991). That Ang II can stimulate
cAMP production has been demonstrated in a variety of tissues types. For example,
there was a close correlation between Ang ll-stimulated aldosterone production and
cAMP levels in rat adrenal ZG cells (Bing and Schulster, 1978); Ang II also
potentiated prostaglandin Ei (PGE^ stimulated cAMP accumulation in intact bovine
adrenal medulla cells (Boarder et al., 1988).
A number of genes are stimulated by the elevation of cAMP and all include a
responsive DNA element, TGACGTCA (Comb et al., 1986). Following the
phosphorylation at Ser133 by cAMP-dependent protein kinase, cAMP response
element binding (CREB) protein binds to CRE, regulating gene transcription
(Gonzalez and Montminy, 1989). The mechanisms of this process are via the three
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functional regions of CREB protein, i.e. (1) a transactivation domain with some
potential phosphorylation sites; (2) a DNA binding domain; and (3) a "leucine zipper"
dimerization domain (Gonzalez and Montminy, 1989; Hoeffler et al., 1988; Lali and
Sassone-Corsi, 1994).
Apart from the activation of PKA, the later studies showed that cAMP mediates new
signalling pathways in endocrine cells including the phosphorylation of protein kinase
B (Richards, 2001). Cyclic AMP, once considered to be a straightforward second
messenger, has been discovered to be a very complicated regulator. The action of
this molecule is not only by stimulating protein phosphorylation through activation of
protein kinase but also by inducing protein-protein interactions independently of any
phosphorylation (Kawasaki et al., 1998).
1.4.2 Phospholipase A2, arachidonic acid and its metabolites
Cellular phospholipids serve not only as the components of membrane structure, but
also as the reservoirs of second messenger molecules that are generated by
phospholipases. At least five types of phospholipases, i.e. Ai (EC 3.1.1.32) , A2 (EC
3.1.1.4), B (EC 3.1.1.5), C (two major types, EC 3.1.4.3) and D (EC 3.1.4.4) have
been identified according to the position of their activity on the phospholipid
backbone. Phospholipase A, C and D have all been proved to function both as
enzymes and as signal transducers. The phospholipase A2s (PLA2s) are prominent
members of the large group of signal-activated phospholipases (Balsinde et al.,
1999; Rhee and Dennis, 1996).
1.4.2.1 Role of phospholipase A2 in the arachidonic acid cascade
The phospholipase A2 is a superfamily which consists of a broad range of enzymes
defined by their ability to catalyse the hydrolysis of the middle {sn-2) ester bond of
substrate phospholipids. Based on biological properties, these enzymes are
considered as three main types, i.e. cytosolic PLA2 (cPLA2), intracellular Ca2+-
independent PLA2(iPLA2) and secretory PLA2(sPLA2) (Balsinde et al., 1999).
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Cytosolic PLA2 ranging from 61 to 114 kDa is specific for arachidonic acid-carrying
phospholipid, which is able to be translocated to membranes where its substrate is
localised in response to increases in intracellular Ca2+-(Dennis, 1994). It is believed to
play an important role in the production of arachidonic acid metabolites, the
eicosanoids. The essential role of cPLA2 in AA metabolism has been proved using
cPLA2 knock-out mice (Bonventre et al., 1997). Intracellular Ca2+-independent PLA2
ranging from 84 to 90 kDa has been considered as a 'housekeeping enzyme'
involved in the maintenance of membrane PL composition. Secretory PLA2s are low
molecular mass enzymes (13-18 kDa) that require Ca2+ to exert their action and do
not exhibit preference for a fatty acyl chain in PL (Six and Dennis, 2000; Yedgar et
al., 2000). More recently, PLA2 have been classified into 11 Groups (l-XI) according
to four criteria and each Group consists of several subgroups. cPLA2 falls into the
category of Group IV, iPLA2 into Group VI and sPLA2 into Group 11 A, I ID, V and X
(Murakami et al., 2000; Rhee and Dennis, 1996; Six and Dennis, 2000).
In intact cells, receptor-dependent activation of PLA2 may occur via a G-protein-
mediated mechanism (Axelrod et al., 1988; Gupta et al., 1990). The hydrolysis
products of PLA2 are free fatty acids such as arachidonic acid and oleic acid and
lysophospholipid (Lyso-PL). They serve as the precursors for other lipid mediators
and have also been considered as downstream effectors in signal transduction. The
liberation of free AA is the rate-limiting step for the synthesis of eicosanoids which
are key cellular mediators. The Lyso-PL can be converted to platelet-activating
factor (PAF), another important lipid-derived mediator (Hirabayashi and Shimizu,
2000).
1.4.2.2 Routes leading to arachidonic acid release
Arachidonic acid (AA; 5, 8, 11, 14-eicosatetraenoic), a polyunsaturated fatty acid, is
a ubiquitous precursor of biologically active eicosanoids and the liberation of AA
from membrane phospholipids is a crucial step in signalling processes. Release of
AA occurs via at least six routes, i.e. (i) cleavage of the glycerophospholipid (PL)
backbone which is catalysed by various forms of PLA2, yields free AA and Lyso-PL;
(ii) activation of phospholipase C (PLC) forms DAG, which is subsequently
hydrolysed by DAG-lipase into free AA and monoacylglycerol (MAG; Piomelli,1993);
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(iii) activation of phospholipase At (PLA^ followed by lysophospholipase
(phospholipase B) (Martin and Wysolmerski, 1987); (iv) activation of phospholipase
D (PLD) followed by phosphatidate phosphohydrolase and DAG/MAG (Exton,
1990); (v) breakdown lipid esters from low density lipoproteins (LDL) (Habenicht et
al., 1990); (vi) inhibition of the utilisation of lysophosphatidates in reacylation results
in the increase in AA levels (Fuse et al., 1989). Under physiological conditions, the
direct cleavage of AA from the sn-2 position of phospholipids via PLA2 is a key step
for AA liberation (Balsinde et al., 1999).
1.4.2.3 Arachidonic acid and its metabolites
Arachidonic acid itself is associated with a number of cellular process, for example,
the regulation of PKC, PLC, NADPH oxidase and Ca2+ oscillations (Hirabayashi and
Shimizu, 2000). AA stimulates the conversion of cholesterol into pregnenolone in rat
adrenal ZF cells (Mele et al., 1996).
More importantly, as shown in Fig. 1-4-2-3, AA can be metabolised to diverse
eicosanoids leading to more cellular responses via three pathways: (i)
Cyclooxygenase (COX) catalyses the conversion of AA into two reactive
intermediates, prostaglandin G (PGG) and prostaglandin H (PGH), which are
precursors of the prostaglandins (PGs), prostacyclin (PGI2) and thromboxane A2
(TXA2); (ii) Lipoxygenase (LOX) forms hydroperoxyeicosatetraenoic acids (HPETE)
as primary products, which can undergo a complex metabolism including reduction to
corresponding hydroxyacids (HETE), or conversion into leukotrienes,
epoxyhydroxides, etc; (iii) Cytochrome P-450 dependent monooxygenase (NADPH-
P450 dependent epoxygenase) catalyses the conversion of AA into
epoxyeicosatrienoic acids (EET), which can be hydrolysed to the corresponding
dihydroxyeicosatetraenoic acids (diols/DHTs) by epoxide hydrolase (Piomelli, 1993).
Pharmacological and cell biology studies have demonstrated that COX-1, a
constitutive isozyme, is limited to the acute phase of PG biosynthesis, which is
elicited by Ca2+-mobilizing agonists. On the other hand, COX-2, an inducible
isozyme, is a prerequisite for the chronic response, which lasts for several hours
following proinflammatory stimuli (Kuwata et al., 1998).
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Fig. 1-4-2-3 Schematic overview of the cascade of arachidonic acid release
(in part) and metabolism. PL: Glycerophospholipid; PLA2: Phospholipase A2;
PLC: Phospholipase C; DAG: Diacylglyerol; MAG: Monoacylglycerol; AA:
Arachidonic acid; AA-CoA: Arachidonoyl-coenzyme A; Lyso-PL; Lysophospholipid;
Cyt P450: Cytochrome P450-dependent monooxygenase; LOX: Lipoxygenase;
COX: Cyclooxygenase; HPETE: Hydroperoxyeicosatetraenoic acids; EET:
Epoxyeicosatrienoic acid; HETE: Hydroxyeicosatetraenoic acids; PGG:
Prostaglandin G; PGH: Prostaglandin H; PGs: Prostaglandins; PGI2: Prostacyclin;
TXA2: Thromboxane A2; LTs: Leukotrienes; DHTs: Dihydroxyeicosatetraenoic
acids. Modified from Piomelli,1993.
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Several LOX products of AA have been found to have potent biological activities and
modulate physiological processes in various cells such as pancreatic p cells (Metz et
al., 1983), pituitary cells (Snyder et al.„ 1983) and adrenocortical cells (Nishikawa et
al., 1994).
Three types of LOX (5-, 12- and 15- LOX) have been identified in different tissues or
species. The 5-LOX is present in rat adrenocortical cells. AA861, a 5-LOX inhibitor,
reduced ACTH-stimulated corticosteroid secretion without changing the cAMP level,
suggesting that the 5-HPETE, 5-LOX metabolite, may mediate steroidogenesis (Hirai
et al., 1985). The 15-LOX metabolites have been shown to enhance steroidogenesis
induced by as low as 10"12 M ACTH in bovine adrenocortical cells (Yamazaki et al.,
1996). Bovine tracheal epithelial cells express a 12-LOX that has immunological
reactivity similar to the leukocyte form and distinct from platelet 12-LOX; this LOX
heterogeneity may provide a basis for their different roles (Hansbrough et al., 1990).
Cytochrome P450-dependent monoxygenase (MOX) pathway, the third route of AA
metabolism, also performs important roles in cellular responses, presenting in the
kidney (Morrison and Pascoe, 1981), liver (Oliw et al., 1982), pituitary gland
(Capdevila et al., 1984), cornea (Schwartzman et al., 1987) and the adrenal cortex
(Nishimura et al., 1989). This pathway is involved also in receptor-mediated signal
transduction (McGiff, 1991).
In addition to generation of biologically active eicosanoids, AA can be reincorporated
into phospholipids via reacylation of lysophosphatides by two enzymes (arachidonyl-
CoA synthase and arachidonyl-CoA lysophosphatide acyltransferase) (Fuse et al.,
1989). The reincorporation and various AA metabolites result in the AA cycle.
1.4.3 Calcium
Calcium (Ca2+) is a ubiquitous messenger with both versatility and universality and
has an important role in controlling cellular responses. Cells in their resting state
have free Ca2+ concentrations of 100 nM but are activated when the level of Ca2+
rises to approximately 1000 nM. Ca2+ signals often present in a temporal pattern
such as Ca2+ spikes (Berridge et al., 2000).
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There exist many possible routes of Ca2+ participation in the regulation of
metabolism. Ca2+ can act as both a primary and secondary messenger in mediating
many essential cellular functions. Several Ca2+-selective channels have been
identified, i.e. voltage-, extracellular ligand-, intracellular messenger- and
mechanically-operated channels. For each channel there are several subtypes, for
example, voltage-operated Ca2+ channel includes L-, T-, N-, P-, Q- and R- type
(Rossier, 1997).
A requirement for Ca2+ in steroidogenesis of the adrenal cortex is well established.
Ca2+ is a major second messenger for NPS-ACTH-stimulated steroidogenesis in
bovine adrenal ZFR cells (Yamazaki et al., 1998). ACTH at 10"12 M causes a transient
increase in cytoplasmic free calcium concentration ([Ca2+ ]c) by a cAMP-independent
mechanism and this effect appears to be saturated at 10"10 M ACTH in bovine ZG
cells (Kojima and Ogata, 1986). In bovine adrenal ZF cells, the addition of ACTH
(10"13-10"1° M) triggers oscillations or sustained elevation of intracellular calcium
concentration ([Ca2+ ]i) (Kimoto et al., 1996). The increase in [Ca2+ jiiriay result in the
rise in intramitochondrial Ca2+ concentration, which can induce the acute
steroidogenic response possibly due to the activation of mitochondrial enzymes
involved in NAD(P)H production in bovine adrenal ZF cells (Hoolahan et al., 2000).
Enyeart et al proposed Ca2+ as a primary intracellular messenger regulating
steroidogenesis, particularly at picomolar ACTH concentrations (Enyeart et al.,
1993). More recently, some results suggest that capacitative calcium entry (i.e. Ca2+
entry triggered by depletion of intracellular Ca2+ stores) is involved in steroidogenesis
in bovine adrenal ZF cells (Ebisawa et al., 2000).
Python and co-workers showed that Ca2+ levels regulated the production of both
pregnenolone and aldosterone in bovine ZG cells. The formation of pregnenolone
from freely diffusible analogues of cholesterol was not affected by Ca2+. This is
suggestive that the potential target of Ca2+ occurs at the very early steps of
steroidogenesis prior to cleavage of cholesterol (Python et al., 1995).
The mechanism of Ca2+ on steroidogenesis was further studied by Cherradi et al
who demonstrated that one of the main functions of the Ca2+ messenger is to
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increase cholesterol supply to CYP11A by enhancing intermembrane cholesterol
transfer. Studies using submitochondrial fractions revealed that stimulation of
bovine adrenal ZG cells with Ca2+ led to a decrease in cholesterol content at the
outer membrane and a concomitant increase in cholesterol at both contact site and
inner membrane (Cherradi et al., 1996).
Furthermore, Ca2+ also mediates steroidogenesis induced by other stimuli. A rapid
rise in cytosolic free calcium triggers aldosterone production in response to Ang II
and potassium in bovine adrenal ZG cells (Brandenburger et al., 1996; Capponi et
al., 1984). Ang II enhances aldosterone biosynthesis through the stimulation of two
distinct Ca2+ entry pathways: (1) Opening the voltage-operated calcium channel
(VOC); and (2) activation of a capacitative Ca2+ entry (Burnay et al., 1998). The
changes in cytosolic calcium and aldosterone stimulated by Ang II show a complex
dose-response pattern in rat adrenal ZG cells, basically including a sustained Ca2+
response and an oscillating Ca2+ response (Quinn et al., 1991).
1.4.4 Interaction between signalling pathways
The signalling network is composed of multiple components. It has became
increasingly important to understand that a signalling pathway not only works in a
linear fashion but also interacts with other pathways, resulting in a complex network.
Interaction of signal transduction systems leads to substantial amplification of the
original signal at each stage of the cascade, ensuring not only efficient stimulation of
steroid biosynthesis but possibly also efficient switching off the initial steroidogenic
stimulus.
Ca2+ is known to interact with other intracellular messenger systems such as cAMP.
Ca2+- and PKC-mediated regulation of cAMP production has been documented in
several studies (Cooper et al., 1995; Morimoto and Koshland, 1994; Warhurst et al.,
1994). The changes of cAMP can affect the levels of Ca2+ by acting on both Ca2+
channels and pumps (Berridge et al., 2000). In the bovine adrenal ZF cells, ACTH-
induced cAMP increase may be potentiated by Ang II through a capacitative calcium
influx (Baukal et al., 1994).
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Analysis of the CYP11B2 promoter in H295R cells showed that the cAMP-, K+- and
Ang II responsive regions localise to a common responsive element, implying a
potential cross-talk among multiple signalling pathways (Clyne et al., 1997). Another
interaction may be through the AA cascade. AA and/or its LOX products modulate K+
channels (Kim and Clapham, 1989; Ordway et al., 1989). The AA metabolites
produced by cytochrome P450 monooxygenase also inhibited Na+/K+ ATPase activity
(McGiff, 1991).
Signal networking results in several emergent properties that the individual pathways
do not have, including extended signal duration, activation of feedback loops,
definition of threshold stimulation for biological effects and multiple signal outputs
(Bhalla and Iyengar, 1999). At present, the studies on signal transduction can also be
conducted by computational methods, providing a more comprehensive scenario in
this field.
1.5 PROTEIN KINASE SYSTEMS
The phosphorylation and dephosphorylation of proteins are important regulatory
mechanisms in response to a number of stimuli, modulating the protein functions in a
rapid and reversible manner. Protein phosphorylation is particularly prominent for
signal transduction (Edelman et al., 1987).
1.5.1 Protein kinase A
Protein kinase (PKA)-dependent phosphorylation is a key intermediate step in the
action of ACTH (Wong et al., 1992). PKA exists as a heterotetramer, consisting of a
dimer of regulatory subunits (R) and two monomeric catalytic subunits (C) (Francis
and Corbin, 1994). Cyclic AMP activates PKA which phosphorylates serine (Ser) /
threonine (Thr) residues in target proteins containing the consensus sequence Arg-
Arg-X-Ser/Thr-X (Arg: Arginine; X: any amino acid) (Kennelly and Krebs, 1991).
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1.5.2 Ca2+/calmodulin-dependent kinase II
Many intracellular effects of Ca2+ are mediated by Ca27calmodulin-dependent (CaM)
kinase II. CaM kinase II is a complex of 12 subunits that exists in four differentially-
expressed forms (a, (3, y and 8). In the inactive state there is a strong interaction
between the inhibitory and catalytic domains of the enzyme. The binding of
Ca2+/calmodulin allows the catalytic domain to phosphorylate the inhibitory domain.
Once activated, CaM kinase II retains significant activity even after the removal of
Ca2+, thereby prolonging the duration of kinase activity (Quadroni et al., 1998;
Schulman, 1988; Siekevitz, 1991).
1.5.3 Protein kinase C
Protein kinase C, a serine/threonine kinase, is composed of a single polypeptide
chain of 77-83 kDa, containing the regulatory and the catalytic domain (Azzi et al.,
1992) and classified into 11 isotypes on the basis of structural and functional
characteristics (Parker, 1996). The PKC isozymes act differentially according to the
properties of their activators, and fall into three groups (1) Calcium- and
phospholipid-dependent PKC (a, (3|, (3n and y); (2) calcium-independent and
phospholipid-dependent PKC (8, e, rj, 6 and p); and (3) calcium- and phospholipid-
independent PKC (AA and £) (Zoukhri et al., 1997).
PKC can be activated by a number of agents including Ca2+, lipid (fatty acids), and
phorbol ester, etc. PKC is directly activated by the tumour promoter, 12-0-
tetradecanoyl phorbol-13-acetate (TPA) and presumably acts as a binding site and
cellular mediator of TPA (Kikkawa et al., 1984). The computational analysis based on
the experimental concentration-effective curves has demonstrated that PKC is
activated by Ca2+, AA and DAG synergistically (Bhalla and Iyengar, 1999; Schaechter
and Benowitz, 1993; Shinomura et al., 1991).
The involvement of protein kinases in the signalling pathways controlling
steroidogenesis has been well established. Furthermore, the dephosphorylation by
phosphoprotein phosphatase is also an important regulatory mechanism for
steroidogenesis (Jones et al., 2000; Sayed et al., 1997).
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1.6 CANDIDATE PROTEINS FOR REGULATION OF STEROIDOGENESIS
Steroid hormone synthesis is regulated via controlling cholesterol delivery to the inner
mitochondrial membrane. The diffusion of the hydrophobic cholesterol through the
aqueous layer between the outer and the inner mitochondrial membrane is extremely
slow (Phillips et al., 1987), the transfer of cholesterol must therefore occur in an
assisted manner (Stocco, 1997), i.e. this process is mediated by an acute regulator
or regulators. In early 1960s, Ferguson discovered a puromycin-sensitive protein
which could be a key factor for increasing steroid output (Ferguson, 1962 and 1963).
The studies using protein synthesis inhibitors (puromycin and cycloheximide) showed
both inhibitors blocked ACTH-induced steroid production in the adrenal cortex, which
may be caused by the inhibition of the synthesis of a rapidly turning-over protein
(Garren et al., 1965). Cycloheximide treatment had resulted in cholesterol
accumulation in the outer mitochondrial membrane but had no direct effect on the
activity of CYP11A itself (Privalle et al., 1987). Furthermore, acute steroidogenesis
evidently excludes the involvement of newly synthesised CYP11A as the change in
this steroidogenic enzyme was only significant after 6-12 hr ACTH treatment
(Simpson and Waterman, 1983). This implied that an action prior to the first
steroidogenic reaction was a critical step. Thus, a number of experiments have been
carried out to search for a "labile protein" required for cholesterol transport from the
outer to the inner mitochondrial membrane. Several candidate proteins have been
proposed.
1.6.1 Sterol carrier protein
Sterol carrier protein (SCP2), a 13 kDa protein, may be related to delivery of
cholesterol from lipid droplet stores into mitochondria for initiation of steroid hormone
synthesis (Chanderbhan et al., 1982; Vahouny et al., 1983). However, SCP2 is not
affected by cycloheximide treatment and not acutely regulated by hormone (van
Amerongen et al., 1989). Moreover, SCP2 is non-specific lipid transfer protein
because it promotes the transfer of a variety of lipids including sterols, phospholipids
and glycolipids (Kallen et al., 1998b).
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1.6.2 Steroidogenesis activator polypeptide
Steroidogenesis activator polypeptide (SAP), a 3.2 kDa small molecular (the
precursor is 78 kDa glucose-regulated protein, GRP78) exhibits cycloheximide
sensitivity that is the characteristic of ACTH-induced labile activator for adrenal
steroidogenesis (Li et al., 1989; Mertz and Pedersen, 1989; Pedersen and Brownie,
1983; Pedersen and Brownie, 1987).
1.6.3 Peripheral benzodiazepine receptor
Peripheral benzodiazepine receptor (PBR), a 18 kDa protein, is primarily located on
the outer mitochondrial membrane of adrenal gland and is involved in cholesterol
transfer from the outer to the inner mitochondrial membrane for steroidogenesis
(Anholt et al., 1986; Krueger and Papadopoulos, 1990; Papadopoulos, 1993). A 3-
dimensional protein model indicates that PBR contains five transmembrane domains,
forming a channel-like structure that can accommodate a cholesterol molecule
(Bernassau et al., 1993). The ability of PBR to bind benzodiapines is associated with
a 34 kDa voltage-dependent anion channel, suggesting that PBR is a multimeric
complex (Gamier et al., 1994). PBR may serve as a channel by which cholesterol
can freely enter mitochondria and PBR ligands may control the opening of this
channel, i.e. cholesterol is captured by PBR and released upon ligand binding (Amri
et al., 1998).
1.6.4 Steroidogenic acute regulatory protein
Some work has demonstrated that inhibition of protein synthesis had no effect on the
increased delivery rate of cholesterol from cellular stores to the outer mitochondrial
membrane, but that the subsequent delivery from the outer to the inner mitochondrial
membrane was completely inhibited by cycloheximide (Privalle et al., 1983; Privalle et
al., 1987). The characteristic of cycloheximide sensitivity implies that the labile
protein for cholesterol transport is de novo synthesised in response to trophic
hormone treatment. Initially the investigation using 2-dimensional gel electrophoresis
revealed protein i produced in response to ACTH, differing from protein p in
unstimulated rat adrenal ZFR cells (Krueger and Orme-Johnson, 1983). Further
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studies demonstrated that steroidogenesis was regulated by ACTH-induced 28, 30,
32 and 37 kDa phosphoproteins with various pi values (Epstein and Orme-Johnson,
1991; Pon et al., 1986; Pon and Orme-Johnson, 1986). The direct evidence of a
cause and effect relationship between the expression of a 30 kDa protein and an
increase in steroidogenesis was established in transient transfection of MA-10 Leydig
tumor cells by Clark and co-workers in 1994. They concluded that this protein is
required in the acute regulation of steroidogenesis and proposed to call it
Steroidogenic Acute Regulatory protein, later abbreviated to StAR protein (Clark et
al., 1994). More importantly, congenital lipoid adrenal hyperplasia (CAH), a steroid
deficiency disease (i.e. a human gene knockout for StAR gene) has demonstrated
that truncated and non-functional StAR protein leads to steroidogenic disorder (Lin et
al., 1995). In contrast, other candidates (SCP2, GRP78 and PBR) are normal in this
clinical condition (Lin et al., 1993; Lin et al., 1991). This discovery provided
compelling evidence for the function of StAR in steroidogenesis on a genetic basis.
Furthermore, an essential role for StAR protein in adrenocortical and gonadal
steroidogenesis has also been demonstrated by the experimental model for StAR
knockout in mice (Caron et al., 1997).
1.6.5 Arachidonic acid-related thioesterase involved in steroidogenesis
A novel phosphoprotein protein (43 kDa) named as arachidonic acid-related
thioesterase involved in steroidogenesis (ARTISt) also participates in the control of
acute steroid synthesis and was found in adrenal, ovary placenta and brain
(Cymeryng et al, 1995; Finkielstein et al, 1998; Maloberti et al, 2000).
1.7 StAR PROTEIN
Since StAR protein was established as meeting many of the expected criteria for a
labile regulatory protein that facilitates cholesterol delivery for initiation of the




1.7.1 Further characteristics of StAR protein
StAR protein may be a transporter that binds and transfers cholesterol through the
mitochondrial intermembrane space thereby playing a key role in steroid hormone
synthesis.
1.7.1.1 Organisation of StAR gene structure and protein
The StAR locus was detected in chromosome 8p11.2 by fluorescence in situ
hybridisation and a StAR pseudogene was mapped to chromosome 13 in the human
(Sugawara et al., 1995a). StAR gene spans 8 kb and consists of seven exons
interrupted by six introns ranging from 141 nt to 2 kb (Sugawara et al., 1995b). Fig.
1-7-1-1a illustrates that the mouse StAR gene is rather compact and contains seven
exons and six introns consisting totally of 6.5 kb (Clark et al., 1995).
^500 bp
ATG STOP
Exon 1 2 3 4 5 6 7
Fig. 1-7-1-1a Schematic representation of mouse StAR gene structure
StAR protein sequence is highly conserved with over 80% homology and 90%
similarity across mouse (Clark et al., 1994), human (Sugawara et al., 1995) and rat
(Lee et al., 1997; Mizutani et al., 1997).
The bovine StAR cDNA encodes a 285 amino acid protein (Fig.1 -7-1 -1 b) (Flartung et
al., 1995) and its DNA and protein sequence accession number are EMBL: BTY







AGACATGTGCGCAGCATGAAGGGGCTGCAGCAGCAGGCTGTGCTGGCCATCGGCCAGGAG 2 4 O
RHVRSM KGLQQQAVLAIGQE 34
CTGAACCGGAGGGCCCTAGGGGGCCCGGCCCCAGCTGCGTGGATTAACCAGGTTCGGCGT 3 O O
LNRKALGGPAPAAWINQVRR 54
CGCGGCTCTCTCCTAGGTTCTCAGCTGGAAGACCCTCTCTACAGCGACCAAGAGCTGGCC 3 6 O
RGSEEGSQEEDPEYSDQELA 74
CATATCCAGCAGGGAGAGGAGGCCATGCAGAGGGCCCTGGGCATCCTCAAAGACCAGGAG 4 20
H X QQGEE AMQRALG I LKDQE 94
GGCTGGAAGAAGGAGAGCCGGCAGGCCAATGGGGACGAGGTGCTGAGTAAAGTGATCCCT 4 80
GWKKESRQANGDEVLSKVX P 114





K V LQK X GKDTVI THEEAAEV 174
GCAGGAAACCTTGTGGGGCCCCGAGACTTTGTGAGCGTACGCTGTACCAAGCGCCGGGGC 7 20
AGNEVGPRDFVSVRCTKRRG 194
TCCATGTGTGTGCTGGCTGGCATGGCCACACTCTATGAGGAGATGCCCCAGCAGAAGGGT 7 8 O
SMCVEAGMATEYEEMPQQKG 214
GTCATCAGAGCGGAGCACGGCCCCACCTGCATGGTGCTCCGCCCCTTGGCTGGAAGTCCC 8 4 O
VIRAEHGPTCMVERPLAGSP 234
TCAAGGACCAAACTCACCTGGCTGCTCAGCATTGACCTCAAGGGATGGCTGCCGAAGACC 9 O O
SRTKLTWLLSIDEKGWLPKT 254
ATCATCAACCAGGTCCTCTCGCAGACCCAGGTGGATTTTGCCAATCACCTGCGCAAGCGC 9 6O
I I NQVLSQTQVDFANHLRKR 274
CTGGAGTCCTGCCCTGCTCTTGAAGCTAGGTGTTGAAGGCCAACTTGCGGCTCCACCAGC 1020
LESCPALEARC 285
TCCCGGCTGAATGGGTTTGAGGGCTCACGAGGAGGCCCCTGCTAGAAGACTCCAAGTCTG 10 8 O
TTAAAGATCTCATCTGAGGACAGTGGGACAAGGTGGTGGCACGTTTTCAATAAGATACTA 11 4 O
CAGCTCAGCTACTACAGCAGOATTTTAGTACCAAGAGAATGCGGACAAGGCTCTTCTAAC 12 OO
TTCATTCACTGATGAGCTGTAAAATGAAGCATAAGGGTCTCAAAACATTTGTGAAACTTT 1 2 6O
TTTTTCCTGGGTCCTGACAGCGTCTACCTAAAAATATCTTGAAAATGCTACCAGTTAAGG 1 3 2 O
AATGCAGGGTGCAGAGGGTGCAGAACCCAAGGATCAGGTTGTCAAGCTTGAGGAGGTCAA 1 3 8O









AATTTTACTACTTTCCCACTAGTTGCTTTAGATCTGAAATAGGAACTGAATCTTTAGTCT 2O 4 O
GGAGTCTATTCTGCCCTCTTAGCTTGACTCGGGGCTGCAATTTCTCTGCTTTAACAGGTC 210O
AACATCTTACTATCTTGGAGGAGATGGCTGGAAGAAGGTGTGATAGCATGAGAGCAAXAA 216O
TCCTTTCCAAGGTCTGAGAATTGGTGCTCTAAACATCTAAGTTGAGATGGGGTTATCTGG 2 2 2O
CTAAAATACATATGCAGGATGAAAACCCAACCATTATCACTTGAAGTGTTTCCATTCCAG 2 28 0
TGCTACAGCATTGATGATTTACACCATGTGGAATGTCAGGCTAGCTAATTAAACAAATTA 23 4 0
GCAGTAGCAGAAATGCTGGTATTTATTGAGGCATTGAGACTGTACAACTGACACAGGTAT 2 4 O O
ATATTAATATTTATTGTTTCTTATTAGTCTATTTTTGGCATAGATGAAATTATGTTTTTC 2 4 6 O
CAGCCTGGAAGCTTCAGAGTGAGAAGGAGTAACTGTGGAAGTATTTCAAGAACAGAATTC 252 0
TCCACTCCCAGCTAAGAGAAAGGGTTGCTTGTTGAAAGGTGTGTACAGCAACACATGCTC 2 5 8O
TGGTTTTGAGAACAGGCTGACAGTGAGAAATGGGCTTTCAACACACACCATGTTTGCCTT 2 6 4 O
TTCCAAACTATGCTACTGTGTCTTTGAGGGGCCTGGGGAGATCTTTTCTCACTTGTTTTT 27 OO
poly(A) 2736
Fig. 1-7-1-1 b Complete nucleotide sequence of bovine StAR gene transcript
and amino acid sequence of StAR protein. The position of peptide StAR antigen is
indicated in the box (Adapted from Hartung et al, 1995).
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1.7.1.2 Distribution of StAR
The expression of StAR is predominantly restricted to organs that carry out
mitochondrial sterol hydroxylation reactions, which are under acute regulation by
tropic hormones. Immunoblotting and in situ hybridisation analysis demonstrated that
StAR protein was specifically expressed in the adrenal cortex, ovary and testis of
adult mice (Clark et al., 1995). Low levels of StAR transcripts in rat brain were
observed using RT-PCR (Furukawa et al., 1998) which is more sensitive than the
analysis by Northern blot analysis. StAR was also found expressed in porcine and
bovine placenta (Pilon et al., 1997). As summarised in Table 1.7.1.2, two StAR
mRNA species (1.6 and 3.5 kb) were found in rat adrenal and the amount of the
larger mRNA species was consistently much higher than that of the small size
(Ariyoshi et al., 1998). Two major transcripts (3.4 and 1.6 kb) and a minor one (2.7
kb) were revealed in MA-10 Leydig tumor cells (Clark et al., 1995). A major StAR
transcript of 1.6 kb and less abundant transcripts of 4.4 and 7.5 kb were detected in
human ovary and testis, but not in placenta or the urogenital system (Gradi et al.,
1995; Sugawara et al., 1995a). The StAR gene is transcribed as 3.0 and 1.8 kb in
bovine ovarian corpora lutea (Hartung et al., 1995), and a minor transcript (1.3 kb)
was observed later (Bao et al., 1998). The ovine StAR cDNA hybridised to a major
band (2.8 kb) and a minor band (1.6 kb) in ovine corpora lutea and in the adrenal
gland (Juengel et al., 1995). Two major transcripts of 1.7 and 2.7 kb of StAR was
detected in H295R cells (Clark and Combs, 1999).
Table 1-7-1-2 StAR transcripts in various species
Species and tissues Transcripts (kb) Reference
Rat adrenal
MA-10 cells





3.4, 1.6 and 2.7




(Ariyoshi et al., 1998)
(Clark et al., 1995)
(Sugawara et al., 1995).
(Hartung et al., 1995)
(Juengel et al., 1995)
(Clark and Combs, 1999)
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Apart from adrenal and gonadal glands, the presence of StAR protein in other organs
(e.g. kidney and placenta) appears variable among different species, which may be
due to species specificity. However, the possibility that this variation could be caused
by the sensitivity of detection methods employed can not be ruled out. More recently,
StAR transcripts were also found in lower vertebrates, for example in the ovary,
testis, kidney and brain of zebrafish (Bauer et al., 2000).
1.7.1.3 Various forms of StAR protein
StAR appears as a family of proteins. A set of four protein species in rat could be
produced from a core protein and combination of two different modifications (Epstein
and Orme-Johnson, 1991). The 2-D data show two sets of labelled protein (four of
28.5 kDa and four of 30 kDa) in terms of molecular mass and isoelectric points. The
set of smaller proteins 1-4 (pl=6.90, 6.59, 6.44, 6.33) exhibit a systematic relationship
to the larger proteins 5-8 (pl=7.05, 6.67, 6.53, 6.43). Each smaller protein has a pi
that is approximately a value of 0.1 lower than the corresponding larger proteins in
bovine ZG cells and similar results were obtained from bovine fasciculata cells (Elliott
et al., 1993, Elliott, 1997). Jefcoate's group also demonstrated that a set of eight
proteins were formed after modification in response to cAMP in the bovine adrenal
(Kim et al., 1997). StAR is synthesised as a 37 kDa precursor, imported into the
mitochondria, processed to its 30 kDa mature forms, and localised to the
intermembrane space (King et al., 1995).
1.7.1.4 Phosphorylation of StAR protein
StAR is a phosphorylated protein (Epstein and Orme-Johnson, 1991; Hartigan et al.,
1995), it contains three PKA/calmodulin-dependent kinase II and one PKC
phosphorylation sites. Two consensus sequences for phosphorylation by PKA are
conserved across all species in which StAR protein has been sequenced. Serine 195
(human StAR amino acid sequence) is important for biological activity of StAR
protein. Serine 277 exists in bovine, human and rat but not in mouse (Arakane et al.,
1997; Ariyoshi et al., 1998).
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1. 7.1.5 Up- and down-regulation of StAR protein
The expression of StAR protein is acutely up-regulated by trophic hormones. Besides
ACTH and Ang II, other trophic hormones such as luteinizing hormone (LH) also
elevated StAR mRNA and protein in bovine ovary (Ivell et al., 2000). LH and/or
growth hormone (GH) increased amounts of StAR mRNA in ovine corpora lutea
(Juengel et al., 1995). Follicle-stimulating hormone (FSH) increased StAR mRNA
levels in porcine granulosa cells (Balasubramanian et al., 1997; Pescador et al.,
1997). Both insulin and insulin-like growth factors enhanced the StAR gene
expression in bovine luteinized granulosa cells (Mamluk et al., 1999).
In contrast, a hormone such as prostaglandin F2„ (PGF2a), a luteolytic agent, caused
a decrease in StAR mRNA in human and ovine corpora lutea (Chung et al., 1998;
Juengel et al., 1995). PGF2a induced a rapid decline in progesterone production and
StAR protein expression in isolated rat corpus luteum without altering mRNA
expression (Fiedler et al., 1999). StAR protein gene transcription is decreased by
atrial natriuretic peptide (ANP) in bovine adrenal ZG cells (Cherradi et al., 1998b).
Tumour necrosis factor-a (TNFa) reduces porcine Leydig cell testosterone secretion
induced by LH/hCG (human chorigonadotropin) mainly through the inhibition of StAR
protein expression (Mauduit et al., 1998). Transforming growth factors-(3s (TGF-(3s)
decrease cholesterol supply to mitochondria via repression of StAR, which occurs at
the transcription level (Brand et al., 1998). The negative regulatory role of hormones
may be a balance mechanism, in contrast to the major positive agents such as
ACTH, LH and FSH, which controls overall endocrine functions of the adrenal and
the gonads.
1.7.1.6 Models of the mechanisms for StAR protein action
Although the precise mechanism of StAR's action in transferring cholesterol to the
inner mitochondrial membrane is not well understood, several models have been
proposed to reflect the possible machinery.
1) Model A: StAR import to mitochondria is obligatory for stimulation of
steroidogenesis (Stocco and Clark, 1996). The observation that StAR is localised
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to contact sites between the outer and inner mitochondrial membrane (Cherradi et
al., 1997) is likely to support the hypothesis for the mitochondrial import
mechanism of StAR protein.
2) Model B: StAR protein acts on the outside of mitochondria to stimulate
steroidogenesis (Arakane et al., 1998). This model was based on: NH2-terminal
deletion mutants of StAR had steroidogenic activity equivalent to wild-type StAR
although the mutants could not enter the mitochondria (Arakane et al., 1996) and
His-tag StAR lacking the mitochondrial targeting sequence stimulated
pregeneolone synthesis to the same extent as wild-type StAR. The C-terminal
region of StAR protein is extremely important in cholesterol transfer (Arakane et
al., 1998). The observation on the effect of wild-type StAR and several modified
forms of StAR on intramitochondrial cholesterol transfer also suggested that StAR
did not enter the mitochondria to facilitate cholesterol transfer (Wang et al., 1998).
Furthermore, the recombinant StAR protein expressed in COS-1 cells indicated
that StAR protein retained activity even without entry into the inner mitochondria
(Kallen et al., 1998b).
3) Model C: The translocation of cholesterol from the outer to inner mitochondrial
membrane is a putative transfer action, a process that involves probably several
mediators and particularly StAR protein, which may rely on the complex of StAR,
PBR, SAP and perhaps other as yet unidentified protein (Stocco, 1999). StAR
protein might act as a molecular ferry or it could activate a ferry system which
transports the cholesterol through PBR from the outer to inner mitochondrial
membrane (Thomson, 1998). Furthermore, StAR protein probably plays a role in
forming a channel for cholesterol entry by interacting with a protein on the outer
mitochondrial membrane (e.g. PBR). PBR is an absolute requirement for
determining the ability of uptake cholesterol, whereas StAR protein may offer a
continuous supply (Amri et al., 1998). More recently, the study on fluorescence
energy transfer between proteins using green fluorescent protein (GFP, donor
fluorophore) and yellow fluorescent protein (YFP, acceptor flourophore) has
demonstrated that StAR protein and PBR are associated in the process of
cholesterol delivery (West et al., 2001).
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4) Model D: The action of StAR protein is a transient and subtle process. It was
proposed that StAR is only active immediately after cleavage of the matrix
targeting sequence; StAR functions at very low concentrations, and the targeting
sequence of StAR facilitates this high affinity process through interactions within
the mitochondrial matrix (Artemenko et al., 2000).
5) Model E: Several recent studies have begun to shed light on the mechanisms of
the precise structure and function of StAR protein. The comparison between wild-
type and CAH mutant StAR structures indicates differences in protein folding. The
wild-type and a partially active mutant are predominantly a-helical with some
intramolecular (3-sheets. While, the inactive mutants that lost charged residues
retain much of their a-helical and tend to form intermolecular (3-sheet. This is
suggestive that mutant StAR proteins that cause lipoid CAH are probably due to
protein misfolding (Bose et al., 1998). The active form of StAR protein appears to
be a molten globule. The molten globule state would provide an efficient pathway
for minimising the energetic cost, a compact protein is therefore easily insert into a
membrane. StAR may undergo a conformational shift to an extended structure
that interacts with the outer mitochondrial membrane, permitting this molten
globule to act as an on/off switch (Bose et al., 1999).
6) Model F: StAR protein contains a StAR-related lipid transfer (START) domain
which is a 200-210 amino acid motif that appears to be a common feature for a
remarkably wide range of proteins involved in diverse functions such as lipid
transport and metabolism. The START domain structure is a predominantly
hydrophobic tunnel which is 26A x 12A x 11A in size extending almost the entire of
the protein and is likely to be large enough to hold a single cholesterol molecule
Both StAR and MLN64 START domains can bind 1 mole cholesterol per mole of
protein in vitro. This binding stoichiometry implies that StAR protein may act by
shuttling one cholesterol molecule at a time across the mitochondrial
intermembrane space (Ponting and Aravind, 1999; Tsujishita and Hurley, 2000).
The START domain suggests that Serine 195 does not play any part in the overall
conformational regulation nor a direct role in cholesterol binding, implying that
phosphorylation of this domain may involve the N-terminal mitochondrial targeting,
rather than the ability of binding cholesterol (Tsujishita and Hurley, 2000).
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1.7.1.7 Other possible functions of StAR protein
The actions of StAR protein are not only specific to steroidogenesis but also extend
to other mitochondrial cholesterol-metabolising enzymes. StAR protein increases the
formation of 3p-hydroxy-5-cholestenoic acid via stimulating mitochondrial cholesterol
27-hydroxylase activity in transfected COS-1 cells (Sugawara et al., 1995b). StAR
transcripts have been also found in the human kidney, in which StAR increases 1a-
hydroxylation of vitamin D in response to parathyroid hormone (Gradi et al., 1995;
Sugawara et al., 1995a). FSH-treated Sertoli cells contains immunoreactive StAR but
neither protein nor mRNA of CYP11A. This is suggestive that the function of StAR
protein is not providing cholesterol to CYP11 A-catalysed reaction and the possible
function is to enhance free fatty acid uptake into mitochondria (Gregory and DePhilip,
1998).
1.7.1.8 StAR-related protein
MLN64, a 50 kDa protein, is highly expressed in certain carcinomas and localised
within bundle-like structure which distributed throughout the cytoplasm and
condensed in a perinuclear patch. Its C terminus shares significant homology with
StAR protein and the F26F4.4 protein of Caenorhabditis elegans. This novel protein
domain was termed as StAR Homology Domain (SHD). MLN64 expressed in human
placenta and brain might play a similar role to StAR protein in promoting
steroidogenesis by virtue of its homology to StAR (Moog-Lutz et al., 1997; Watari et
al., 1997). Moreover, there is homology between StAR and members of the RhoGAP
family of GTPase activating protein (Arakane et al., 1998).
1.7.2 Transcriptional regulation of StAR gene
The transcription factor has emerged as an essential regulator of steroidogenic cell
functions in the adrenal and the gonads (Ikeda et al., 1994; Parker and Schimmer,
1996; Parker and Schimmer, 1997). StAR gene transcription is regulated by the
orphan nuclear receptor, steroidogenic factor 1 (SF-1), which is also termed adrenal
4-binding protein (Ad4BP). The promoter of genes regulated by SF-1 contains a
consensus, i. e. AGGTCA-derived motif (Bertherat, 1998). SF-1 is a global regulator
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within the hypothalamic-pituitary-adrenal and -gonadal axes (Parker and Schimmer,
1996).
Cloning and sequencing of SF-1 cDNA established that SF-1 is an orphan member of
the nuclear receptor family of ligand-inducible transcription factors (Morohashi et al.,
1992). Recently, certain oxysterols have been considered as SF-1 ligands that can
stimulate SF-1-dependent transcription (Lala et al., 1997). Transcriptional activation
of StAR gene by a SF-1-dependent mechanism may represent a common approach
for the actions of ACTH and Ang II in stimulating steroidogenesis (Clark and Combs,
1999). Moreover, SF-1 appears to be involved in cAMP regulation of transcription in
the adrenal cortex (Bertherat, 1998).
Secretory protein 1 (Sp1) is a widely expressed member of the zinc finger family of
transcription factors (Kadonaga et al., 1987). Several putative Sp1 binding sites have
been identified in the human StAR promoter, which may participate in regulation of
StAR gene (Sugawara et al., 1995b; Reinhart et al., 1999 ).
In contrast, a powerful repressor, DAX-1 (dosage-sensitive sex reversal adrenal
phoplasic congenita critical region on the X-chromosome, gene-1) was shown to
inhibit StAR gene expression by binding to a hairpin structure in a region of single-
stranded DNA found in the promoter region of the StAR gene (Zazopoulos et al.,
1997).
1.7.3 Translation regulation and post-translational modification of StAR protein
The activity of StAR can be increased by a co- or post-translational modification. The
findings by Arakane and co-worker demonstrate that serine 194/195, a potential site
of phosphorylation mediated by protein kinase A, is an important residue in StAR.
Phosphorylation of StAR may be part of the mechanism of the immediate increase in
steroid production following tropic hormonal stimulation (Arakane et al., 1997), a
process that is essential to maximising StAR activity (Kallen et al., 1998a).
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1.8 HYPOTHESIS AND GENERAL AIMS
The crucial role of StAR protein in steroidogenesis by various tissues is well
recognised (Stocco, 2000; Stocco and Clark, 1997). However, the mechanisms
controlling acute ACTH-induced Cortisol section by adrenal ZF cells have not yet
been clearly established, especially under physiologically relevant conditions which is
vital in elucidating the acute response to tropic hormones.
StAR protein may regulate the onset of the elevated steroidogenesis and the
maintenance of high level steroidogenesis through distinct mechanisms. The
initiation of steroidogenesis may be induced by pre-existing StAR via the post-
translation modification, whereas the maintenance of steroidogenesis relies on newly
synthesised StAR protein produced from mRNA translation. The signalling systems
mediating steroidogenesis at different levels of hormonal treatment are activated by a
more complicated mechanism (e.g. various signalling pathways and/or cross-talks
between intracellular signals).
This work has focused on the primary bovine adrenal ZF cells, an excellent in vitro
model for studying steroidogenesis, which addresses not only the questions of
StAR's function in hormonal-stimulated steroidogenesis but also the signalling
systems involved the activation of steroid production. The general aims were:
• To observe the expression of StAR protein in the absence and the presence of
various concentrations of ACTH.
• To determine the temporal relationships between StAR synthesis and steroid
production in response to trophic hormone (ACTH and Ang II) treatments.
• To compare the intracellular signalling systems of steroidogenesis activated by
physiological (1012 M) and pharmacological (10 8 M) concentrations of ACTH.
• To evaluate the role of protein kinase C in ACTH-induced steroidogenesis.
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CHAPTER 2 METHODS AND MATERIALS
2.1 MATERIAL SUPPLIES
2.1.1 Materials obtained from commercial sources
Chemicals, reagents and media from commercial sources were listed in Appendix I.
2.1.2 Materials from other sources
Bovine peptide StAR antigen and sheep anti-bovine peptide StAR antibody (primary
antibody) were produced for Prof. Ian Mason, Department of Clinical Biochemistry,
University of Edinburgh and Prof. Paul Stewart, Department of Medicine, University
of Birmingham by The Binding Site (P. O. BOX 4073, Birmingham B29 6AT, UK).
The StAR antigen was a 26-amino acid peptide (position 82-107 residues of StAR
protein), consisting of A-M-Q-R-A-L-G-l-L-K-D-Q-E-G-W-K-K-E-S-R-Q-A-N-G-D-E
(Hartung et al., 1995). The primary antibody was raised in sheep using this peptide
in a proprietary matrix.
Rabbit anti-mouse recombinant antibody raised against a GST-fusion protein (StAR
cDNA, bp 208-1467) was kindly supplied by Dr. Dale B. Hales, Department of
Physiology & Biophysics, University of Illinois at Chicago, USA (Clark et al., 1997;
LeHoux et al., 1999).
Bovine ovary and ovarian theca cells were kindly were kindly provided by Dr. Tony
Bramley (Centre for Reproductive Biology, University of Edinburgh) and Prof.
Richard Ivell (Institute for Hormone and Fertility Research, University of Hamburg,
Hamburg, Germany) respectively.
Rabbit anti-cAMP antibody (batch R1B7) was generously provided by Dr. Brent C
Williams, Department of Medicine, University of Edinburgh. [125l]-cAMP tracer was




2.2 CELL CULTURE MANIPULATION AND HORMONAL TREATMENT
REGIMES
2.2.1 Preparation ofprimary bovine adrenal ZF cells
i) Protocol 1: Isolation of adrenal ZF cells using collagenase digestion
Fresh bovine adrenal glands were collected from the local abattoir in Edinburgh
(January-May 1998) and the abattoir in Linlithgow, Scotland (June 1998-present).
Cattle (steers and heifers) were aged from 12 to 30 months. After being trimmed of
fat, the adrenal glands were kept in a beaker with sufficient sterile 0.2% (w/v)
BSA/EBSS. Approximately 100 pm slices of tissue were carefully cut using a
Staddle-Riggs Microtome. The first slice containing ZG cells and some ZF cells was
discarded. The second and third slices representing mainly ZF cells were collected
for isolation.
Tissue slices were minced with scissors in EBSS and repeatedly washed with the
same buffer until most of the red blood cells were removed and then digested using
2 mg/ml collagenase in 0.2% BSA/EBSS at 37°C for 2 hr with occasionally shaking.
The digestion mixture was filtered through a coarse-mesh nylon gauze (200 pm)
and a medium-mesh (100 pm), then centrifuged at 400 x g for 20 min. The cell
pellet was suspended in 0.2% BSA/EBSS, and the suspension was filtered by a
fine-mesh gauze (30 pm). Subsequently the suspension was loaded into a
Sephadex column (4 cm in height G-10 plus 0.5 cm in height G-50 on top). Cell
debris, blood cells and smaller ZR cells were washed off slowly with 0.2%
BSA/EBSS while the adrenal ZF cells were trapped by Sephadex G-10. Afterwards,
the trapped cells and Sephadex mixture were gently resuspended with the same
buffer and filtered through a fine-mesh gauze to trap the Sephadex. Finally, cells
were collected by centrifuging (400 x g, 30 min, room temperature) and
resuspended in the growth medium, consisting of Ham's F10 containing 10% (v/v)
process serum replacement-1 and 1% antibiotics (100 lU/ml penicillin, 100 pg/ml
streptomycin and 2.5 pg/ml amphotericin B).
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Cells were plated out at a density of 1.5 x 106 cells per well (35 mm in diameter, 6-
well-plate) and incubated at 37°C in 5% C02. The day of cell isolation is described
as Day 0.
ii) Protocol 2: Isolation of adrenal ZF cells using trypsin digestion
Bovine adrenal glands were sectioned as described in Protocol 1. The slices were
rinsed with warm (37°C) DMEM/F12 medium containing 1% antibiotics (see protocol
1), then transferred to the siliconised glass flasks (25 ml and 50 ml, Bello Glass,
Inc., NJ, USA or Wheaton Science Products, NJ, USA). The supernatant was
discarded after the tissue was slowly stirred with a siliconised glass rod plus a
paddle-shape accessory in 0.25% trypsin digestion solution for 15 min. This
procedure was repeated once. Then tissue was slowly stirred in 20-30 ml of warm
(37°C) digestion solution for about 30 min. The suspension was transferred to a
beaker and the slice remains were broken down with the end of a 5 ml pipette (the
end broken off). The digestion procedure was repeated once or possibly twice until
only connective tissue was left. The suspension was filtered with a coarse pan filter
and centrifuge at 400 x g for 20 min (room temperature). Each cell pellet was
washed in 5-10 ml of the growth medium. Finally, cells were resuspended and
plated out in a similar manner to collagenase-digested cells.
Hi) Maintenance of primary bovine zona fasciculata cells
On the day following isolation (Day 1), cells were washed with EBSS to remove
debris and unattached cells before addition of fresh growth medium. On Day 2 the
medium was replaced with Ham's F10 containing 0.2% BSA and 1% antibiotics, i.e.
serum-free medium.
2.2.2 Hormonal treatments
All experiments of bovine adrenal ZF cells were conducted using 6-well plate
(1.5x106 cells) and 3 ml medium.
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i) ACTH treatments on separate day of cell culture
Cells were treated with 10~8 M ACTH on each day respectively from Day 0 to Day 4.
At 6 hr and 24 hr time points, cells were gently scraped off from dishes in EBSS or
PBS, then the suspension was transferred to a 20 ml universal tube and spun at
600 x g for 10 min. The cell pellets were washed with EBSS or PBS, then stored at
-70°C.
ii) Concentration-response analyses
3-Day cultured cells were treated with various concentrations of ACTH ranging from
10~14 M to 10"7 M at 10 times intervals. At 1 and 6 hr, 0.5 ml of medium was
transferred to a glass tube for cAMP measurement (see details in Section 2.6.1)
and the remains were collected for Cortisol assay. Cells were harvested as
described in section 2.2.2.i.
Hi) ACTH and Ang II Time courses
3-Day cultured cells were treated with 10"8 M ACTH, 10~12 M ACTH, 10"8 M Ang II,
the combined Ang II and ACTH (1012 M) respectively. Cells and media were
collected at 0.5, 1, 2, 4, 6, 8, 12 and 24 hr.
iv) Inhibition experiments
4-Bromophenacyl bromide, nordihydroguaiaretic acid and indomethacin were
dissolved in absolute ethanol, then diluted to 0.05-0.1% (v/v) in the media.
Bisindolylmaleimide I (GF 109203X) in dimethyl sulphoxide (DMSO), then diluted to
0.05-0.1% (v/v) in the media. After being preincubated with various compounds for
15 or 60 min, cells were treated with 10~12 M or 10"8 M ACTH in the presence of
compounds. At 1 hr and 6 hr, after collecting media, cells were washed with EBSS
twice. 6-well plates were overlaid initially with liquid nitrogen and stored at -70°C.
This was an alternative method for harvesting cells, especially when larger number
of samples were involved.
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v) Phorbol ester treatment
Phorbol-12-myristate 13-acetate (PMA) was dissolved in DMSO and diluted to
0.05% (v/v) in the media. 3-Day cultured cells were treated with 10"8, 10"7 and 10~6 M
PMA respectively; and 10~8 M ACTH plus various concentrations of PMA. Cells and
media were collected at 6 and 24 hr.
2.3 PREPARATION OF PROTEIN SAMPLES
2.3.1 Protein preparation from tissues and cells
i) Total cellular extract from bovine adrenal tissue
Tissues were homogenised in the lysis buffer, i.e. PBS buffer containing 1%
deoxycholic acid (sodium salt) and 0.1% SDS (Naville et al., 1991). The volume of
the homogenising/lysis buffer containing protease inhibitors (in the ratio of 1:25)
was 5 times (v/w) of the tissue weight. Proteins were extracted by centrifuging at
800 x g for 10 min and subsequently centrifuging again at 10,000 x g for 15 min
(4°C). The protein concentration was estimated (Bradford, 1976, see details in
section 2.3.3). The protein samples were combined with the boiling mix in the ratio
of 2:1 (in volume). The boiling mix consisted of 1% SDS, 4% glycerol, 0.3%
mercaptoethanol and 0.7% saturated bromophenol blue solution. Finally, the
mixture was boiled for 2-5 min. After cooling to room temperature, the samples
were loaded on to gels or stored at -20°C.
ii) Preparation ofmitochondria-enriched fractions from bovine adrenal tissue
Tissues were homogenised in 5 times (v/w) TSE buffer (10 mM Tris, 25 M Sucrose,
and 0.1 mM EDTA, pH 7.4) with a glass tube and a Teflon pestle. Mitochondria-
enriched fractions were extracted by centrifuging at 600 x g for 30 min (4°C),
followed by centrifuging the resultant supernatant at 9000 x g for 30 min (4°C). The
mitochondrial pellet was solubilised in the lysis buffer.
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iii) Total cellular extract from primary BAC cells
Cells were homogenised in the lysis buffer using a Soniprep, e.g. 150-200 pi per
1.5 x 106 cells. Afterwards, other steps are the same as those of the total protein
preparation of the bovine adrenal cortex tissue.
iv) Preparation of mitochondria-enriched fraction from primary BAC cells
Fresh cell pellets were homogenised in TSE buffer (10 mM Tris, 0.25 M Sucrose
and 0.1 mM EDTA, pH 7.4). Mitochondrial protein was prepared using the same
procedure as those of the bovine adrenal tissue.
2.3.2 Crude subcellular fractionation
i) Homogenisation
Fresh bovine adrenal tissues (ZG, ZFR and medulla) were homogenised
respectively using a Teflon homogeniser in 5 times (v/w) TS buffer (5 mM Tris and
0.275 M Sucrose, pH 7.4).
ii) Nuclei extraction
The homogenate mixture was spun at 600 x g for 20 min (4°C), then supernatant
was transferred to a fresh tube and the nuclear pellet was washed with TS buffer.
After centrifugation, the pellet was solubilised in the lysis buffer.
iii) Mitochondrial -enriched extraction
The supernatant from the previous step was spun at 9000 x g for 30 min (4°C), then
this supernatant was transferred to special centrifuge tubes. The mitochondrial
pellet was washed with TS buffer and solubilised in lysis buffer.
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iv) Cytosol and microsome extraction
The supernatant from the previous step (iii) was centrifuged at 100,000 x g for 1 hr
(4°C) using an ultracentrifuge. This supernatant was considered a cytosol fraction
and the pellet was a microsomal fraction. Solubilisation of microsomes was
conducted as for the mitochondrial fraction.
2.3.3 Protein measurement by the Bradford assay
i) Working principle
The Bradford assay (Bradford, 1976) is based on the observation that Coomassie
Brilliant Blue G-250 exists in two different colour forms, red and blue. The red form
is converted to the blue form upon the binding of the dye to protein (Reisner et al.,
1975), which causes a shift in the absorption maximum of the dye from 465 to
595 nm. The signal can therefore be monitored as the protein-dye complex has a
high extinction coefficient thus leading to great sensitivity.
ii) Standards
Stock BSA (1000 mg/L in PBS buffer) was diluted in a 1:10 ratio with distilled water
to obtain 2ml of 100 mg/L standard, then this standard was diluted further to 20, 40,
60 and 80 mg/L. The protein dilution included 0, 20, 40, 60, 80 and 100 mg/L for
generating a standard curve.
iii) Bradford assay
The samples were diluted in an appropriate manner (for example 1:50 for cell
homogenate) with distilled water and vortexed before the assay. The standards
were used as the calibration curve to determine the unknown protein concentration.
The assay was carried out by using a Cobas Fara centrifugal analyser (Roche
Diagnostics, Welwyn Garden City, UK). Samples greater than 100 mg/L were
diluted in series with distilled water until they fell into the range of the standard




2.4.1 SDS-PAGE and protein transfer to membranes
SDS-PAGE is based on the method by Laemmli (Laemmli, 1970). One-dimensional
electrophoresis was performed in a 12.5% SDS gel (Table 2-4-1).




2 x Large gel (12.5%) 2 x mini-gel (12.5%)
Distilled water 17.00 3.40
1.0 M Tris/HCI, pH 8.85 30.00 6.00
30% Acrylamide plus 0.8%
Bis-acrylamide
32.00 6.40
10% SDS 0.80 0.16
TEMED 0.15 0.03
10% AMPS (daily fresh) 0.15 0.03
Stacking gel
Distilled water 32.00 6.40
0.375 M Tris/HCI, pH 6.8 20.00 4.00
30% Acrylamide plus 0.8%
Bis-acrylamide
7.20 1.44
10% SDS 0.60 0.12
TEMED 0.20 0.04
10% AMPS (daily fresh) 0.20 0.04
Note: The size of molecular mass marker vary among various batch products as the
controls for the measurement are different.
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The proteins were electrophoretically transferred on to Immobilon-P polyvinylidene
difluoride (PVDF) membrane which had been pre-wetted in methanol then
equilibrated in transfer buffer (25 mM Tris and 192 mM glycine). The transfer
conditions for 12.5% mini-gels were: 250 mA (constant) and 1.5-2 hr running time.
For 12.5% large gels, the conditions were 45-50 voltage (constant) and 4 hr.
Afterwards, the membranes were placed in PBS buffer containing 5-10% non-fat
milk or Pierce blocking buffer overnight at 4°C.
2.4.2 Enhanced chemiluminescence (ECL) detection
i) Working principle
ECL is a light emitting non-radioactive method for detection of immobilised specific
antigens (proteins of interest) which bond directly or indirectly with horseradish
peroxidase-labelled (or biotinylated) antibody (Fig. 2-4-2).
ECL is achieved by performing the oxidation of luminol by the horseradish
peroxidase in the presence of chemical enhancers. This has the effect of increasing
the light output approximately 1000 fold and extending the time of light emission
(ECL protocols provided by Amersham Life Science).
ii) Primary antibody incubation
After blocking overnight, the membrane was washed with PBS buffer containing
0.05% (v/v) Tween 20 on an orbital shaker at room temperature. The routine
washing procedure for ECL detection was of 5, 10, 15 and 15 min with fresh buffer
on each occasion. Subsequently, the membrane was incubated with the primary
antibody for 1 hr. The antibody was diluted in PBS or PBS/10% Pierce blocking
buffer containing 0.5-5% non-fat milk. The optimal dilution (e.g. 1:10,000 for StAR
peptide sheep antibody) and buffer composition were determined by testing various
combined conditions.
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Protein on PVDF membrane
Fig. 2-4-2 Schematic representation of the principle of
enhanced chemiluminescence (ECL) Western immunoblot Ab:




iii) Secondary antibody incubation
The membrane was washed with PBS buffer according to the routine washing
procedure. The excess primary antibody was removed completely. The secondary
antibody conjugated to horseradish peroxidase (HRP) was diluted and applied to
the membranes using the same procedures as those of the primary antibody (e.g.
1:100,000 for donkey anti-sheep/goat antibody). After 1 hr incubation, the
membrane was washed following the routinely procedure except that Tween 20 was
omitted from the last wash step.
iv) ECL Detection
ECL detection was carried out by following a protocol provided by Pierce Ltd:
SuperSignal West Dura Stable Peroxide Solution was equally mixed with West Dura
Luminol/Enhancer solution to sufficiently cover the membranes. The membranes
were incubated for 5 min at room temperature. After draining off excess detection
reagent, the membranes (protein side up) were placed on a piece of SaranWrap
and sealed with autoclave tape. The signal was firstly visualised by exposing the
membranes to X-OMAT LS film or X-OMAT film (more sensitive) for 1 min or
longer/shorter depending on the working conditions such as milk concentration and
dilution of antibodies. Afterwards, the wrapped membrane was exposed to a
chemiluminescence screen (Bio-Rad Image screen-CH) for 3-4 hr. In the first
instance, the screen (20 x 25 cm) was scanned (Bio-Rad, Model GS-525) at a
resolution of 800 pm. Regions of interest were marked manually and scanned at a
resolution of 200 or 100 pm to obtain a close up view of the image picture.
For the Amersham ECL kit, equal volumes of solution 1 and solution 2 were mixed
before use. The protein side of the membrane was incubated with the detection
reagent for 1 min at room temperature. Other procedures were the same as those
of Pierce ECL detection.
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2.5 CORTISOL MEASUREMENT BY RADIOIMMUNOASSAY ('IN HOUSE'
ASSAY)
2.5.1 Working Principle
Radioimmunoassay (RIA) is a competitive immunoassay in which the antigen
labelled with a radioisotope competes with the unlabelled antigen (known standards
or unknown samples) to bind to a specific antibody. After an appropriate reaction
time, antibody-bound and unbound labelled antigens are separated by double
antibody precipitation and centrifugation, or other techniques (Yalow, 1992).
2.5.2 Radioimmunoassay for Cortisol
i) Preparation of preprecipitate (PPT)
Firstly, a 1 ml vial of lyophilised sheep anti-cortisol primary antibody was
reconstituted with distilled water for 1 hr. Afterwards, the following components were
mixed in a universal tube and left in the refrigerator overnight: 650 pi sheep anti-
cortisol, 530 pi normal sheep serum, 15 ml Donkey anti-sheep/goat IgG secondary
antibody and 10 ml 0.1 M citrate buffer. On the following day, the mixture was
centrifuged at 230 x g for 15 min (4°C), then the pellet resuspended in 500 ml of
citrate buffer and stored in refrigerator.
ii) Standard Cortisol
Cortisol was dissolved in absolute ethanol to 10 mM and stored in -70°C. The stock
solution was diluted with Ham's F10 medium containing 0.2% BSA to obtain the
following standards: 0, 1,5, 10, 20, 50, 100, 200, 500, 1000, 2000 nM; and 8, 80
and 800 nM as controls (concentration known samples).
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iii) Working tracer solution
The stock tracer (10 pCi, 500 jal of methanol was added to 100 pi of cortisol-3-com-
(2-[125l] iodohistamine) was diluted with 0.1 M citrate buffer in the ratio of 1: 2800.
iv) Cortisol measurement
All reagents, standards and samples were warmed to room temperature. Samples
were centrifuged briefly to remove any debris if it was necessary and the
supernatant was retained for assay. Certain samples were required to be diluted
further before the RIA.
Each 100 pi o f standard or sample was added to 700 pi working solution of [125l]-
cortisol tracer in duplicate using an automatical diluter (HAMILTON, Switzerland),
then added 250 pi of PPT. The assay tubes were shaken on a multivortex an d
incubated at 37°C for 1.5-2.0 hr. After spinning for 30 min at 1200 x g (4°C) the
supernatant was discarded, then the tubes were blotted on wadding. The retained
[125l]-cortisol was counted for 2 min by Gamma Counter (LKB 1261 Multigamma,
Pharmacia, Turku, Finland) and Cortisol contents were determined against a
standard curve.
The intra-assay of coefficient of variation (%CV) was less than 10%. The inter-
assay %CV was less than 10% for the range from 50 nM to 2000 nM and 15% for
the range from 10 to 50 nM (Vanessa J. Cobb, 1999, PhD thesis. Department of
Clinical Biochemistry, University of Edinburgh).
2.6 cAMP MEASUREMENT BY RADIOIMMUNOASSAY ('IN HOUSE'
ASSAY)
2.6.1 Acetylation of samples
To increase the accuracy of measurement of low levels of cAMP, the medium
samples were required to be acetylated within 1 hour after collection. 500 pi of
medium was transferred to a glass tube and acidified to pH 5.0 by the addition of 5
pi of 20% (v/v) acetic acid prior to acetylation. Subsequently, 15 pi of the acetylation
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reagent (triethylamine and acetic anhydride in a ratio of 2:1 (v/v) was added to each
sample. All samples then were stored at -20°C prior to assay.
2.6.2 Radioimmunoassay for cAMP
i) Primary antibody
Rabbit anti-cAMP antibody (batch R1B7) was diluted 1:100 (v/v) in 50 mM sodium
acetate buffer, pH 5.0 (add 0.1% BSA prior to assay).
ii) Secondary antibody
20 ml of Donkey anti-rabbit serum was mixed with 1.5 ml normal rabbit serum in a
universal tube and left in the refrigerator overnight. On the next day the mixture was
spun at 230 x g for 15 min and resuspended in 80 ml of 0.05 M phosphate buffer.
Hi) Standards
Stock cAMP (10 mM in acetate buffer without BSA) was diluted with Ham's F10
medium containing 0.2% BSA to give 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32 nM
samples for a standard curve and 320 nM for blank (non-specific binding) plus 0.04,
0.08,0.16 and 1.6 nM for control. All standards were acetylated in glass tubes prior
to assay.
iv) cAMP measurement
50 pi of medium samples and standards were added in duplicate with 100 pi of 125I-
cAMP tracer (in acetate buffer containing 0.1% BSA, approximately 5000cpm), then
100 pi primary antibody (1:100 in the same buffer as the tracer). This mixture was
incubated overnight at 49C. On the next day, after the addition of 100 pi secondary
antibody, the tubes were vigorously shaken for 1 hr. Then, 1.5 ml of wash solution
(a small amount of microcrystalline cellulose plus 1.5 ml of BriJ detergent in 1 litre
of distilled water) was added to the tubes and centrifuged at 1200 x g for 30 min
(4°C). After discarding supernatant the tubes were blotted on wadding. The [125"l]-
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cAMP signal was counted for 6 min in the Gamma Counter and cAMP contents
were determined in duplicate against the standard curve.
The minimum detectable level was 0.33 nM and the intra-assay %CV was less than
10% over the working range of the assay.
2.7 DATA ANALYSIS
Unless otherwise stated, data presented in Chapter 4 were obtained from 3-4
independent experiments; data presented in Chapter 5 were obtained from an
experiment conducted in triplicate and the same experiment was repeated twice and
data in Chapter 6 (except PMA treatments) were obtained from an experiment
conducted in triplicate. Values were expressed as mean ± SEM. The mean values
were compared by analysis of variance (ANOVA), followed by Student-Newman-
Keuls (SNK) test. Non-normal distribution data were transformed by log 10 or
square root. A value of P<0.05 was considered as statistically significant, P<0.01
and P<0.001 were considered as highly significant. The analysis was performed by
using Minitab Version 12 (Minitab Inc., PA, USA) and GraphPad InStat Version 3.0
(GraphPad Spftware Inc., San Diego, CA, USA).
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CHAPTER 3 CHARACTERISATION OF A POLYCLONAL ANTIBODY
GENERATED AGAINST A PEPTIDE SEQUENCE OF BOVINE
STEROIDOGENIC ACUTE REGULATORY (StAR) PROTEIN
3.1 INTRODUCTION
StAR protein plays a crucial role in the regulation of steroidogenesis, facilitating the
translocation of cholesterol from the outer to the inner mitochondrial membrane
where CYP11A, the first enzyme of the steroid synthetic pathway, is located.
Western blot analysis using ECL or autoradiography is a basic method for
visualising proteins, which is extremely useful for the identification and the
quantitation of target protein in complex mixture of proteins. Reagents for detecting
StAR protein, reported to date, are summarised below:
Three distinct polyclonal primary antibodies directed against StAR protein have
been described in the literature. A rabbit anti-mouse peptide StAR antibody
produced by Dr. DM Stocco (Texas Tech University Health Science Center,
Lubbork, USA) has been used in a number of laboratories. This is an anti-peptide
antibody generated in rabbit against a peptide sequence (amino acid 88-98) of
mouse StAR protein (Clark et al, 1994; Pescador et al, 1996; Cherradi et al, 1997;
Ronen-Fuhrmann et al, 1998; Manna et al, 1998; LeHoux et al, 1998; Roy et al,
2000). The second one is a rabbit anti-human recombinant StAR antibody which
was obtained with a StAR protein from a cDNA encoding amino acid residues 63-
285. The localisation of StAR protein in human adult and fetal tissues was
established (Pollack et al, 1997) and the several forms of StAR protein under
different physicochemical conditions (e.g. pH and urea concentrations) were
observed using this anti-recombinant StAR antibody (Bose et al, 1999). In addition,
a rabbit anti-mouse recombinant StAR antibody was generated using a StAR-GST
(Schistosoma japonicum glutathione S-transferase) fusion protein from mouse StAR
cDNA fragment (position 208-1467 bp). This primary antibody was used for




Secondary antibodies conjugated with horseradish peroxidase (HRP) have been
used to visualise StAR protein-antibody complexes; donkey anti-rabbit IgG
conjugated with HRP (Clark et al, 1994; Pescador et al, 1996; Roy et al, 2000) and
goat anti-rabbit IgG conjugated with HRP (Bose et al, 1998; Ariyoshi et al, 1998). In
addition, radioisotopically-labelled secondary antibody such as [125l]-goat anti-rabbit
IgG was also used for immunocytochemical and immunoblot analysis of StAR
protein (Nishikawa et al, 1996; Nishikawa et al, 1997).
Several ECL detection kits are available for Western immunoblotting. The
Amersham ECL kit has been extensively used for the studies on StAR protein in
MA-10 Leydig tumour cells (Manna et al, 1998), the rat adrenal (LeHoux et al, 1999)
and the bovine adrenal ZFR (Roy et al, 2000). The Pierce SuperSignal, a relatively
new ECL kit, was employed to estimate StAR protein in rat ovarian luteal cells
(Sandhoff et al, 1998).
Because the primary antibodies described above were available in insufficient
amounts to complete this and other projects and no primary antibody against StAR
protein is yet available from a commercial source, it was necessary to generate a
sufficient supply of antibody for use in our laboratory. The sheep anti-bovine peptide
antibody, a novel antibody generated against bovine StAR protein amino acids 82-
107 has been explored in some detail. This strategy necessitated the
characterisation and development of methodology to establish optimisation of
detection conditions for this antibody. Thus, the purposes of this work described in
this chapter were:
• To optimise the experimental conditions (e.g. antibody dilution and detection
reagent) to obtain a strong signal with clean background for quantification of
immunoactive StAR protein band.
• To examine the antibody specificity using antigen competition test (validation test).
• To determine the subcellular distribution of StAR protein in bovine adrenal.
• To evaluate StAR protein in various bovine tissues.
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3.2 OPTIMISATION OF EXPERIMENTAL CONDITIONS FOR WESTERN
IMMUNOBLOT
3.2.1 Comparison of various Western immunoblot detection systems
i) Comparison between colour detection and Amersham-ECL (A-ECL) methods
Protein samples were prepared from tissues or cells and resolved on a 12.5% SDS-
PAGE gel. Subsequently, proteins were electrophoretically transferred from the
polyacrylamide gels on to polyvinylidene difluoride (PVDF) membranes.
StAR protein was initially detected using a colour development reagent (4-chloro-1-
naphthol in methanol mixed with H202 in Tris-buffered saline, pH 7.4). This
detection method, however, required a relatively high concentration of antibodies
(1,000-fold dilution for the primary antibody and 2,000-fold dilution for the secondary
antibody). A principal shortcoming was that the colour reaction did not provide a
permanent record. The peroxidase-stained bands on the membrane faded quickly
and the sensitivity of this detection was very low. Compared to colour detection, A-
ECL detection was quickly revealed to be more efficient in terms of the increased
antibody dilution, signal visibility and maintenance (Fig. 3-2-1 a ).
ii) Comparison between A-ECL and Pierce-ECL (P-ECL) detection systems
The chemiluminescence signal developed by A-ECL detection reagent was easily
visualised on X-OMAT film; however, it was too faint for quantification using the Bio-
Rad image analysis. As the wavelength of the light emission produced by a P-ECL
kit well matches with that of the chemiluminescence screen, the P-ECL detection
was therefore explored to establish a more robust approach for quantification. The
results obtained with a P-ECL kit demonstrated some major advantages compared
to the A-ECL kit (Fig. 3-2-1 a & b): The signal produced by the P-ECL reagent was
efficiently captured on the chemiluminescence screen and analysed by the Bio-Rad
image system, thereby making it possible to quantify protein bands after Western
blotting. The chemiluminescence signal is highly sensitive to both X-OMAT film and
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the Bio-Rad image system and is of long duration (lasts about 20 hr). Furthermore,
highly diluted amounts of both primary and secondary antibodies still generated a
strong signal with a clean background, e.g. a 1:100,000 dilution of the secondary
antibody remains effective (see details in Section 3.2.4).
3.2.2 Blocking buffer
The most appropriate blocking buffer for ECL Western immunoblot is dependent on
the detection system. Western blotting using PBS buffer containing 5% non-fat milk
presented strong protein bands with little background on the film (Fig. 3-2-1 a).
Western blotting using the Pierce blocking buffer resulted in sharp and intensive
signals with a clear background (Fig. 3-2-1 b). Both milk/PBS and Pierce blocking
buffers were suitable for the HRP-StAR protein detecting system. However, for
some detection systems such as secondary antibody conjugated with biotin, the
milk blocking buffer should be avoided because milk contains variable amounts of
biotin and other components which may cause non-specific binding.
3.2.3 Buffer for antibody dilution
Basically, two buffer systems were found to be useful for StAR protein Western
immunoblot, i.e. PBS buffer containing milk (Fig. 3-2-3a) and PBS/10% Pierce
blocking buffer containing milk (Fig. 3-2-3b). The milk concentration was varied
between 1% and 5% depending on specific requirements (Fig. 3-2-3c).
3.2.4 Antibody dilution optimisation
The initial work was conducted by using the Amersham ECL detection system.
However, as this reagent was not ideally suited for analysis on the Bio-Rad Image
Analyser, the working conditions were modified for P-ECL detection. Sheep anti-
bovine peptide antibody and donkey anti-sheep/goat IgG were diluted in various









Fig. 3-2-1 a StAR protein Western immunoblot using the Amersham-ECL
detection system. Lane 1: Total cellular extract of freshly isolated bovine adrenal
ZF cells (due to edge effect, the protein band appeared intensive); lane 2:
Mitochondrial-enriched fraction of freshly isolated bovine adrenal ZF cells. The
samples (25 fig of protein) were resolved on a 12.5% mini SDS-PAGE gel and
blotted on to a PVDF membrane. The membrane was blocked in 5% milk/PBS
buffer overnight. Sheep anti-bovine peptide antibody (1:5,000) and donkey anti-
sheep/goat antibody conjugated with PIRP (1: 75,000) were diluted in PBS buffer
containing 5% milk, then incubated with PVDF membrane for 1 hr respectively. The
membrane was washed with PBS buffer for 45 min before and after applying







Fig. 3-2-1 b StAR protein Western immnuoblot using the Pierce-ECL detection
system. Lane 1: Total cellular extract of freshly isolated bovine adrenal ZF cells;
lane 2: Mitochondrial-enriched fraction of freshly isolated bovine adrenal ZF cells.
The samples (25 pg of protein) were resolved on a 12.5% mini SDS-PAGE gel and
blotted on to a PVDF membrane. The membrane was blocked in 5% milk/PBS
buffer overnight. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-
sheep/goat antibody conjugated with HRP (1:100,000) were diluted in PBS buffer
containing 5% milk, then incubated with PVDF membrane for 1 hr respectively. The
membrane was washed with PBS buffer for 45 min before and after applying









Fig. 3-2-3a StAR protein Western immunoblot using 5% milk/PBS buffer for
blocking. Lane 1 and 3: Bovine adrenal cortex tissue; lane 2 and 4: Freshly isolated
bovine adrenal ZF cells. All samples (25 pg of total cellular protein) were resolved
on a 12.5% mini SDS-PAGE gel and blotted on to a PVDF membrane. The
membrane was blocked in PBS buffer containing 5% milk overnight. Sheep anti-
bovine peptide antibody (1:10,000) and donkey anti-sheep/goat antibody conjugated
with HRP (1:100,000) were diluted in PBS buffer containing 3% milk, then incubated
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Fig. 3-2-3b StAR protein Western immunoblot using the Pierce blocking buffer
for blocking. Lane 1: Bovine adrenal cortex tissue; lane 2 and 3: Freshly isolated
bovine adrenal ZF cells. All samples (25 pg of total cellular protein) were resolved
on a 12.5% mini-gel and blotted on to a PVDF membrane. The membrane was
blocked in Pierce blocking buffer overnight. Sheep anti-bovine peptide antibody (1:
10,000) and donkey anti-sheep/goat antibody conjugated with HRP (1:100,000)
were diluted in PBS/10% Pierce blocking buffer containing 3% milk, then incubated
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Fig. 3-2-3c A representative of Western immunoblot of comparison of milk
concentration for antibody dilution (Bio-Rad image print). Strip A: PBS buffer
containing 5% milk; Strip B: PBS buffer containing 3% milk; Strip C: PBS buffer
containing 1% milk. Lane 1 and 3: Bovine adrenal cortex tissue; lane 2 and 6:
Frozen supernatant of bovine adrenal cortex tissue; lane 4: Freshly isolated bovine
adrenal ZF cells; lane 5: Frozen supernatant of adrenal ZF cells (possibly sample
was partially degraded). All samples (25 gg of protein) were resolved on a 12.5%
large gel and blotted on to a PVDF membrane. The membrane was blocked in
Pierce blocking buffer overnight and was divided into three strips. Sheep anti-bovine
peptide antibody (1:10,000) and donkey anti-sheep/goat antibody conjugated with
HRP (1:100,000) were diluted in PBS buffer containing various concentrations of




Fig. 3-2-4 shows a representative experiment of the optimisation, indicating that a
ratio of 1:10,000 for primary antibody and 1:25,000-100,000 for secondary antibody
are suitable for detecting StAR protein.
In summary, optimal conditions were very closely associated with the particular
detection system used, i.e. detection reagent, blocking buffer and antibody dilution
buffer.
3.2.5 Homogenising buffer
Specific homogenising buffers were chosen based on the nature of the protein
fractions. The TSE buffer (10 mM Tris, 0.25 M Sucrose, and 0.1 mM EDTA, pH 7.4)
was suitable for the homogenisation of mitochondrial-enriched fraction differentiated
by centrifugation; while a PBS buffer containing 1% deoxycholic acid (sodium salt)
and 0.1% SDS produced a satisfying resolution for total cellular extract preparation
as 0.1% SDS dissolves all membrane proteins (Fig. 3-2-1 b). The TS buffer (5 mM
Tris-HCI, 0.275 M Sucrose, pH 7.4) was suitable for crude multiple fractionation
(See details in Section 3.5).
3.2.6 Alternative protocols for Western immunoblot
Because the combined buffer for antibody dilution (10% Pierce blocking containing
specific amounts of milk) was formulated in our laboratory, several protocols were
evaluated for observing StAR protein (Table 3-2-6). Protocol A was best suited for
the Bio-Rad image analysis (Fig. 3-2-6-A); however, Protocol B provided satisfying
profiles for both X-OMAT film and the Bio-Rad image analysis (Fig. 3-2-6-B); while
Protocol C was suitable for detecting low concentration protein and weak signals
(Fig. 3-2-6-C). The range of the various dilutions necessary in these protocols is























Fig. 3-2-4 StAR protein Western immunoblots-comparisons of various
antibody dilution. 1°: Dilution fold of sheep anti-bovine peptide antibody; 2°:
Dilution fold of donkey anti-sheep/goat antibody. All samples (25 pg of total cellular
protein from bovine adrenal cortex tissue) were resolved on two 12.5% mini SDS-
PAGE gels and blotted on two PVDF membranes. The membranes were blocked in
Pierce blocking buffer overnight, then divided into 6 strips. All strips were incubated
with the antibodies diluted with various folds in PBS/10% Pierce blocking buffer
containing 3% milk. Protein bands were finally visualised using a Pierce-ECL kit.
3-9
Chapter 3
Table 3-2-6 Alternative protocols for StAR peptide antibody and donkey anti-
sheep/goat HRP antibody
Protocol A B c
Dilution of anti-peptide antibody 10,000 10,000 7,500
Dilution of donkey anti-goat/sheep HRP antibody 100,000 25,000 10,000
Non-fat milk concentration (%) 0.5 2.0-3.0 1.0
3.3 QUANTIFICATION OF WESTERN IMMUNOBLOT
3.3.1 Quantification of StAR protein Western immunoblot
Fig. 3-3-1 a illustrates a StAR protein (lower bands) Western immunoblot captured
on the Bio-Rad CH screen. Fig. 3-3-1 b was plotted as volume counts (integrated
intensity) of the imaging signal versus various amounts of protein loaded on the gel.
The data demonstrate that the signal intensity linearly increases with the increment
of total protein amounts over a 5.0-40.0 gg range. The positive correlation (r=0.99,
P<0.001) between the volume counts of StAR protein and total protein
concentrations permits the use of this method for quantification of StAR protein.
3.3.2 Quantification of actin levels on Western immunoblot
To confirm the ability of quantification strategy described above for Western
blotting, the levels of actin (a 42 kDa protein expressed ubiquitously in cells) were
evaluated using the same method (Fig. 3-3-2a). Similar to StAR protein, there was
also a positive linear correlation (r=0.99, P<0.001) between the volume counts and
protein concentrations (Fig. 3-3-2b), indicating that this method fulfils the





A Bio-Rad image print
Fig. 3-2-6 StAR protein Western immunoblots using the protocol A, B and C.
All samples (25 pg for A and B; 10 pg for C) are total cellular protein from freshly
isolated bovine adrenal ZF cells. They were resolved on 12.5% large gels and
blotted on to PVDF membranes. The membrane was blocked in Pierce blocking
buffer overnight. Sheep anti-bovine peptide antibody and donkey anti-sheep/goat
antibody conjugated with HRP (see details in Table 3-2-6) were diluted in PBS/10%
Pierce blocking buffer containing various concentrations of milk (Table 3-2-6), then
incubated with PVDF membranes for 1 hr respectively. Protein bands were finally
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Fig. 3-3-1 a Western immunoblot of StAR protein in bovine adrenal ZF cells
(Bio-Rad image print). All samples are freshly isolated bovine adrenal ZF cells.
Total cellular proteins ranging from 5 to 40 pg were resolved on a 12.5% mini SDS-
PAGE gel and blotted on to a PVDF membrane. The membrane was blocked in
Pierce blocking buffer. Sheep anti-bovine peptide antibody (1:10,000) and donkey
anti-sheep/goat antibody conjugated with HRP (1:25,000) were diluted in PBS/10%
Pierce blocking buffer containing 2% milk, then incubated with PVDF membrane for
1 hr respectively. The membrane was washed with PBS for 45 min before and after
applying antibodies, and protein bands were finally visualised using a Pierce-ECL
kit.
Total protein (ug)
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Fig. 3-3-2a Western immunoblot of actin in bovine adrenal ZF cells. All samples
are freshly isolated bovine adrenal ZF cells. Total proteins ranging from 5 to 40 pg
were resolved on a 12.5% mini SDS-PAGE gel and blotted on to a PVDF
membrane. The membrane was blocked in Pierce blocking buffer overnight. Goat
anti-human peptide actin antibody (1:2,000) and donkey anti-sheep/goat antibody
conjugated with HRP (1:20,000) were diluted in PBS/10% Pierce blocking buffer
containing 2% milk, then incubated with PVDF membrane for 1 hr respectively. The
membrane was washed with PBS for 45 min before and after applying antibodies,












0 5 10 15 20 25 30 35 40 45
Total portein (ug)
Fig. 3-3-2b Dilution curve for actin of bovine adrenal ZF cells.
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3.4 VALIDATION OF ANTI-PEPTIDE StAR ANTIBODY SPECIFICITY BY
ANTIGEN COMPETITION TEST
In order to determine the antibody specificity (sheep antibody versus bovine StAR
protein), the effects of bovine antigen (26-amino acid peptide, see details in Section
2.1.2) on immunoblot signals were investigated by adding various amounts of
antigen to the primary antibody reaction buffer. Firstly (Group A), the peptide
antigen was diluted with PBS buffer at 100 times intervals (two orders of magnitude)
between 10"17 and 10"5 mg/L and two PVDF membranes were divided into eight
strips. Each one was incubated with the antibody reaction buffer containing a
separate concentration of antigen (one control strip without the antigen). The
observed protein bands (28-30 kDa and 37 kDa) were eliminated by addition of 10"5
mg/L antigen, while they appeared again when the antigen concentration was 10"7
mg/L and below (Fig. 3-4A). In a second experiment (Group B), the antigen
concentration was adjusted variously between 10~7 and 10"5 mg/L. The profound
difference was apparent between strips with 3 x 10~6 and 1 x 10"6 mg/L antigen, i.e.
3 x 10"6 mg/L antigen and beyond this amount resulted in no immunoreactive protein
bands. StAR protein bands presented when the antigen was equal to and below 1 x
10"6 mg/L (Fig. 3-4B). Therefore, for the third test (Group C), the dilution of antigen
was confined to a narrow range, which was between 1 x 10~6 and 3 x 10"6 mg/L.
StAR protein bands were abolished by 2.0 x 10"6 mg/L or higher concentrations of
antigen and were not affected by 1.5 x 10~6 mg/L or lower concentrations of antigen
(Fig. 3-4C). These neutralisation results are strongly suggestive that the sheep
antibody is specific to bovine StAR protein and recognises 28-30 kDa doublet StAR
protein and possibly a StAR-associated minor band.
3.5 SUBCELLULAR FRACTIONATION OF StAR PROTEIN
3.5.1 StAR protein in bovine adrenal cortex
Subcellular fractions including nuclei, mitochondria, microsomes and cytosol were
isolated from bovine adrenal ZG, ZFR and medulla respectively. The total
homogenate of bovine liver was used as negative control. The results showed that
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28-30 kDa protein bands existed in all the above adrenal cortex fractions, and these
bands were very intense in mitochondrial-enriched fractions from ZG and ZFR (Fig.
3-5-1). As the nuclei were isolated by crude fractionation, the protein bands in this
fraction may come from unbroken cells or other organelles. Apart from 28-30 kDa
protein bands, two other bands (approx. 37 and 50 kDa) also existed in cytosol
fraction, although the intensities of 28-30 kDa band were much decreased in the
cytosol compared to mitochondrial-enriched fractions.
3.5.2 StAR protein in bovine adrenal medulla
The bovine medulla fractions were analysed in parallel with bovine adrenal cortex
fractions. Unexpectedly, doublet bands (28-30 kDa) existed in medullary
mitochondrial-enriched fractions, which are identical to the bands observed in the
adrenal cortex (Fig. 3-5-1). The positive immunostaining of StAR protein has been
observed in medulla sections (Lo et al, 1998). While the medulla sample is
supposedly free from the contamination with the adrenal cortex, there may well be
islands or infiltration of cortical cells into the medulla. On the other hand, StAR
protein might play a role in medulla, which may be distinct to its role in adrenal
cortex and gonads. This latter issue was not taken forward in this study.
3.5.3 Confirmation of StAR protein in subcellular fractions
To confirm StAR protein in subcellular fractions, the mitochondrial-enriched fractions
(kindly prepared by the Dr. David Apps, Department of Biomedical Sciences,
University of Edinburgh) from the adrenal cortex ZG and ZFR were analysed by
Western blotting combined with neutralisation of peptide antigen. Three PVDF
membrane strips were incubated in 10,000-fold diluted primary antibody without
antigen (control) and with 10"7 mg/L and 10"5 mg/L antigen respectively. After
washing off excess primary antibody and antigen, all strips were incubated with
100,000-fold secondary antibody. Clearly, the Western immunoblot on addition of
105 mg/L antigen showed that the protein bands from all fractions disappeared,
while a Western immunoblot with 10"7 mg/L antigen revealed all the protein bands
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Fig. 3-4 Validation of sheep anti-bovine peptide StAR antibody- All samples (25
pg of total cellular protein from bovine cortex tissue) were resolved on 12.5% mini
SDS-PAGE gels and blotted on to PVDF membranes. Each membrane was divided
into four or five strips. Sheep anti-bovine peptide antibody (1:10,000) plus various
concentrations of antigen and donkey anti-sheep/goat antibody conjugated with
HRP (1:100,000) were diluted in PBS buffer containing 3% milk, then incubated with
strips for 1 hr respectively. The strips of each group were combined together prior to
the visualisation of StAR protein bands using a Pierce-ECL kit. Details of the
experimental conditions (antigen concentration mg/L) are listed below:
Group A Group B Group C
Strip no. Antigen Strip no. Antigen Strip no. Antigen
S1 Control S9 Control S17 3.0x10"6
S2 1.0x10"5 S10 1.0x10"5 S18 2.5x10"6
S3 1.0x10"7 S11 6.0x10"6 S19 2.0x10"6
S4 1.0x10"9 S12 3.0x10"6 S20 1.5x10"6
S5 1.0x10"11 S13 1.0x10"6 S21 1.0x10"6
S6 1.0x10"13 S14 6.0x10'7
S7 1.0x10"15 S15 3.0x10"7
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Fig. 3-5-1 StAR protein Western immunoblot of subcellular fractions of bovine
adrenal cortex and medulla. Lanes 1, 4, 7 and 10: ZG; lanes 2, 5, 8 and 11: ZFR;
lanes 3, 6, 9 and 12: medulla; lane 13: Negative control (bovine liver); lane 14:
Positive control (bovine adrenal cortex). All samples (25 pg protein) were resolved
on a 12.5% large SDS-PAGE gel and blotted to a PVDF membrane. Sheep anti-
bovine peptide antibody (1:10,000) and donkey anti-sheep/goat antibody conjugated
with HRP (1:100,000) were diluted in PBS buffer containing 3% milk. Protein bands
were finally visualised using a Pierce-ECL kit.
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Fig. 3-5-3 StAR protein Western immunoblots of mitochondrial-enriched
fractions of bovine adrenal tissues confirmed by antigen competition test.
Strip A: Control group without antigen; strip B: Sheep anti-bovine antibody mixed
with 1.0x10"5 mg/L peptide antigen; strip C: Sheep anti-bovine antibody mixed with
1.0x10"7 mg/L peptide antigen. Lanes 1, 3 and 5: Fractions of ZG; lanes 2, 4 and 6:
Fractions of ZFR. All samples (25 gg of total cellular protein) were resolved on a
12.5% mini SDS-PAGE gel and blotted on to a PVDF membrane. This membrane
was blocked in 5% milk/PBS buffer overnight, then divided into three strips. Sheep
anti-bovine peptide antibody (1:10,000) with or without different concentrations of
antigen and donkey anti-sheep/goat antibody conjugated with HRP (1:100,000)
were diluted in PBS buffer containing 3% milk, then incubated with strips for 1 hr
respectively. Protein bands were finally visualised using a Pierce-ECL kit.
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3.6 COMPARISON OF ANTI-PEPTIDE BOVINE StAR ANTIBODY AND
ANTI-RECOMBINANT MOUSE StAR ANTIBODY
Western immunoblot using the anti-peptide antibody produced very strong doublet
StAR bands (approx. 28-30 kDa) with some possibly StAR protein-associated bands
(approx. 34, 40 and 50 kDa) (Fig. 3-6-1 &2). Anti-recombinant StAR antibody only
revealed the doublet bands around 28-30 kDa, suggesting its specificity may be
better than that of peptide antibody (Fig. 3-6-3&4). However, it also gave a more
unsatisfactory background. Although the background might be reduced or removed
by purifying the antibody, the signal appeared not strong enough for analysis on the
Bio-Rad image system (Fig. 3-6-4). This would therefore pose a problem for
quantification of the low basal level of StAR protein in cultured untreated cells.
Moreover, our very limited supply of this polyclonal antibody also precluded any
further detailed study. Generally, the 28-30 kDa doublet bands of StAR protein
appeared only as a single band on mini SDS-PAGE gels due to the limited
resolution of the mini-gel.
3.7 DETECTION OF StAR PROTEIN IN BOVINE OVARY
StAR protein was also observed in bovine ovarian theca tissue and granulosa cells
in which StAR protein levels were much lower compared with those in the adrenal
cortex tissue and cells (Fig. 3-7-1). More importantly, StAR protein was revealed in
6-day cultured untreated bovine theca cells, but at an extremely low level. The
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Fig. 3-6-1 StAR protein Western immunoblot using anti-peptide StAR
antibody. Lane 1: Bovine liver tissue; lane 2 and 3: Bovine adrenal cortex tissue;
lane 4 and 5: Freshly isolated bovine adrenal ZF cells; lane 6: 3-Day cultured
adrenal ZF cells. All samples (25 pg of total cellular protein) were resolved on a
12.5% mini SDS-PAGE gel and blotted on to a PVDF membrane. The membrane
was blocked in Pierce blocking buffer overnight. Sheep anti-bovine peptide antibody
(1:10,000) and donkey anti-sheep/goat antibody conjugated with HRP (1:25,000)
were diluted in PBS/10% Pierce blocking buffer containing 2% milk, then incubated
with strips for 1 hr respectively. The membrane was washed with PBS for 45 min








Lane 1 2 3 4 5 6
Fig. 3-6-2 StAR protein Western immunoblot using anti-peptide StAR antibody
(Bio-Rad image print of Fig. 3-6-1).










Fig. 3-6-3 StAR protein Western immunoblot using anti-recombinant StAR
antibody. Lane 1: Bovine liver tissue; lane 2 and 3: Bovine adrenal cortex tissue;
lane 4 and 5: Freshly isolated bovine adrenal ZF cells; lane 6: 3-Day cultured
adrenal ZF cells. All samples (25 pg of total cellular protein) were resolved on a
12.5% mini SDS-PAGE gel and blotted on to a PVDF membrane. The membrane
was blocked in Pierce blocking buffer overnight. Rabbit anti-mouse recombinant
StAR antibody (1:5,000) and donkey anti-rabbit antibody conjugated with HRP
(1:25,000) were diluted in PBS/10% Pierce blocking buffer containing 1% milk, then
incubated with membrane for 1 hr respectively. The membrane was washed with
PBS buffer for 45 min before and 2 hr after applying antibodies. Protein bands were









Fig. 3-6-4 StAR protein Western immunoblot using anti-recombinant StAR
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Fig. 3-7-1 StAR protein Western immunoblot of various bovine tissues. Lane 1:
COS-1 cells (negative control); lane 2: Liver tissue (negative control); lane 3:
Ovarian theca tissue; lane 4: Ovarian granulosa cells; lane 5: adrenal cortex tissue
(positive control) and lane 6: Freshly isolated adrenal ZF cells. All samples (25 pg of
protein) were resolved on a 12.5% mini SDS-PAGE gel. Sheep anti-bovine peptide
antibody (1:7,500) and donkey anti-sheep/goat antibody conjugated with HRP
(1:10,000) were diluted in PBS/10% Pierce blocking buffer containing 1% milk.
B C - + - +- +- + +
0 1 2 4 6 12 Time (hr)
Fig. 3-7-2 StAR protein Western immunoblot in cultured bovine ovarian theca
cells in the absence and presence of 10 ng/ml LH. B: Adrenal cortex tissue
(positive control); C: Zero time point untreated cells. All samples (15 pg of sample B
and 25 pg of all others) were resolved on a 12.5% large SDS-PAGE gel. Sheep
anti-bovine peptide antibody (1:7,5000) and donkey anti-sheep/goat antibody





The optimisation of the Western immunoblot methodology was taken through four
stages. Firstly, the evaluation of colour detection indicated that this method was
impractical for quantification due to transient and insensitive signals. Secondly, the
Amersham ECL kit was employed, which worked well for X-OMAT film. However,
the signal produced by this reagent was very poorly detected by the Bio-Rad image
analysis system, i.e. too weak for quantification. This was probably because the
wavelength of light emission did not exactly match with the sensitive range of the
chemiluminescence screen. Although there are some other analyses for Western
immunoblot quantification, the Bio-Rad image system is the one currently available
in our laboratory. Therefore, the utility of another ECL product made by Pierce Ltd.
was explored and found to be of value in obtaining quantitative results.
The working conditions of Western immunoblot using the Pierce ECL kit were
optimised and they were suitable for both X-OMAT and Bio-Rad image system.
However, the ideal conditions (particularly the antibody dilution buffer) for X-OMAT
film were not consistent with those of Bio-Rad image system. Thus, the conditions
were further modified to meet the requirement for accurate quantification. The
signals were intensified again in a combined PBS/10% Pierce blocking buffer for
antibody dilution, permitting the quantification of weak signals produced by
conventional Western blotting. Pierce blocking buffer appears to have at least two
functions: blocking the non-specific banding and enhancing the signal (presumably
the enhancing principle of this buffer is different from that of ECL detection reagent).
The strong positive correlation between the volume counts (integrated signal
intensity) and protein concentration demonstrated that newly established method
was linear, reproducible and sensitive for quantification of StAR protein.
In fact, sometimes working conditions needed to be re-evaluated when a new batch
of reagent was used as there were subtle variations among different batches
products (the reason remains unknown and unresolved as the P-ECL kit is a
patented product). The recommended starting point for StAR protein Western
immunoblot are 10,000-fold dilution for primary antibody and 100,000-fold for
secondary antibody dilution in 3% milk PBS buffer or 10% Pierce blocking buffer, in
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general, an appropriate detection system can be established empirically for the
proteins of interest.
The optimisation of Western immunoblot conditions has provided an efficient
approach to observe and quantify StAR protein. Importantly, the validation data for
the primary antibody demonstrated the specificity of the sheep anti-bovine peptide
StAR antibody. Western immunoblot of subcellular fractions also proved that mature
StAR protein predominated in mitochondrial-enriched fractions. Moreover, this
detection method allowed visualisation of StAR protein in bovine ovarian theca and
granulosa cells that expressed StAR protein at very low levels. These are
suggestive that sheep anti-bovine peptide StAR antibody as a primary antibody is
well suitable for Western immunoblot analysis.
Western immunoblot of large SDS-PAGE gels demonstrate clear doublet bands of
StAR band at 28-30 kDa (appear as a single band in a mini-gel), which is consistent
with previous work on bovine adrenal ZF cells (Nishikawa et al, 1996) and ZG cells
(Cherradi et al, 1997). The doublet may represent the protein species derived from
one core protein with different cleavage or phosphorylation proteins. This requires to
be clarified by 2-D electrophoresis. A band closed to the 39.5 kDa marker was
demonstrable and neutralised by peptide antigen competition, suggesting that it
may be the precursor form of StAR protein. However, it did not appear using anti-
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Steroidogenesis is positively or negatively regulated by a number of agents. It is well
established that ACTH has an important role in the regulation of steroid production in
adrenal zona fasciculata cells. The actions of ACTH can be divided into two phases
on a temporal basis. Acute (short-term) responses occur within seconds to minutes
and chronic (long-term) responses require hours/days. The acute effect is to mobilise
and deliver cholesterol, the precursor of all steroid hormones, to the mitochondrial
inner membrane. On the other hand, the chronic effect involves regulation in
transcription of genes that encode steroidogenic enzymes, maintaining optimal
glucocorticoid productive capacity (Jefcoate et al., 1987; Simpson and Waterman,
1988). The chronic effects may involve changes in the levels of CYP11A, CYP11B1,
CYP17, CYP21B and 3(3-HSD.
The primary event of acute ACTH action is an intramitochondrial step to translocate
cholesterol. Early studies established that a labile protein appeared to facilitate the
translocation of cholesterol to the inner mitochondrial membrane where the first
enzymic reaction of steroid synthesis occurs (Stone and Hechter, 1954). After several
decades of investigation, StAR protein has been recognised as a most promising
candidate to fulfil this task. The essential role of StAR in adrenal steroidogenesis has
been exemplified by studies of StAR-null mice and humans with a dysfunctional StAR
gene, which demonstrated that the substantial decrease in the conversion of
cholesterol to pregnenolone was clearly associated with dysfunctional StAR protein
(Kallen et al., 1998a). Both biochemical and genetic findings are indicative that StAR
is a key regulator in controlling cholesterol transfer in the adrenal cortex.
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4.1.2 Angiotensin ll-regulated steroidogenesis
Angiotensin II (Ang II) is another major hormonal regulator of steroid synthesis in the
adrenal glands. The principal function of Ang II on steroidogenesis is
mineralocorticoid production in adrenal ZG through IP3 and Ca2+ signalling pathway
(Rossier, 1997).
In some species Ang II also stimulates Cortisol production in the adrenal ZF. In bovine
adrenal ZF cells, Ang ll-induced Cortisol secretion may be mediated by
depolarization-dependent Ca2+ entry and through inhibition of a novel potassium
channel (lAc)- The mechanism for this steroidogenesis is distinct from that involving
IP3-triggerred Ca2+ release from intracellular stores (Mlinar et al., 1995). Other
evidence has demonstrated that Ang II is able to stimulate cAMP formation in a
concentration and time-dependent manner with a significant increase at 10"9 M Ang II
and a maximal response at 10"7 M Ang II. A subtype of the Ang II receptor is
responsible for stimulating cAMP production and steroidogenesis in bovine adrenal
ZF cells (Rainey et al., 1991). Furthermore, Ang II significantly augments the cAMP
levels induced by ACTH. Potentiation of ACTH-induced cAMP production by Ang II
was also observed in COS-7 cells which were transiently expressing the AT1a
receptor, indicating that this combined effect of Ang II and ACTH on the increase in
cAMP formation may be a more general biochemical process (Baukal et al., 1994).
The parallel time courses of StAR protein and aldosterone production were indicative
that Ang II (10"8 M)-induced steroid synthesis was correlated with the increase in the
expression of StAR protein in a temporally co-ordinated manner in H295R human
adrenocortical carcinoma cells (Clark et al., 1995b). On the other hand, the question
of whether Ang ll-induced steroidogenesis is regulated by StAR protein in bovine ZF
cells has not been addressed.
4.1.3 Aims of this study
Although ACTH-induced steroidogenesis in bovine ZF cells has been extensively
studied in vitro, most attention has focused on the effects of pharmacological
concentrations of ACTH and the more chronic response. The regulation of
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steroidogenesis acutely and at concentrations of ACTH that are profoundly important
in terms of physiological implications has yet to be more clearly defined.
The purposes of this study were:
• To obtain information on the abundance of StAR protein in the absence and
presence of ACTH (10~8 M) over a five-day cell culture period.
• To determine an appropriate treatment starting time and effector concentrations for
the further study of StAR protein expression, steroidogenesis and signalling
pathways.
• To establish the cell responsiveness to various concentrations of ACTH in both
acute and chronic phases with respect to the temporal relationship of StAR protein,
Cortisol secretion and cAMP production.
• To evaluate the integrative effects of ACTH and Ang II on StAR protein and Cortisol
levels in bovine adrenal ZF cells.
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4.2 CHANGES OF StAR PROTEIN LEVELS WITH ACTH TREATMENT ON
DIFFERENT DAYS OF CULTURE
The effect of 6 and 24 hr ACTH (10 8 M) treatment schedules on StAR protein levels
after a culture period of 0-4 days as demonstrated on a Western immunoblot is
shown in Fig. 4-2-1 a. After quantification these data are shown in Fig. 4-2-1 b, the
open columns indicate the abundance of StAR in untreated cells, demonstrating the
initial level declining to a stable lower level after two days of culture, whereas the solid
columns showed treated cells in response to ACTH (108 M). The levels of StAR
protein were high at 6 hr on Day 0 in both untreated and treated cells and distinct
from the basal levels after ACTH treatment at 6 hr on Day 2 and Day 3 of culture.
Fig. 4-2-2 illustrates that the levels of StAR protein increased with respect to the
basal at 6 hr in the presence of 10"8M ACTH from Day 0 to Day 4. In general, the cell
responsiveness to ACTH at 6 hr was greater than that at 24 hr. StAR protein showed
a marked change (5.1 ± 1.8 fold, P<0.05) after 6 hr treatment on Day 2 and Day 3
(3.9 + 1.3 fold, P<0.05).
According to these observations, cells on both Day 2 and Day 3 were clearly
responsive to ACTH treatment, i.e. the culture periods were best suited for
subsequent experiments. As cells need to be serum-deprived overnight in order to
minimise the interference of serum components on Cortisol secretion, this work was
conducted by initiating cell treatment on Day 3 of culture.
4.3 CONCENTRATION RESPONSE CURVES OF StAR PROTEIN
LEVELS, CORTISOL SECRETION AND cAMP PRODUCTION
To evaluate the effect of various concentrations of ACTH on the expression of StAR
protein, Cortisol secretion and cAMP formation, cells were treated with 10"14 to 10"7 M
ACTH starting on Day 3 of culture. The media and cells were collected after 1 and
6 hr treatments in this study.
Fig 4-3-1 a&b show the levels of StAR protein established by Western immunoblot in
response to various concentrations of ACTH. At 1 hr StAR protein levels were
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Fig. 4-2-1 a Western immunoblot of StAR protein in response to ACTH
treatment DO: Day 0; D1: Day 1; D2: Day 2; D3: Day 3 and D4: Day4. Cells were
treated with and without ACTH (10"8 M) independently on each day and harvested
after 6 and 24 hr culture. All samples (25 pg protein) were resolved on a 12.5%
large SDS-PAGE gel and blotted on to a PVDF membrane. Sheep anti-bovine
peptide antibody (1:10,000) and donkey anti-sheep/goat antibody conjugated with




Fig. 4-2-1 b StAR protein levels in response to ACTH treatment. Cells were
treated with ACTH (10 8 M) on each day and collected at 6 and 24 hr time points.
StAR protein bands were quantified using Bio-Rad image analysis. A representative
single experiment is shown.
*
Fig. 4-2-2 Changes of StAR protein levels in response to ACTH treatment.
Cells were treated with and without ACTH (10 s M) on each day independently and
collected at 6 and 24 hr time points. StAR protein bands were quantified using Bio-
Rad image analysis. Values from four experiments are expressed as mean ± SEM
(treated over untreated value at each time point), n=4. Data were tested by ANOVA,
followed by Dunnett multiple comparison (*P<0.05).
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increased with the incremental ACTH concentrations, starting from 10"12 M ACTH
and attaining to high levels at 10"10 -10"7 M ACTH.
In addition, after 6 hr ACTH (1010-10"8 M) treatment, a minor band appeared with a
size about 34 kDa. This may represent a newly synthesised precursor of StAR
protein; it appeared to have a unstable character.
Fig. 4-3-2 demonstrated that after 1 and 6 hr of treatment Cortisol levels were
remarkably elevated when cells were treated with 10"12 M ACTH compared with 10"14
and 10"13 M ACTH. Further increases occurred at 10"11 M ACTH, plateauing at 10"10-
10"8 M ACTH.
As shown in Fig. 4-3-3, the changes in cAMP were hardly detectable at 10"14-10"12 M
ACTH but elevated at 10'11 M ACTH and reached maximal levels at 10~9-10~7 M
ACTH at both 1 and 6 hr. The detailed changes of all above treatments are
summarised in Table 4.3.
Table 4.3 A representative concentration response experiment performed in
triplicate. Values are expressed as fold increase (mean ± SEM)
Incubation 1 hr 6 hr
[ACTH] StAR Cortisol cAMP StAR Cortisol cAMP
10"14M 1.1 ±0.2 0.9 ±0.2 0.9 ±0.1 1.0 ±0.2 1.1 ±0.1 0.6 ±0.1
10"13 M 1.1 ±0.3 1.2 ± 0.1 0.8 ±0.1 1.2 ±0.2 1.2 ± 0.1 0.6 ±0.03
10"12 M 1.2 ± 0.1 17.2 ±0.4 1.4 ± 0.1 1.5 ±0.3 12.6 ±0.7 1.6 ±0.1
10"11 M 1.4 ±0.2 38.3 ±3.3 50.1 ±6.9 2.7 ±0.5 50.7 ±2.8 339.7±29.0
10"1° M 1.2 ±0.2 38.2 ± 1.2 233.9±11.4 3.8 ±0.8 89.1 ±4.6 347.7±34.5
10'9 M 1.2 ±0.2 39.1 ±2.5 275.5±8.2 3.9 ±0.7 84.8 ±3.8 501.5±3.7
10"8 M 1.2 ±0.2 66.9 ± 1.9 348.3±13.3 3.6 ±0.4 106.1 ±3.3 560.9±32.5














Lane 1 23 4 56 78 9 10 11
Fig. 4-3-1 a Western immunoblot of StAR protein in response to various
concentrations of ACTH at 1 hr (upper panel) and at 6 hr (lower panel). Lane 1
and 7: Zero time point control; Lane 2: 1 hr or 6 hr untreated cells; Lane 3: ACTH
(10"14 M) treated cells; Lane 4: ACTH (10"13 M) treated cells; Lane 5: ACTH (10"12
M)treated cells; Lane 6: ACTH (10"11 M) treated cells; Lane 8: ACTH (10"1° M)
treated cells; Lane 9: ACTH (10"9 M) treated cells; Lane 10: ACTH (10"8 M) treated
cells; Lane 11: ACTH (10-7 M) treated cells. Samples (25 pg protein) were resolved
on two 12.5% large SDS-PAGE gels. Sheep anti-bovine peptide antibody (1:10,000)
and donkey anti-sheep/goat antibody conjugated with HRP (1: 25,000) were diluted
in PBS/10% Pierce blocking buffer containing 2% milk.
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Fig. 4-3-1 b Concentration response curves for StAR protein in response to
various concentrations of ACTH. Cells were treated with ACTH ranging from 10"14
M to 10"7 M and collected for Western blotting after 1 hr and 6 hr treatment. Values
are expressed as fold increase over the basal level (mean ± SEM), n=3. An
experiment conducted in triplicate is shown.
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Fig. 4-3-2 Concentration response curves for Cortisol levels in response to
various concentrations of ACTH. Cells were treated with ACTH ranging from 10"14
M to 10~7 M and the media were collected for Cortisol after 1 hr and 6 hr treatment.
Values are expressed as fold increase over the basal level (mean ± SEM), n=3.
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Fig. 4-3-3 Concentration response curves for cAMP levels in response to
various concentrations of ACTH. Cells were treated with ACTH ranging from 10"14
M to 10"7 M and the media were collected for cAMP assay after 1 hr and 6 hr
treatments. Values are expressed as fold increase over the basal level (mean ±
SEM), n=3. Data were obtained from the same experiment as Fig. 4-3-1 b.
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At 1 hr the changes of StAR protein were poorly correlated with the elevated Cortisol
level (r=0.14, P>0.05; Fig. 4-3-4a). However, at 6 hr the StAR protein level was
strongly correlated with the Cortisol levels (r=0.76, p<0.0001; Fig. 4-3-4b).
There was no correlation between the increase of StAR protein versus cAMP at 1 hr
(r=0.16, P>0.05; Fig. 4-3-4c). In contrast, the changes of StAR protein were closely
correlated with the cAMP levels at 6 hr (r=0.77, P<0.0001; Fig. 4-3-4d).
The Cortisol levels were tightly coupled to the elevation of cAMP at both 1 hr
(r=0.82, p<0.0001; Fig. 4-3-4e) and 6 hr (r=0.91, P<0.0001; Fig. 4-3-4f).
The effects of ACTH on the expression of StAR protein and Cortisol secretion were
time- and concentration-dependent over the range of 10 14-107 M ACTH. The profile
of changes in StAR protein at 6 hr were different from that at 1 hr. In the acute phase
(1 hr), although cAMP levels were rapidly increased, the levels of StAR protein were
not significant, this may be due to the delayed newly synthesised protein from StAR
mRNA. At relatively chronic phase (6 hr) the Cortisol levels were dramatically elevated
with more expression of StAR protein at 10~11-10"7 M ACTH, in parallel with the
increase in cAMP production. The profiles for Cortisol and cAMP concentration
response curves ranging from 10 11-107 M ACTH were very similar to those at both 1
and 6 hr, suggesting that cAMP was a major second messenger.
On the basis of the concentration response experiment, 10"8 M ACTH was selected
as representative of high concentration (pharmacological or supraphysiological
level) and 10"12 M ACTH as representative of lower, perhaps a more physiological
concentration for treatments.
4.4 EFFECTS OF HIGH-CONCENTRATION ACTH (10 8 M) TREATMENT
ON THE LEVELS OF StAR PROTEIN, CORTISOL AND cAMP
To understand further the relationship between the expression of StAR protein and
steroidogenesis the effects of high-concentration ACTH treatment were evaluated in
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Fig. 4-3-4a Correlation between the levels of StAR protein and Cortisol for
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Fig. 4-3-4c Correlation between levels of StAR protein and cAMP for
concentration (1014 -10"7 M ACTH) response curve at 1 hr.
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Fig. 4-3-4d Correlation between levels of StAR protein and cAMP for
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Fig. 4-3-4e Correlation between levels of cAMP and Cortisol for concentration
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Fig. 4-3-4f Correlation between levels of cAMP and Cortisol for concentration
(1014 -10 7 M ACTH) response curve at 6 hr.
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cAMP in response to ACTH (10~8 M) were established in a 0.5-24 hr time course
including acute, intermediate and chronic phases.
Fig 4-4-1 a shows a Western immunoblot for a high-concentration ACTH time course.
StAR protein significantly increased at 4 hr (3.9 ± 1.1 fold) and was maintained above
the basal levels until 12 hr. The changes of StAR protein at 4, 6 and 8 hr were
significantly different from those at 0.5, 1,2 12 and 24 hr (P<0.05), and values at 2
and 4 hr were ambiguous between low and high levels (Fig. 4-4-1 b).
Cortisol output increased dramatically at 1 hr and reached a peak (144.0 ± 36.6 fold)
at 4 hr and declined after 12 hr incubation. The level of Cortisol at 0.5 hr was
significantly different from that at 24 hr (P<0.05) and also 2, 4, 6, 8 and 12 hr
(P<0.001 for 0.5 hr versus four time points respectively). The level of Cortisol at 1 hr
was different from that at 0.5, 2, 4, 6, 8 hr (P<0.05 for 1 hr versus five time points
respectively). There was no marked changes among the levels at 2, 4, 6 and 8 hr
(Fig. 4-4-2).
The level of cAMP production at 0.5 hr was different from those at 1 hr (P<0.05), 2
hr (P<0.01), 4, 6 8, 12 and 24 hr (P<0.001); the level at 1 hr was different from
those levels at 4, 6, 8, 12 and 24 hr (P<0.001); and the level at 4 hr was different
from that at 6 hr (P<0.05), but not those at 8, 12 and 24 hr (Fig. 4-4-3).
High-concentration ACTH treatment resulted in a strongly correlated relationship
between the expression of StAR protein and the production of Cortisol (r=0.81,
P<0.0001; Fig. 4-4-4), indicating that StAR protein may be a key factor for
regulation of steroidogenesis.
4.5 EFFECTS OF LOW-CONCENTRATION ACTH (1012 M) TREATMENT
ON THE LEVELS OF StAR PROTEIN, CORTISOL AND cAMP
To evaluate the expression of StAR, Cortisol secretion and cAMP production in
response to ACTH (1012 M), i. e. a concentration within the physiologic range, cells
were treated over the same time course as that used for high-concentration ACTH
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Fig. 4-4-1 a Western immunoblot of StAR protein after high-concentration
ACTH treatment. Untreated cells;ACTH (10"8M) treated cells; C: Zero time
point cells for control. All samples (25 pg protein) were resolved on a 12.5 % SDS-
PAGE gel. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-
sheep/goat antibody conjugated with HRP (1:25,000) were diluted in PBS/10%
















Fig.4-4-1b Changes of StAR protein levels for high-concentration ACTH time
course. Cells were treated with ACTH (10 s M) and ceils were harvested at various
time points. Values from three independent experiments are expressed as fold
increase over the corresponding basal level (mean ± SEM), n=3. Columns without
























Fig. 4-4-2 Changes of Cortisol output for high concentration ACTH time
course. Cells were treated with or without ACTH (10 s M) and the media were
collected at various time points. Values from three independent experiments (two of
them conducted in duplicate and one single treatment) are expressed as fold
increase over the basal level (Mean ± SEM), n=5. Columns without the same
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Fig. 4-4-3 Changes of cAMP levels for high-concentration ACTH time course.
Cells were treated with ACTH (10 s M) and the media were collected for cAMP
assay at various time points. Values are expressed as fold increase over the
corresponding basal level (mean ± SEM), n=3. Columns without the same
superscript(s) were significantly different.
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Fig. 4-4-4 Correlation between the changes of StAR protein and the Cortisol
levels for high-concentration ACTH time course.
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Fig. 4-5-1 a&b shows the levels of StAR protein in response to 10"12 M ACTH. The
level at 6 hr was significantly different from those at 1, 2 and 12 (P<0.01), and 0.5, 4
and 24 hr (P<0.05).
Treatment with 10~12 M ACTH led to a maximal increase of Cortisol at 2 hr and the
Cortisol level gradually declined thereafter (Fig. 4-5-2). The Cortisol level at 2 hr was
markedly different from the levels at 6, 8 and 12 (P<0.05), 0.5 hr (P<0.01) and 24 hr
(p<0.001). Table 4-5 shows the details of the multiple comparisons of each level with
others.
The changes of cAMP were extremely small across all time points; there was no
notable difference among various time points (Fig. 4-5-3).
In contrast to high-concentration ACTH treatment, the changes of StAR protein
were poorly correlated with Cortisol levels (r=0.04, P>0.05; Fig 4-5-4).
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Table 4-5 Multiple comparisons test for 10"12 M ACTH-induced Cortisol levels
Comparison P value
0.5 hr vs 1 hr NS
0.5 hr vs 2 hr P<0.01
0.5 hr vs 4 hr NS
0.5 hr vs 6 hr NS
0.5 hr vs 8 hr NS
0.5 hr vs 12 hr NS
0.5 hr vs 24 hr NS
1 hr vs 2 hr P<0.05
1 hr vs 4 hr NS
1 hr vs 6 hr NS
1 hr vs 8 hr NS
1 hr vs 12 hr NS
1 hr vs 24 hr P<0.05
2 hr vs 4 hr NS
2 hr vs 6 hr P<0.05
2 hr vs 8 hr P<0.05
2 hr vs 12 hr P<0.001
2 hr vs 24 hr P<0.001
4 hr vs 6 hr NS
4 hr vs 8 hr NS
4 hr vs 12 hr P<0.05
4 hr vs 24 hr P<0.01
6 hr vs 8 hr NS
6 hrvs 12 hr NS
6 hr vs 24 hr P<0.05
8 hr vs 12 hr NS
8 hr vs 24 hr P<0.05
12 hr vs 24 hr NS
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Fig. 4-5-1 a Western immunoblot of StAR protein after low-concentration ACTH
treatment. Untreated cells;ACTH (10'12 M) treated cells; C: Zero time point
cells for control. All samples (25 gg protein) were resolved on a 12.5 % SDS-PAGE
gel. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-sheep/goat
antibody conjugated with HRP (1:25,000) were diluted in PBS/10% Pierce blocking
















Fig. 4-5-1 b Changes of StAR protein levels for low-concentration ACTH time
course. Cells were treated with ACTH (10~12 M) and were harvested at various time
points. Values from three independent experiments are expressed as fold increase
over the corresponding basal level (mean ± SEM), n=3. Columns without the same
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Fig. 4-5-2 Changes of Cortisol levels for low-concentration ACTH time course.
Cells were treated with ACTH (10~12 M) and the media were collected at various time
points. Value from three independent are expressed as fold increase over the
corresponding basal level (mean ± SEM), n=3. Columns without the same
superscript letter were significantly different.
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Fig. 4-5-3 Changes of cAMP levels of low-concentration ACTH time course.
Cells were treated with or without ACTH (1012 M) and the media were collected for
cAMP assay at various time points. Values are expressed as fold increase over the
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Fig. 4-5-4 Correlation between the changes of StAR protein and Cortisol levels
for low-concentration ACTH time course
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4.6 EFFECTS OF ANG II AND THE COMBINED ANG II AND ACTH
TREATMENT ON StAR PROTEIN AND CORTISOL SECRETION
The maximal StAR protein level occurred at 6 hr when cells were treated with Ang II
(10~8 M) alone (Fig. 4-6-1 a & b), and was different from the levels at 0.5, 4 and 24 hr
(P<0.05), 2, 8 and 12 hr (P<0.01) and 1 hr (P<0.001). When cells were treated with
both Ang II (10~8 M) and ACTH (10~12 M), the change of StAR protein at 6 hr was
different from levels at 0.5, 1, 2, 12 and 24 hr (P<0.001), and also at 4 and 8 hr
(P<0.01, Fig. 4-6-1 a & c).
The Cortisol changes in response to Ang II (10~8 M) were more modest compared to
those of 10~12 M ACTH. The levels at 0.5 and 1 hr were different from those at 4, 6
and 8 hr (P<0.05, Fig. 4-6-2a).
In comparison with Ang II (108 M) or ACTH (10~12 M) alone, combined Ang II and
ACTH resulted in further elevated Cortisol production (32.5 ± 4.6 fold) at 2 hr,
indicating that Ang II enhanced 10"12 M ACTH-induced Cortisol secretion (24.3 ± 3.0
fold). The Cortisol levels at 0.5 and 24 hr were different from those at 2, 4, 6 and 8 hr
(P<0.05 for all tests) and there were no distinct changes compared with levels at 1
and 12 hr (Fig. 4-6-2b&c).
Correlation between the changes of StAR protein and Cortisol induced by Ang II was
not strong (r=0.40, P<0.05; Fig. 4-6-3a). The effect of the combined Ang II and
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Fig. 4-6-1 a Western immunoblots of StAR protein after Ang II and combined
Ang II and low-concentration ACTH treatments (Bio-Rad image print). Lanes 1,
5 10, 14, 18, 22, 27 and 37: untreated cells; lanes 2, 6, 11, 15, 19, 23, 28, and 32:
Ang II (10-8 M) treated cells; lanes 3, 7 12, 16, 20, 24, 29 and 33: ACTH (10"12 M)
treated cells; lanes 4 (a & b), 8, 13, 17, 21, 25, 30 and 34. Ang II and ACTH treated
cells; Lanes 9 and 26: Zero time point cells for control. All samples (25 pg protein)
were resolved on 12.5 % SDS-PAGE gels. Sheep anti-bovine peptide antibody
(1:10,000) and donkey anti-sheep/goat antibody conjugated with HRP (1:100,000)
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Fig. 4-6-1 b Changes of StAR protein levels for Ang II treatment. Cells were
treated with Ang II (108 M) and were harvested at various time points. Values from
three independent experiments are expressed as fold increase over the
corresponding basal level (mean ± SEM), n=3. Columns without the same
















Fig. 4-6-1 c Changes of StAR protein levels for the combined Ang II and low-
concentration ACTH treatment. Cells were treated with Ang II (10 8 M) and ACTH
(1012 M) and were harvested at various time points. Values obtained from three
independent experiments are expressed as fold increase over the corresponding





















Fig. 4-6-2a Changes of Cortisol levels for Ang II treatment. Cells were treated
with Ang II (10 8 M) and ACTH (10"12 M), and the media were collected at various
time points. Values obtained from three independent experiments are expressed as
fold increase over the corresponding basal level (mean ± SEM), n=3. Columns






















Fig. 4-6-2b Changes of Cortisol levels for combined Ang II and low
concentration ACTH treatment. Cells were treated with or without Ang II (10~8 M)
and ACTH (1012 M), and the media were collected at various time points. Values
from three independent experiments are expressed as fold increases over the
corresponding levels (mean ± SEM), n=3. Columns without the same superscript
letter were significantly different.
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Fig. 4-6-2c Comparison of Cortisol output induced by Ang II (10 8 M), ACTH
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Fig. 4-6-3a Correlation between the changes in StAR protein and Cortisol for





















Fig. 4-6-3b Correlation between the changes in StAR protein and Cortisol over




The expression of StAR protein in adrenal ZF cells after ACTH treatment was
monitored to provide a preliminary evaluation on 5 separate days of cell culture. On
the basis of this work, a standard regime was established that initiated treatment on
Day 3.
Data from other laboratories also support this selection. The binding of ACTH to
cultured bovine ZF cells was lower on Day 1 than the level on Day 2. One
suggested reason might relate to an incomplete recovery of cell membrane function
after cell isolation by enzymatic digestion. From Day 2, the binding level remained
fairly constant for at least further 2 days (Penhoat et al., 1989a). Furthermore, the
daily changes of ACTH-R mRNA in freshly isolated and cultured bovine ZFR cells
over five consecutive days demonstrated that the constitutive level of ACTH-R
mRNA slightly decreased on Day 1 but increased thereafter. After investigating the
time course of ACTH-R mRNA in the presence of ACTH (109 M), all their
subsequent experiments were started on Day 2 or Day 3 and continued for one or
two additional days (Penhoat et al., 1994).
Day 3 cells were also chosen for studies of steroidogenesis in other reports. For
instance, experiments were usually started on Day 3 of culture when looking at Ang
II receptor and steroidogenic responsiveness in bovine adrenal ZF and ZG cells
(Penhoat et al., 1988). To study the effect of transforming growth factor (31 on StAR
mRNA levels in a time course up to 24 hr, bovine adrenal ZF cells were used on
Day 2 or 3 of primary culture (Brand et al., 1998).The 3-day cultured cells were also
used for observing capacitative calcium entry in bovine adrenal ZF cells (Ebisawa et
al., 2000).
In the current study the fundamental aspects of StAR protein expression, Cortisol
and cAMP formation in response to various concentrations of ACTH was
investigated. The changes of StAR protein at 6 hr were similar to the results
obtained by Yamazaki's group. In bovine adrenal ZFR cells StAR protein was
increased by 6 hr incubation with ACTH (10~12 -10"8 M). Moreover, dose dependence
of the expression of StAR protein by ACTH was correlated with that of
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steroidogenesis (Yamazaki et al., 2000). The maximum Cortisol and cAMP levels in
response to ACTH were consistent with previous work in bovine adrenal ZF cells. A
dose-response to ACTH (1010-10"6 M) demonstrated that the fluorogenic
corticosteroid accumulation reached maximum at about 10~8 M ACTH during 60 min
incubation (Peytremann et al., 1973). The ACTH (10 12-108 M) dose-response curve
for cAMP production showed that 10"9-10"8 M ACTH induced the maximum cAMP
levels. On the other hand, ACTH at 10~12 M resulted in elevated Cortisol levels but no
change in cAMP levels (Penhoat et al., 1989a).
In addition to exhibiting the general profiles of StAR protein and steroid production in
response to ACTH treatment, the concentration response experiments have
demonstrated different correlation between StAR protein and Cortisol after 1 hr and 6
hr treatment. Following this work, the relationship between StAR protein and Cortisol
production was further evaluated throughout a 0.5-24 hr trophic hormone treatments.
With high-concentration ACTH (10~8 M) treatment, the maximum increase of StAR
was 3.9 ± 1.1 fold at 4 hr and the elevated levels of StAR protein were sustained
thereafter until 12 hr. A similar result showed that the expression of StAR protein was
increased maximally at 6 hr by 10"7 M ACTH compared with the StAR levels at 2 and
18 hr (Nishikawa et al., 1996). The treatment with 10"8 M ACTH resulted in a
considerable increase in steroid synthesis; Cortisol showed a maximum 144.0 ± 36.6
fold increase, maintained at a high level from 2 until 12 hr. There was a strong
positive correlation (r=0.81, P<0.0001) between StAR protein and Cortisol production.
StAR protein appeared tightly coupled to the rapid elevation of Cortisol, indicating that
the expression of StAR protein is crucial to steroidogenesis. This result is supported
by a high correlation between StAR mRNA level and ACTH-induced Cortisol secretion
in bovine adrenocortical cells (Roy et al., 2000). However, after the low-concentration
ACTH (10"12 M) treatment, the maximum increase of StAR was 2.5 ± 0.2 fold at 6 hr,
with Cortisol secretion increasing to 24.3 ± 4.3 fold at 2 hr. In fact, the Cortisol
secretion rose significantly prior to any changes in StAR protein synthesis, as
confirmed by the lack of correlation (r=0.04, P>0.05) between the changes of StAR
protein and Cortisol levels. This finding is suggestive that the level of StAR protein
may not be limiting for steroidogenesis at physiological levels of ACTH, but never the
less a small "pool" of StAR might be critical to promote steroidogenesis.
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Several mechanistic possibilities are plausible:
(i) The time lag between the expression of StAR protein and Cortisol output implies
that the acute response to ACTH may be independent of newly synthesised StAR
protein. Low-concentration ACTH treatment clearly demonstrated distinct profiles
between StAR protein and Cortisol changes. Furthermore, with high-concentration
ACTH treatment although there was strong correlation between StAR protein and
Cortisol changes overall, the acute response of steroid production was also ahead
of marked increases in StAR protein.
The time lag of StAR protein expression has also been observed by other groups.
An in vivo study showed that acutely ACTH elevated corticosterone to peak levels
before any changes in total StAR protein in both intact and hypophysectomized
(HPX) rat adrenals. Following in vivo ACTH stimulation the increase of StAR
protein appeared to follow the rise in StAR mRNA in HPX rats and the ratio of the
two measurements remained approximately constant during this process.
Chronically (up to 24 hr) ACTH-treated HPX rats showed paralleled changes of
adrenal StAR protein and serum cortocosterone levels (Ariyoshi et al., 1998). A
correlation between StAR mRNA and protein as well as cholesterol levels
demonstrated that maximum rates of cholesterol metabolism were attained in Y-1
cells within a few minutes of ACTH treatment, prior to any increase in StAR mRNA
(Artemenko et al., 2000).
Acute ACTH treatment provoked a rapid increase in plasma corticosteroids in rat
adrenal ZG and ZFR. An increase of StAR protein levels, after a delay, followed
the increase of newly transcribed StAR mRNA (LeHoux et al., 1998). Moreover,
some studies have shown that actinomycin D, a transcription inhibitor, did not
change the hormonal stimulation of corticosterone production in rat adrenal
(Farese, 1966), indicating that transcription may not be required for the acute
response. Post-translational modifications of StAR precursor may occur during the
early stimulatory phase and before the apparent translation of newly formed
mRNA (LeHoux et al., 1998).
The somewhat slow translation step suggests that the mechanism for initiating the
acute steroidogenesis may rely on a labile StAR pool or the modification of pre-
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existing StAR protein or other factor(s). Acute steroidogenesis may therefore be
independent of a net change of total StAR protein.
(ii) A subtle change in StAR protein may result in a profound response of steroid
output. In other words, only a very small amount of StAR protein (e.g. at
nanomolar level) is required for steroidogenesis, and this could be below the
detection limits and therefore not measurable by semi-quantitative Western
immunoblotting analysis. Arakane and co-workers have demonstrated that the
purified C-His-tag StAR (lacking the first 62 amino acids) can increase rapidly
pregnenolone production at concentrations as low as 20 nM within 20 min and that
the stimulatory effect of C-His-tag StAR protein is dose- and time-dependent in
isolated bovine corpus luteum mitochondria (Arakane et al., 1998). A possible
mechanism may be that a very low level of high affinity StAR protein is functional
for acutely elevating steroid levels, with further expression of StAR protein playing
a key role on the sustenance of steroid synthesis.
It has been speculated by Strauss Ill's group that StAR protein can facilitate
cholesterol transfer either through very high affinity stable interactions which are
difficult to detect because of low number, or through a transient interaction which
is too fast to be observed (Arakane et al, 1998). Conformational or topological
changes of StAR protein might also be responsible for the regulation the
cholesterol mobilisation.
(iii) Various StAR protein species classified in terms of isoelectric point value and
molecular mass (i.e. pi vs. kDa) may also be important in regulation of
steroidogenesis. The 2-D PAGE studies of in vivo expression of StAR protein
demonstrated that the mobility of some StAR species varied between controls
and Na+-restricted rat adrenal ZG, suggesting that qualitative changes in StAR
species content occurred in regulating aldosterone synthesis (Fleury et al.,
2000). Using 35S-methionine/cysteine pulse followed by cAMP stimulation,
Artemenko and co-workers showed that two major StAR forms were diverted to
two more acidic (phosphorylated) forms without a net increase in protein
synthesis (Artemenko et al., 2000). The immunoblot results of whole adrenal
gland mitochondria (MT) and supernatant (SN) revealed four bands in SN of
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control rats and five bands in SN of ACTH-treated rats. The intensity of one band
was increased and that of another one was decreased on treatment. Upon 2-D
PAGE analysis, four StAR species were observed in untreated rat ZG and their
intensity was increased after 5 hr, but not after 1 hr, in vivo ACTH treatment;
additional acidic species also appeared (LeHoux et al., 1999).
iv) StAR protein is not the single limiting factor for cholesterol transfer but it may act
in concert with other proteins such as PBR or an unidentified factor which may
be an ancillary protein. Some evidence shows that adrenal PBR is able to
change rapidly in response to acute ACTH treatment (Boujrad et al., 1994;
Boujrad et al., 2000; Li and Papadopoulos, 1998; Papadopoulos et al., 1997).
More recently, a study on fluorescence energy transfer has demonstrated that
StAR protein and PBR are associated in the process of cholesterol delivery
across the intramitochondrial membrane (West et al., 2001). StAR protein may
act thus as part of a heteromeric complex StARosomes.
Moreover, StAR protein participates in a process involving GTP hydrolysis which is
known to be important for delivering substrate to CYP11A (Kwoluru et al., 1995).
Other factors also contribute to acute steroidogenesis. The proto-oncogene mRNA
levels of c-jun, c-fos, jun-B and fos-B were increased within 30 min following ACTH
administration in both rat adrenal ZG and ZFR. The high levels of these mRNA were
only sustained for a short-term and diminished after 3 hr, and then returned to near or
below basal levels at 5 hr (LeHoux et al., 1998). The rapid increase of c-fos and jun-B
mRNA occurred after the addition of ACTH in bovine adrenal ZF cells (Viard et al.,
1992). A comprehensive regulatory mechanism of StAR protein involvement in
steroidogenesis may be through a dynamic combination of two or more of the above
possibilities depending on the effective time and the agonist concentrations.
The relationships between StAR protein and Cortisol secretion as well as cAMP
formation at various concentrations of ACTH reflect not only that StAR protein and
cAMP are important in steroidogenesis but also that other factor(s) and/or alternative
pathways may be involved in steroidogenesis.
Low-dose ACTH is of clinical interest and can be useful to estimate the adrenal
sensitivity under physiological conditions. The examination of the dose-response
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relationship between plasma ACTH and Cortisol concentrations after i.v.
administration of increasing doses (1, 5 or 250 pg) of ACTH showed that an
increase in plasma ACTH as low as 13 pM (i.e. the increase obtained with the 1 pg
dose) induced a near maximal Cortisol response (Darmon et al., 1999). 1 pg of
ACTH administration via i.v. injection is the lowest ACTH dose to cause a maximal
Cortisol response and 0.6 pg of ACTH is sub-maximal dose for normal human
(Dickstein et al., 1997). Concentration response curves and high- and low-
concentration ACTH treatments indicated that the levels of cAMP were hardly
changed at concentration of 10"12 M ACTH, while Cortisol levels were significantly
elevated. In other words, ACTH stimulates Cortisol secretion at concentrations that
are lower than those required to produced measurable in cAMP (Buckley and
Ramachandran, 1981; Enyeart et al., 1996; Lefkowitz et al., 1971). In contrast, the
cAMP levels were significantly increased when cells were treated with 10"11 M and
higher concentrations of ACTH, paralleling with remarkable increases in Cortisol
levels. This is suggestive that cAMP may not be the sole second messenger which
mediates the action of ACTH. The study of steroidogenesis in rat ZG cell
demonstrated that ACTH activated a chloride channel via the Ras protein, providing
evidence in which ACTH action in the adrenal is complex and most certainly not
limited to the cAMP pathway, in particular for the low concentrations of ACTH. It is
becoming increasingly apparent that ACTH triggers complex signalling systems in a
closely interacting way (Gallo-Payet et al., 1999).
In addition to the mechanisms at the level of the second messenger systems, the
promotion of steroidogenesis may also occur at a receptor level. The Scatchard
analysis of bound and free ligand revealed two binding site populations for 125l-
ACTH in bovine adrenal ZF cells. One site has high affinity (KD = 2.3 ± 0.4x10"10 M)
and low capacity (1910 + 300 sites per cell), whereas another site is low affinity (KD
= 1.6 ± 0.6x10"7 M) and high capacity (32,000 - 90,000 sites per cell) (Penhoat et
al., 1989a). Possibly there are two types of receptors coupling with high- and low-
concentration ACTH: one is able to bind both 10~8 M and 10"12 M ACTH, mediating
cAMP and another signalling pathway respectively and one may principally be
responsive to 10~8 M ACTH. Alternatively, it could be that one receptor class
contains two different binding sites. The consequence of changes in receptor
binding might lead to activation of different signalling pathways.
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In mammals, ACTH and Ang II are the main hormones that regulate steroid
production by the adrenal gland. Most work on the effects of Ang II are focused on
the adrenal ZG cells. In addition, some evidence has shown that Ang II also regulates
steroidogenesis in adrenal ZFR cells. Ang II can acutely stimulate Cortisol production
in bovine adrenal ZF cells (Crozat et al., 1986; Rainey et al., 1991).
The fold increase of Cortisol production declined sharply after 2-4 hr treatment with low-
concentration ACTH. However, it was sustained from 2 until 8 hr in the combined Ang
II and ACTH treatment (Fig. 4-6-2b&c), suggesting a sensitising effect of Ang II on low-
concentration ACTH induced-steroidogenesis. Both Ang II and ACTH induced the
expression of StAR protein individually. However, the integrative effect of the combined
Ang II and ACTH treatment on StAR protein did not correspond to additive Cortisol
output. The reason for this remains unclear.
Ang II and ACTH stimulate steroid secretion through their separate signalling
systems. There may be at least two distinct mechanisms to link their effects on
steroidogenesis. The results from combined 10"8 M Ang II and 10"12 M ACTH showed
that Ang II enhanced ACTH-stimulated Cortisol production, and suggests a
steroidogenic regulatory process that may be important at physiological levels of
ACTH.
The mechanism of the combined effects of ACTH and Ang II on steroidogenesis have
been investigated by other groups. Interaction of ACTH (2x10"7 M) and Ang II (106 M)
for 3 min resulted in a cAMP increase greater than the sum of the effect of each
hormone alone in bovine ZF cells (Peytremann et al., 1973). Ang II (3x 10"8 M)
treatment also potentiated the stimulatory actions of ACTH (10"9 M) on cAMP
formation in the presence of extracellular calcium in COS-7 and bovine adrenal ZG
cells (Baukal et al., 1994).
On the other hand, both ACTH and Ang II increased the mRNA levels of the ACTH
receptor in a time- and dose-dependent manner. ACTH caused a 2.7-fold increase in
3.6 kb major transcript with an ED50=10"11 M and Ang II produced a 2.4-fold increase
with an ED50=5x10"8 M. ACTH receptor number and mRNA are positively regulated by
ACTH and Ang II, which regulates adrenocortical functions in vivo. The regulation of
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ACTH receptors may be a mechanism by which ACTH and Ang II control
steroidogenesis under both normal and pathological conditions (Lebrethon et al.,
1994).
In addition, there exists a discrepancy with regard to the combined effect of Ang II
and ACTH, that may be caused by different treatment regimes. For instance, after
cells were pretreated with Ang II (10~7 M) for 48 hr and then treated with ACTH (10~9
M), Ang II inhibited the stimulatory effect of ACTH on its receptor (125I-ACTH bound)
by 50% in bovine adrenal ZF cells (Penhoat et al., 1989).
The combined Ang II and ACTH treatments might well induce a biphasic
steroidogenic response. During acute and intermediate phases, Ang II may enhance
ACTH-stimulated steroid synthesis. In contrast, chronically it may desensitise the
effect of ACTH. One possible reason is that Ang II may inhibit the expression of one
or more steroidogenic enzyme(s) after prolonged hormonal treatment. For example,
Ang II appears to attenuate the ACTH-stimulated expression of CYP17 following a 24
hr treatment (Bird et al., 1993), resulting in a decrease in Cortisol output.
Taken together, these results suggest a need to consider a more comprehensive
notion to include parallel investigations on steroidogenesis, StAR protein and
various intracellular signalling systems.
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CHAPTER 5 SIGNALLING SYSTEMS AND THEIR
RELATIONSHIPS TO StAR PROTEIN IN RESPONSE TO HIGH-
AND LOW-CONCENTRATION ACTH TREATMENTS
5.1 INTRODUCTION
5.1.1. cAMP is not the sole second messenger of ACTH-induced
steroidogenesis
It has been well established that cAMP mediates ACTH-induced steroidogenesis.
This is based on two major pieces of evidence: ACTH stimulates a continuous
increase in cAMP levels and the cAMP analogs such as Bu2cAMP and 8-Br-cAMP
are able to induce steroidogenesis to similar levels as ACTH treatment (Beall and
Sayers, 1972; Cooke, 1999; Hanukoglu et al., 1990; Sala et al., 1979) .
Certain observations have weakened, however, an earlier hypothesis that cAMP is
the sole second messenger for ACTH-induced steroidogenesis in the adrenal cortex.
It has been found that there are concentrations of ACTH capable of stimulating
steroidogenesis but apparently incapable of affecting cAMP production. cAMP
appears to play a significant role as a second messenger for steroid synthesis only at
ACTH concentrations greater than 10~11 M (Yamazaki et al., 1998). ACTH stimulates
Cortisol secretion at concentrations that may be lower than required to produce
measurable changes in cAMP levels. Ca2+ was found to serve as a direct messenger
in the physiological activation of steroidogenesis in isolated rat adrenocortical cells,
whereas cAMP was claimed to be a subserving factor maintaining full
steroidogenesis (Schulster and Schwyzer, 1980). cAMP and Ca2+ appear to act as
dual second messengers in the ACTH-induced signalling pathways that are linked
through lac K+ channels. Both of these are required for a full steroidogenic response in
adrenal ZF cells (Enyeart and Enyeart, 1998). Comparison of the effects of ACTH
and NPS-ACTH (in which the position 2 on indole ring of tryptophan residue of ACTH
was substituted by the O-nitrophenylsulfenyl group) on cAMP and steroid production
were suggestive that although the integrity of the tryptophan residue in ACTH was
essential for maximal cAMP formation, it was not so for maximal steroidogenesis.
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This may also imply that another factor exists for mediating steroidogenesis (Moyle et
al., 1973).
The results presented in Chapter 4 demonstrated that the significant increases in
Cortisol levels occurred at 10"12 M ACTH without notable changes of cAMP levels,
suggesting the existence of other mechanism(s) for steroidogenesis in bovine
adrenal ZF cells. Thus, further work was carried out to investigate a cAMP-
independent signalling system, the arachidonic acid cascade, that may also mediate
ACTH-induced steroidogenesis.
5.1.2 Arachidonic acid cascade and inhibitors
Briefly, the arachidonic acid (AA) cascade consists of two parts depending upon
sequential activation process. The upstream pathways are the routes leading to AA
liberation while the downstream pathways relate to the metabolism of AA to a
variety of derivatives. Fig. 5-1-2 illustrates the AA cascades as well as action sites
of the enzyme inhibitors .
Fig. 5-1-2 Arachidonic acid metabolism and the inhibitors of pathways. 4-BPB:
4-Bromophenylacyl bromide; NDGA: Nordihydroguaiaretic acid; INDO:
indomethacin; HPETE: Hydroperxyeisatetraenoic acid; HETE:
Hydroxyeicosatetraenoic acid; PG: Prostaglandin; TX: Thromboxane; X. Inhibitory
effect.
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5.1.2.1 Inhibition of PLA2 activity
PLA2 catalyzes the hydrolysis of membrane phospholipids, releasing AA as the
substrate or as a mediator for cellular process. As PLA2 initiates the production of
AA and a number of its metabolites that play roles as second messengers, it is
obligate to determine whether the inhibition of PLA2 affects steroidogenesis.
4-Bromophenacyl bromide (4-BPB, also known as p-BPB), a selective PLA2
inhibitor, has been used in studying PLA2 activity and steroidogenesis in rat cerebral
cortex (Piomelli and Greengard, 1991), rat ZF cells (Mele et al., 1996) and bovine
adrenal chromaffin cells (Morgan and Burgoyne, 1990). The roles of PLA2 on
Cortisol production and StAR protein in bovine adrenal ZF cells remain unclear.
5.1.2.2 Downstream arachidonic acid cascade
Certain studies have demonstrated that the LOX and the COX aspects of the AA
cascade functioned differentially in the adrenal cortex. In rat adrenal ZF cells
pretreatment with INDO, a COX inhibitor, significantly suppressed prostaglandin F2a
(PGF2a) production, indicating that AA can be metabolized to PGF2ot by COX. On
the other hand, INDO had no effect on corticosterone levels, suggesting that PGs
did not serve as mediators of adrenal steroidogenesis (Swartz et al., 1983). The
results by Hirai et al also showed that INDO affected neither corticosterone
production, nor cAMP levels. In contrast, two LOX products, 5-
hydrooxyeicosatetraenoic acid (5-FIETE) and leukotriene B4 (LTB4) were induced by
ACTH, and furthermore augmented steroidogenesis in rat adrenocortical cells (Hirai
et al., 1985). The results obtained by Yamazaki and co-workers indicated that LOX
products might be involved steroidogenesis. In bovine ZF cells, the addition of AA or
15-hydroperoxyeicosatetraenoic acid (15-HPETE) increased pregnenolone
production and the stimulatory effect of AA was blocked by NDGA (100 pM), a




5.1.3 Aims and experimental strategies
A comprehensive mechanism by which ACTH stimulates steroidogenesis remains
incompletely delineated. This work aimed at investigating the regulatory
mechanisms of ACTH-induced steroidogenesis, particularly by identifying the
signalling pathways operative at physiologically relevant ACTH levels. The
experiments were conducted using a physiological concentration of ACTH (10~12 M)
in parallel with a supra-physiological concentration of ACTH (10~8 M). Various
compounds were used to examine the effects of AA and its metabolites on ACTH-
induced steroidogenesis and StAR protein (Fig. 5-1-3a). Based on results presented
in Chapter 4, the 1 hr time point was selected for examining the acute effects of
ACTH on steroid production, while a 6 hr treatment was selected for observing the
expression of StAR protein.
Fig. 5-1-3a Strategy of investigating the second messenger system of ACTH-
stimulated steroidogenesis. X axis: Cells were treated with 10~12 M or 10"8 M
ACTH; Z axis: Compounds including 4-BPB, NDGA, INDO and AA; Y axis: Cells
and media were collected at 1 and 6 hr after treatments.
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The aims of this work illustrated in Fig. 5-1-2 and Fig. 5-1-3b were:
• To examine whether the release of AA by PLA2 affects steroidogenesis.
• To test which downstream branch(es) of the AA cascade is/are involved in
steroidogenesis.
• To evaluate the correlation between the concentrations of ACTH and signalling
pathways.
• To evaluate the correlation between the activation of the AA pathways and StAR
protein levels.
• To examine whether there is an interaction between the AA cascade and the
cAMP pathway.
• To test the specificity of compounds using 27-nor-5-cholesten-3p-ol-25-one, a
readily diffusible substrate for steroidogenesis.
• To compare the effects of regular BSA and fatty acid free BSA on Cortisol
production.
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5.2 ROLE OF PHOSPHOLIPASE A2
5.2.1 Effect of 4-BPB on Cortisol output
At 1 hr, the levels of Cortisol after ACTH (1012 M) treatment were markedly
decreased by 4-BPB at concentrations ranging from 10"7-10"5 M (P<0.05), whereas,
the levels of Cortisol stimulated by ACTH (10~12 M) were not affected by 4-BPB at
6 hr (Fig. 5-2-1 A-upper panel). 4-BPB (10~5 M) only slightly inhibited ACTH (10 8 M)-
induced Cortisol output at 1 hr. All concentrations of 4-BPB failed to alter the
increases in Cortisol by ACTH (10~8 M) at 6 hr (Fig. 5-2-1 A-lower panel).
In the medium containing 0.2% fatty-acid-free (FAF) BSA, 4-BPB significantly
inhibited ACTH (1012 M)-induced Cortisol production at concentrations of 10"6 and
10"5 M (P<0.05). The effect of 4-BPB on Cortisol output was not significant at 6 hr
(Fig. 5-2-1 B-upper panel). 4-BPB (10"7-105 M) markedly impaired ACTH (10~8 M)-
induced Cortisol increase (P<0.01) at 1 hr, but not that at 6 hr (Fig. 5-2-1 B-lower
panel).
In summary, the effects of 4-BPB on Cortisol occurred acutely (1 hr) and the
inhibitory effect on 10"8 M ACTH-induced Cortisol was more clearly seen in the
medium containing 0.2% FAF BSA than that in medium containing 0.2% BSA.
5.2.2 Effect of 4-BPB on StAR protein levels
Western blotting failed to reveal any change in total StAR protein induced by ACTH
(10~12 M) in the presence of various concentrations of 4-BPB compared with ACTH
alone at both 1 and 6 hr treatment periods (Fig. 5-2-2a-upper & lower panels; Fig.
5-2-2b-upper panel).
Similarly, 4-BPB had no effect on ACTH (10"8 M)-stimulated total StAR protein (Fig
















































Fig. 5-2-1A Effects of 4-BPB on Cortisol levels induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments.
Cells were pretreated with various concentrations of 4-BPB for 15 min prior to the
addition of ACTH (1012 M or 10"8 M). Values are expressed as fold increase over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time point data and letters















































4-BPB (10 s M)
ACTH (10"8M)
Fig. 5-2-1B Effect of 4-BPB on Cortisol levels induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments in
FAF BSA medium. Cells were pretreated with various concentrations of 4-BPB for
15 min prior to the addition of ACTH (1012 or 10"8 M). Values were expressed as
fold increase over basal levels (mean ± SEM), n=3. Columns without the same
superscript(s) are significantly different. Letters in lower case indicate 1 hr time








C B C C
4-BPB (10'7M) -
4-BPB (10'6M) - +
4-BPB (10 s M) + - -
ACTH (10"12M) - - .+ + + +
ACTH (10"8M) + + + + .
6 hr
47.5
C B C C
4-BPB (10"7M) - - -
4-BPB (10"6M) - + -
4-BPB (10"5M) + - -
ACTH (10"12M) - - .+ + + +
ACTH (10 ® M) + + + + .
Fig. 5-2-2a Western immunoblots of StAR protein in response to various
concentrations of 4-BPB at 1 hr (upper panel) and at 6 hr (lower panel). C:
Zero time point untreated cells. B: Basal (untreated cells at 1 or 6 hr). Samples (25
pg protein) were resolved on 12.5% large SDS-PAGE gels and blotted on to PVDF
membranes. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-
sheep/goat antibody conjugated with HRP (1:25,000) were diluted in PBS/10%




















4-BPB (10 s M)
ACTH (1012 M)


















Fig. 5-2-2b Effect of 4-BPB on StAR protein induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments.
Cells were pretreated with various concentrations of 4-BPB for 15 min prior to the
addition of ACTH (1012 M or 10"8 M). Values are expressed as fold increase over
basal levels in a representative experiment performed in triplicate (mean ± SEM),
n=3. Columns without the same superscript are significantly different. Letters in






















































Fig. 5-2-3 Effect of 4-BPB on cAMP levels induced by low-concentration ACTH
(upper panel) high-concentration ACTH (lower panel) treatments. Cells were
pretreated with various concentrations of 4-BPB for 15 min prior to the addition of
ACTH (10"12 or 10"8 M). Values are expressed as fold increase over basal levels in a
representative experiment performed in triplicate (mean ± SEM), n=3. Columns
without the same superscript are significantly different. Letters in lower case
indicate 1 hr time points and letters in upper case indicate 6 hr time points.
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5.2.3 Effect of 4-PBP on cAMP formation
ACTH (1012 M) did not alter cAMP levels and the addition of 4-BPB similarly had no
effect at 1 either or 6 hr treatment period (Fig 5-2-3-upper panel). A high
concentration of 4-BPB (10 5 M) caused a minor decrease in ACTH (10~8 M)-induced
cAMP level at 1 hr of treatment but not at 6 hr period (Fig. 5-2-3-lower panel).
5.3 ROLE OF THE LIPOXYGENASE PATHWAY
5.3.1 Effect of NDGA on Cortisol output
Fig. 5-3-1 A-upper panel showed that NDGA significantly reduced ACTH (1012 M)-
induced Cortisol increases (P<0.05 at 2x10"6 M and 10"5M; P<0.001 at 5x10"5 M) and
the inhibitory effects at 5x10"5 M NDGA was more marked than those at 2x10"6 and
10"5 M NDGA (P<0.01) after 1 hr. The stimulatory effect of ACTH (1012 M) was
reduced in the presence of 5x10"5 M NDGA (P<0.01) after 6 hr treatment.
As shown in Fig. 5-3-1 A-lower panel, 5x10"5 M NDGA significantly inhibited ACTH
(108 M)-stimulated Cortisol increase after 1 hr (P<0.01) and 6 hr periods(P<0.001).
With medium containing 0.2% FAF BSA, NDGA notably inhibited the Cortisol levels
induced by 10~12 M ACTH (P<0.01 at 10"5; P<0.001 at 3x10"5 and 5x10"5 M ).
Moreover, the inhibitory effects were concentration-dependent. Compared to ACTH
(1012 M) treatment alone, the Cortisol level in the presence of 3x10"5 M NDGA was
lower than that at 10"5 M (P<0.01) and the level at 5x10"5 M was lower than that at
10"5 M (P<0.001) and 3x10"5 M (P<0.05) after 1 hr of treatment (Fig. 5-3-1 B-upper
panel).
NDGA inhibited ACTH (10"8 M)-induced Cortisol increases (P<0.01 at 3x10"5 M and
P<0.001 at 5x10"5 M respectively) at 1 hr. Similarly, NDGA also inhibited ACTH
(108 M)-induced Cortisol increases (P<0.05 at 3x10"5 M P<0.01 at 5x10"5 M
respectively) at 6 hr. The effect of NDGA at 5x10"5 M on Cortisol output was more

































NDGA (10 s M)
NDGA (5x10"5 M)
ACTH (10 ® M)
+
+
Fig. 5-3-1A Effect of NDGA on Cortisol levels induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments.
Cells were pretreated with various concentrations of NDGA for 15 min prior to the
addition of ACTH (10"12 M or 10~8 M). Values are expressed as fold increase over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time points and letters in




















































Fig. 5-3-1B Effect of NDGA on Cortisol levels induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments in
FAF BSA medium. Cells were pretreated with various concentrations of NDGA for
15 min prior to the addition of ACTH (1012 M or 10"8 M). Values are expressed as
fold increase over basal levels (mean ± SEM), n=3. Columns without the same
superscript are significantly different. Letters in lower case indicate 1 hr time points
and letters in upper case indicate 6 hr time points.
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5.3.2 Effect of NDGA on StAR protein level
There was no marked difference between the levels of StAR protein induced by
ACTH (10~12 M) and those in the presence of ACTH as well as various
concentrations of NDGA (Fig. 5-4-2a-upper and lower panels; Fig. 5-3-2b-upper
panel).
NDGA at 2x10"6 and 10"5 M appeared to slightly affect ACTH (108 M)-induced StAR
protein levels (Fig. 5-4-2a-upper and lower panels; Fig. 5-3-2b-lower panel).
5.3.3 Effect of NDGA on cAMP formation
There was no changes by NDGA alone and in the presence of 10"12 M ACTH on
cAMP levels after 1 and 6 hr treatments (Fig. 4-3-3-upper panel). At 1 hr, NDGA
inhibited ACTH (10 8 M)-stimulated cAMP production (P<0.05 at 10"6 M; P<0.01 at
5x10"5 M). The cAMP level in the presence of 5x10"5 M NDGA was different from
that at 2x10"6 M (P<0.05). Only 5x10"5 M NDGA significantly reduced 10"8 M ACTH-
induced cAMP increases at 6 hr (P<0.05, Fig. 5-3-3-lower panel).
5.4 ROLE OF THE CYCLOOXYGENASE PATHWAY
To examine whether the COX pathway of the AA cascade plays any role in ACTH
action, the effects of INDO on Cortisol output, StAR protein and cAMP were
investigated.
5.4.1 Effect of INDO on Cortisol output
INDO at 10"5 and 10"4 M potentiated ACTH (1012 M)-induced increases in Cortisol
(P<0.05) at 1 hr but had no significant effect at 6 hr (Fig. 5-4-1 A-upper panel). INDO






NDGA (10 s M) -
NDGA (5x10"5M) + +
ACTH (10"12M) - + + + +






NDGA (2x10"6 M) - + +
NDGA (10 s M) -
NDGA (5x10 s M) + +
ACTH (10"12M) - + + + +
ACTH (10"8M) + + + +
Fig. 5-3-2a Western immunoblots of StAR protein in response to various
concentrations of NDGA at 1 hr (upper panel) and at 6 hr (lower panel). C: Zero
time point untreated cells. B: Basal (untreated cells at 1 or 6 hr). Samples (25 pg
protein) were resolved on 12.5% large SDS-PAGE gels and blotted on to PVDF
membranes. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-
sheep/goat antibody conjugated with HRP (1: 25,000) were diluted in PBS/10%
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+
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Fig. 5-3-2b Effect of NDGA on StAR protein induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments.
Cells were pretreated with various concentrations of NDGA for 15 min prior to the
addition of ACTH (1012 M or 10"8 M). Values are expressed as fold increase over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time points and letters in















































Fig. 5-3-3 Effect of NDGA on cAMP levels induced by low-concentration ACTH
(upper panel) and high-concentration ACTH (lower panel) treatments. Cells
were pretreated with various concentrations of NDGA for 15 min prior to the addition
of ACTH (10 8 M). Values are expressed as fold increase over basal levels (mean ±
SEM), n=3. Columns without the same superscript are significantly different. Letters














































Fig. 5-4-1A Effect of INDO on Cortisol levels induced by low-concentration
ACTH (upper panel) and high-concentration ACTH (lower panel) treatments.
Cells were pretreated with different concentrations of INDO for 15 min prior to the
addition of ACTH (1012 M or 10"8 M). Values are expressed as fold increase over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time points and letters in















































Fig. 5-4-1B Effect of INDO on Cortisol levels induced by low-concentration
(upper panel) and high-concentration ACTH (lower panel) treatments in FAF
BSA medium. Cells were pretreated with INDO for 15 min prior to the addition of
ACTH (1012 M or 10"8 M). Values are expressed as fold increase over basal levels
(mean ± SEM), n=3. Columns without the same superscript are significantly
different. Letters in lower case indicate 1 hr time points and letters in upper case
indicate 6 hr time points.
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In the medium containing 0.2% FAF BSA, a high concentration of INDO (10"4 M)
enhanced ACTH (10~12 M)-induced increases in Cortisol levels at both 1 and 6 hr
(P<0.05 and P<0.01 respectively; Fig. 5-4-1 B-upper panel). INDO at 10~4 M slightly
promoted ACTH (10 8 M)-stimulated Cortisol increase at 1 hr, but did not affect the
elevated Cortisol level at 6 hr (Fig. 5-4-1 B-lower panel).
5.4.2 Effect of INDO on StAR protein level
INDO did not alter 10"12 nor 10~8 M ACTH-induced changes of StAR protein levels at
either 1 hr or 6 hr (Fig. 5-4-2a-upper and lower panels; Fig. 5-4-2b-upper and lower
panels).
5.4.3 Effect of INDO on cAMP formation
There was no effect of INDO alone or INDO in the presence of 10"12 M ACTH on
cAMP production at both 1 and 6 hr treatment periods (Fig. 5-4-3-upper panel). Fig.
5-4-3 (lower panel) showed that INDO at 10~5 and 10"4 M markedly inhibited ACTH
(108 M) induced-cAMP production (P<0.05 and P<0.01 respectively) at I hr.
Similarly, INDO at 10"5 and 10~4 M resulted in a decrease in the cAMP levels at 6 hr
(P<0.001).
5.5 ROLE OF ARACHIDONIC ACID
5.5.1 Effects of arachidonic acid on Cortisol output
Exogenous arachidonic acid (10 4 M) did not significantly stimulate Cortisol secretion
but enhanced ACTH (10~12 M)-induced Cortisol increase at both 1 and 6 hr (P<0.01;




















ACTH(10"12M) + + +
ACTH (10"8M) + + +
Fig. 5-4-2a Western immunoblots of StAR protein in response to various
concentrations of INDO at 1 hr (upper panel) and at 6 hr (lower panel). C: Zero
time point untreated cells. B: Basal (untreated cells at 1 or 6 hr). Samples (25 pg
protein) were resolved on 12.5% large SDS-PAGE gels. Sheep anti-bovine peptide
antibody (1:10,000) and donkey anti-sheep/goat antibody conjugated with HRP (1:







































Fig. 5-4-2b Effect of INDO on StAR protein induced by low-concentration
(upper panel) and high-concentration ACTH (lower panel) treatments. Cells
were pretreated with different concentrations of INDO for 15 min prior to the
addition of ACTH (1012 M or 10"8 M). Values are expressed as fold increase over
basal levels in a representative experiment performed in triplicate (mean ± SEM),
n=3. Columns without the same superscript are significantly different. Letters in











































Fig. 5-4-3 Effect of INDO on cAMP levels induced by low-concentration ACTH
(upper panel) and high-concentration ACTH (lower panel) treatments in FAF
BSA medium. Cells were pretreated with INDO for 15 min prior to the addition of
ACTH (1012 or 10"8 M). Values are expressed as fold increase over basal levels
(mean ± SEM), n=3. Columns without the same superscript are significantly
different Letters in lower case indicate 1 hr time points and letters in upper case












































Fig. 5-5-1 Effect of arachidonic acid (AA) on Cortisol secretion induced by low-
concentration ACTH (upper panel) and high-concentration ACTH (lower panel)
treatments in FAF BSA medium. Cells were treated with AA, ACTH and
combination of AA and ACTH (1012 M or 10"8 M). Values are expressed as fold
increase over basal levels (mean ± SEM), n=3. Columns without the same
superscript are significantly different. Letters in lower case indicate 1 hr time points



















Fig. 5-5-2 Effect of arachidonic acid (AA) on StAR protein induced by low- and
high-concentration ACTH treatment in FAF BSA medium. Cells were treated
with AA, ACTH (1012 M or 10~8 M) and combined AA and ACTH. Values are
expressed as fold increase over basal levels in a signal Western immunoblot.
5-27
Chapter 5
5.5.2 Effect of arachidonic acid on StAR protein
Fig. 5-5-2 showed that AA had no notable effects on the basal and ACTH (1012 and
10 8 M)-induced StAR protein levels.
5.6 EXAMINATION OF THE SPECIFICITY OF INHIBITORS
27-Nor-5-cholesten-3p-ol-25-one (25-KETO), a steroidogenic substrate which
readily traverses the mitochondrial membrane due to its hydrophilic nature, was
used to test the specificity of the compounds described above.
Comparison between 25-KETO alone and 25-KETO in the presence of the
compounds showed that 4-BPB (10~5 M) and INDO (105 M) did not change the
Cortisol levels in response to 25-KETO at both 1 and 6 hr (Fig. 5-6-1). On the other
hand, NDGA at 3x10"5 and 5x10"5 M significantly reduced the Cortisol levels in






Fig. 5-6-1 Effects of 4-BPB and INDO on Cortisol output in response to 27-nor-
5-cholesten-3p-ol-25-one (25-KETO) in FAF BSA medium. Cells were pretreated
with 4-BPB (10~5 M) or INDO (10 5 M) for 15 min prior to the addition of 25-KETO
(2x10"5 M). The media were collected for Cortisol assay after 1 hr and 6 hr
treatments. Values are expressed as mean ± SEM, n=3. Data (25-KETO vs. 25-
KETO plus 4-BPB and 25-KETO vs. 25-KETO plus INDO respectively) were




























Fig. 5-6-2 Effects of NDGA on Cortisol secretion in response to 27-Nor-5-
cholesten-3[3-ol-25-one (25-KETO) in FAF BSA medium. Cells were pretreated
with various concentrations of NDGA for 15 min prior to the addition of 25-KETO
(2x10"5 M). The media were collected for Cortisol assay after 1 hr and 6 hr
incubation. Values are expressed as mean ± SEM, n=3. Data (25-KETO vs. 25-





The results presented here again clearly demonstrated that 10"12 M ACTH induced
significant changes in Cortisol levels, which was more apparent acutely (1 hr) than
that at a relatively more chronic phase (6 hr). However, no notable change in cAMP
production by 10~12 M ACTH was observed after either 1 or 6 hr ACTH treatment,
implying that ACTH-stimulated steroidogenesis may be mediated by other second
messenger(s). Previous work has also shown the dissociation between
steroidogenesis and cAMP formation. ACTH stimulates steroidogenesis effectively
at concentrations much lower than those which produce measurable increases in
cAMP output (Beall and Sayers, 1972; Kojima et al., 1985; Perchellet and Sharma,
1979).
The elevation of Cortisol induced by low (1012 M) and high (10 s M) concentrations
of ACTH was reduced by 4-BPB treatment at 1 hr but not 6 hr, suggesting that PLA2
may participate in the AA release and the action of PLA2 may be transient. On the
other hand, the expression of StAR protein induced by both 10"12 M and 10"8 M
ACTH was not altered by 4-BPB, suggesting the role of PLA2 may be independent
of newly synthesized StAR protein.
Although the liberation of AA may result principally from the action of PLA2, other
routes such as phospholipase C-AA cannot be excluded (Naor, 1991). Moreover,
cholesterol esters may be also a source for AA because the adrenal gland contains
cholesterol esters packaged in lipid droplets.
The studies on the downstream AA cascade revealed a complex effect on
steroidogenesis in bovine adrenal ZF cells. NDGA severely impaired ACTH-induced
Cortisol secretion, providing a evidence that LOX pathway of the AA cascade may
act as a major second messenger. This agreed with reports by other groups. AA
can be transformed into two monohydroxy derivatives: 5- and 15-HETE via 5- and
15-LOX respectively (Omura et al., 1990) and the comparison of the effects of
exogenous lipoxygenase metabolites (5-HPETE, 12-HPETE and 15-HPETE) on
pregnenolone production showed that 15-HPETE was more significant in enhancing
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steroidogenic activity in bovine adrenal ZF cells (Yamazaki et al., 2000), implying
that 15-LOX may be a principal form of LOX for AA metabolism.
AA-861, a LOX inhibitor, suppressed the stimulatory effects of ACTH and NPS-
ACTH on steroidogenesis without affecting StAR protein contents and the
administration of 15-HPETE enhanced the steroidogenic activity, but did not
promote the expression of StAR protein. This is suggestive that the action of
lipoxygenase-catalyzed products may be via a StAR-independent mechanism in
bovine adrenocortical cells (Yamazaki et al., 1996; 1998; 2000). In contrast to these
studies, other evidence showed that the AA cascade was correlated with both
steroid synthesis and the levels of StAR protein. The effects of AA on LH- and
Bt2cAMP-stimulated progesterone synthesis were regulated by StAR protein; NDGA
(70 pM) inhibited the expression of StAR protein and progesterone output in MA-10
Leydig tumor cells (Wang et al., 1999; 2000). These observations are suggestive
that the mechanism by which LH-induced progesterone levels in MA-10 Leydig
tumor cells might differ from that of ACTH-stimulated Cortisol secretion in primary
bovine adrenal ZF cells.
The results from this work showed that NDGA did not change the levels of StAR
protein in the presence of 10"12 M ACTH, whereas NDGA appeared slightly to alter
ACTH (108 M)-induced increases in StAR protein. As the quantitative estimations
were ambiguous, more work is required to evaluate the role of StAR protein in this
regard.
In some cases, INDO had modest stimulatory effects on 10"12 M ACTH-induced
Cortisol increases, especially in the medium containing the regular BSA. Possible
mechanisms by which INDO potentiated ACTH-stimulated steroidogenesis are:
i) Because COX-catalyzed AA conversion is blocked by INDO, more AA (substrate)
is redirected to LOX-catalyzed metabolism that may be a major signalling
pathway. Equally, AA may be also diverted to the third pathway of the
downstream AA cascade and metabolized by cytochrome P450-dependent
monooxygenase (MOX) (Nishimura et al., 1989), i.e. INDO may indirectly amplify
the effect of MOX on Cortisol output.
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ii) An increase in Cortisol might be caused by abolishing the down-regulation of a
signalling pathway. It has been found that PGFa treatment attenuated the levels
of StAR mRNA and progesterone in the human corpora lutea (Chung et al.,
1998). A speculation is that the negative regulation of PGs on steroidogenesis
might be eliminated when the route of PG transformation is blocked.
Yamazaki and co-workers found that INDO (100 pM) enhanced pregnenolone
production in bovine adrenal ZFR cells (Yamazaki et al., 1996) and Wang et al
showed that INDO (10 pM) promoted Bt2cAMP-induced progesterone and StAR
protein levels in MA-10 Leydig tumor cells (Wang et al., 2000). However, they did
not state that whether regular BSA or FAF-BSA was used in these experiments.
One should be aware that the regular BSA may lead to an artifact as some
unidentified components in this product may mask the effects of
inhibitors/compounds on steroidogenesis. This issue is discussed further later.
INDO did not change the levels of StAR protein in bovine adrenal ZF cells.
Whereas, the results from MA-10 Leydig tumor cells showed that INDO enhanced
the expression of StAR protein. Whether this is due to species specificity or the
different mechanism in these two cell types remained to be investigated.
As shown in section 5.4. INDO potentiated or had no effect on ACTH-induced
Cortisol output, while it potently inhibited cAMP formation under the same
conditions. Meanwhile, the examination of inhibitor specificity using 25-KETO
demonstrated that INDO did not affect 25-KETO conversion to Cortisol, providing
evidence that INDO did not cause a nonspecific effect. Therefore, this finding
implies that an interaction may exist between AA-COX and cAMP pathways, and
also supports the notions on that ACTH-activated cAMP production may exceed the
level that is required for steroidogenesis and factor(s) apart from cAMP also serve
as second messengers. It has been found that after the Cortisol dose-response
curve reached a plateau, higher doses of ACTH continued to increase cAMP
without further stimulation of steroidogenesis in bovine adrenal ZF cells
(Peytremann et al., 1973).
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The effects of AA alone on Cortisol output and StAR protein were not significant,
consistent with the report by Wang et al on MA-10 Leydig tumor cells. The addition
of AA did not affect progesterone production nor the expression of StAR protein in
MA-10 Leydig tumor cells (Wang et al., 2000). At physiological conditions, free AA
levels are very low since the liberated AA is rapidly metabolized to its downstream
derivatives (Naor, 1991). Thus, the major role of the AA cascade may be through
downstream metabolites rather than AA itself. AA promoted ACTH-induced Cortisol
increases, especially in the presence of 10~12 M ACTH. The mechanism for this
stimulatory effect was probably that AA metabolites also mediated steroidogenesis;
this may be critical at low concentrations of ACTH.
The effects of ACTH clearly demonstrated that 10"8 M ACTH dramatically increased
the cAMP levels, leading to marked Cortisol output. Meanwhile, the inhibitors of AA
cascade also altered 10"8 M ACTH-induced Cortisol secretion. On the other hand,
10"12 M ACTH did not change the cAMP levels and the effects of inhibitors on
Cortisol levels were more marked compared to those of 10"8 M ACTH. In summary,
10~8 M ACTH may activate at least two signalling systems, of which cAMP is a
predominate pathway; while 10"12 M ACTH may activate the PLA2-AA cascade as a
key signaling pathway. Dual signalling systems may co-exist under physiological
conditions.
In parallel with a possible connection between COX-AA and cAMP, it appeared a
cross-talk between the LOX-AA and the cAMP pathway as NDGA was also able to
reduce the cAMP levels. One mechanism of their interaction might be through Ca2+.
Ca2+ is a potent stimulator of intramitochondrial cholesterol transfer in bovine ZG
cells (Cherradi et al., 1996) and it can be enhanced by AA metabolites (Volpi et al.,
1980). The action of cPLA2 (a major isoform of PLA2) in adrenal ZF cells is Ca2+-
dependent (Lin et al, 1992). Other potential links may also play roles. For instance,
prostacyclin, a product of COX action, elevates cAMP levels in platelets (Gorman et
al., 1977). In kidney the AA metabolites by MOX were stimulated by interventions
that increased cAMP (Schwartzman et al., 1985).
Moreover, lipomodulin (also known as annexin I), a 40 kDa regulatory protein may
also be involved in the AA cascade. Non-phosphorylated lipomodulin is a inhibitor of
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PLA2. After phosphorylation by cAMP-dependent protein kinase lipomodulin loses its
inhibitory property, and this feature may regulate the release of AA. Satoh and co¬
workers has proposed that lipomodulin might act as a mediator between cAMP-PKA
and PLA2 (Satoh et al., 1992).
The effect of the PLA2 inhibitor, 4-BPB on Cortisol levels in medium containing 0.2%
FAF BSA was similar to those observed using 0.2% regular BSA, indicating that
regular BSA may not markedly affect the upstream AA cascade. Because the
effects of NDGA and INDO in FAF-BSA medium appeared somehow different from
those in regular BSA, this was suggestive that products associated with regular
BSA may complicate the downstream metabolism in the AA cascade. The regular
BSA may well contain fatty acids such as oleic acid, linoleic acid and AA which
contribute to steroidogenesis by becoming internalized in the cells.
The IC50 of NDGA for 15-LOX is 3x10"5 M (Salari et al., 1984), while the effect of
NDGA on the response to 25-KETO showed that 3x10"5 and 5x10"5 M NDGA
reduced 25-KETO-stimulated Cortisol increases. This inhibitory effect suggests that
NDGA may also impair the activities of other enzymes that may participate in
steroidogenesis. For example, NDGA is also an inhibitor of MOX (Capdevila et al.,
1988). The results presented by Nishimura et al showed that epoxyeicosatrienoic
acids (EETs), the products of MOX stimulated Cortisol production in bovine adrenal
ZF cells which may have capacity to metabolize AA via the MOX pathway
(Nishimura et al., 1989). In rat ZG cells when the MOX-AA pathway was blocked,
AA was converted to COX-AA and LOX-AA products (i.e. PGs and FIETEs)
respectively (Campbell et al., 1991). AA was rapidly converted to PGs/TXs by COX
or LTs by LOX and could also be transformed to epoxyeicosatrienoic acid by the
epoxygenase-cytochrome P450 system (Smith, 1989).
AA-861 is a highly selective and potent inhibitor for 5-LOX (Ashida et al., 1983)
which is a major form of LOX in the rat adrenal ZF (Hirai et al, 1985), but in the
bovine adrenal ZF cell 15-LOX is the principal LOX (Yamazaki et al., 1996). As the
current inhibitors for 15-LOX lack sufficient specificity, the role of 15-LOX in bovine
ZF cells can only be evaluated further when a potent specific inhibitor is available.
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Collectively, 10"8 M ACTH may trigger both cAMP and AA cascade signalling
systems, whereas, 10~12 M ACTH activates AA cascades as major mediators for
steroidogenesis. ACTH-induced steroidogenesis may be up-regulated by LOX-AA
pathway and also through MOX-AA, while it appears to be down-regulated or not
affected by the COX-AA pathway. Furthermore, cAMP and the AA cascade might
interact via other signalling molecules. The synthesis of StAR protein was regulated




CHAPTER 6 ROLE OF PROTEIN KINASE C IN MODULATING
STEROIDOGENESIS AND StAR PROTEIN
6.1 INTRODUCTION
In response to ACTH binding, second messengers exert their biological effects by
activating appropriate protein kinases. Nishikawa and co-workers have
demonstrated that 10"7 M ACTH can enhance the expression of StAR protein as
well as Cortisol synthesis via both PKA- and PKC-dependent processes in bovine
adrenal ZF cells (Nishikawa et al., 1996). On the other hand, 10"12 M ACTH
stimulated pregnenolone production without increasing PKA activity (Yamazaki et
al., 1996) and the dose-response curve of PKA activity showed that the level of PKA
activity was very low at 10"12 M ACTH, attaining a maximum at 10"9-10"8 M ACTH in
bovine adrenal ZF cells (Enyeart and Enyeart, 1998).
The calcium-activated, phospholipid-dependent PKC has been found in bovine
adrenal cortex (Vilgrain et al., 1984). The potent phorbol ester, 12-myristate-13-
acetate (PMA), also known as 12-0-tetrasecanoylphorbol-13-acetate (TPA), is a well
characterized positive regulator of PKC (Ashendel, 1985; Castagna et al., 1982).
Treatment with PMA and A23187 calcium ionophore promoted steroid hormone
synthesis in bovine adrenal ZF cells (Finn et al., 1988; Kenyon et al., 1988). The fatty
acids released from phospholipids may participate in the activation of PKC, an
integral part of the signal-induced degradation cascade that is initiated by the actions
of PLC and PLA2 (Shinomura et al., 1991). The protein kinase C, isoform a (PKCa)
which is present in all cells and tissues so far examined is activated by high
concentrations of AA in the presence of Ca2+. AA has been shown to be an activator
of PKC in a dose- and calcium-dependent fashion in human neutrophils (McPhail,
1984). Both in vivo and in vitro studies suggest that AA and DAG act synergistically to
activate PKC (Lester et al., 1991) and the biological functions of target proteins can
be modulated by PKC in a rapid and reversible manner (Azzi et al., 1992).
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The results presented in Chapter 5 have demonstrated that the AA cascade may also
mediate steroidogenesis, especially for a physiological concentration of ACTH.
Therefore, the aims of this work were:
• To examine whether Cortisol output and StAR protein levels are modulated by
PMA treatment in the absence and presence of ACTH.
• To evaluate the role of PKC in high-and low-concentration ACTH-stimulated
steroidogenesis and its relationship to StAR protein.
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6.2 EFFECTS OF PHORBOL ESTER ON CORTISOL SECRETION, StAR
PROTEIN AND cAMP FORMATION
6.2.1 Effects of PMA alone and combined PMA with ACTH on Cortisol
secretion
At 6 hr, PMA (10"s-106 M) alone had a modest stimulatory effect on Cortisol output;
the Cortisol levels were elevated by 10~8 M PMA (P<0.01) and 10"6 M PMA (P<0.01);
and peaked at 10"7 M PMA (p<0.001). At 24 hr, PMA (10 s and 10"6 M) appeared to
slightly reduce Cortisol levels, while 10"7 M PMA had no effect (Fig. 6-2-1-upper
panel).
PMA (10"8-10"6 M) did not alter ACTH (10~8M)-induced Cortisol increases after a 6 hr
treatment, whereas Cortisol output was inhibited in a concentration-dependent
manner after prolonged treatment (24 hr, Fig. 6-2-1-lower panel). The detailed
comparison is listed in Table 6-2-1.
Table 6-2-1 Multiple comparison tests of the effects of PMA on ACTH (10 8 M)-
induced Cortisol output
Comparisons P value
ACTH vs. ACTH + PMA (10"u M) P<0.001
ACTH vs. ACTH + PMA (10"7 M) P<0.001
ACTH vs. ACTH + PMA (10~6 M) P<0.001
ACTH + PMA (10"8 M) vs. ACTH + PMA (1CT7 M) P<0.001
ACTH + PMA (10~8 M) vs. ACTH + PMA (10 6 M) P<0.001
ACTH + PMA (10~7 M) vs. ACTH + PMA (1CT6 M) P<0.05
6.2.2 Effects of PMA alone and in combination with ACTH on StAR protein
levels
The data presented in Fig 6-2-2a&b illustrate that 10"8 M and 1CT7 M PMA slightly
enhanced StAR protein levels; 10"6M PMA significantly increased StAR protein
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Fig. 6-2-1 Changes of Cortisol production in response to PMA (upper panel),
ACTH and the combined PMA and ACTH (lower panel) treatments. Cells were
treated with PMA (10~8-10~6 M), ACTH (10~8 M) and combined various concentrations
of PMA with ACTH. Values are expressed as fold increases (mean ± SEM), n=3.
Columns without the same superscript are significantly different. Letters in lower














6 hr 24 hr
Fig. 6-2-2a Western immunoblot of StAR protein in response to PMA and
ACTH. C: Zero time untreated cells; B: Basal (untreated cells at 6 or 24 hr). All
samples (25 pg protein) were resolved on a 12.5% large SDS-PAGE gel. Sheep
anti-bovine peptide antibody (1:10,000) and donkey anti-sheep/goat antibody















































Fig. 6-2-2b The levels of StAR protein in response to PMA, ACTH and the
combined PMA and ACTH treatments. Cells were treated with PMA (10"8-10"6 M),
ACTH (10"8 M) and combined ACTH with various concentrations of PMA. Values are
expressed as fold increases (mean ± SEM), n=3. Columns without the same
superscript are significantly different. Letters in lower case indicate 6 hr time point
data and letters in upper case indicate 24 hr time point data. Columns with subscript
"1": Multiple comparison between various concentrations of PMA alone and the
basal; columns with subscript "2" are multiple comparison between ACTH and
ACTH in presence of PMA.
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levels (P<0.05) and also potentiated ACTH (10"8M)-induced StAR increases
(P<0.01) after 6 hr treatment. PMA (10~8 and 10"7 M ) appeared to inhibit both the
basal and ACTH-promoted StAR protein levels; prolonged 1CT6 M PMA treatment
(24 hr), however, potentiated ACTH-induced StAR levels (P<0.001).
The effects of PMA on StAR protein levels were also examined by using 4a-
Phorbol-12, 13-didecanoate (4a-PDD), an inactive phorbol ester. As shown in Fig.
6-2-2c&d, 4a-PDD did not affect StAR protein levels either 6 hr or 24 hr treatment
periods.
6.2.3 Effects of PMA alone and in combination with ACTH on cAMP
accumulation
PMA (10 8-106 M) alone did not alter cAMP production after both 6 and 24 hr
treatment (Fig. 6-2-3-upper panel). PMA at 10"8 M significantly potentiated ACTH
(10~8 M)-induced cAMP increase (P<0.05), and also at 10"7 and 10"6 M (P<0.001 for
both tests) at 6 hr. Only 10"7 PMA significantly enhanced ACTH-induced cAMP level
(P<0.05) at 24 hr (Fig. 6-2-3-lower panel).
6.3 ROLES OF PROTEIN KINASE C IN MODULATING
STEROIDOGENESIS AND StAR PROTEIN
Bisindolymaleimide I (GF109203X), a highly selective, cell-permeant PKC inhibitor
was used to evaluate the role of PKC in Cortisol output and the level of StAR
protein.
The data presented in Fig. 6-3-1 a (left panel) showed GF19203X at 10"7 and 10"6 M
had no effect on the basal level of Cortisol secretion, while it inhibited Cortisol output
at 105 M after 1 hr treatment (P<0.001). A similar profile was obtained after 6 hr
treatment (P<0.001).
Various concentrations of GF109203X (10"7 -10"5 M) significantly reduced ACTH
(1012 M)-induced Cortisol increases (P<0.001 for all three tests) at 1 hr. GF109203X
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(10 6 and 10"5 M) treatment also inhibited ACTH (10"12 M)-elevated Cortisol levels
(P<0.05 and P<0.001 respectively) at 6 hr (Fig. 6-3-1 a-right panel).
As shown in Fig. 6-3-1 b (right panel), GF109203X (10"7-10~5 M) attenuated ACTH
(10~8 M)-stimulated Cortisol increases in a concentration-dependent manner after 1
hr treatment, while only 10"5 M GF109203X inhibited Cortisol output after 6 hr
treatment. The multiple comparison is summarized in Table 6-3-1. In addition,
GF109203X (10~7-10~5 M) appeared not alter the level of StAR protein (Fig. 6-3-2).
Table 6-3-1Multiple comparison tests of the effects of GF109203X on ACTH
(10'8 M)-induced Cortisol output
1 hr 6 hr
Comparisons P value P value
ACTH vs ACTH + GF109203X (10"7 M) P<0.001 P>0.05
ACTH vs ACTH + GF109203X (10 6 M) P<0.001 P>0.05
ACTH vs ACTH + GF109203X (10"5 M) P<0.001 P<0.01
ACTH + GF109203X (10 7 M) vs ACTH + GF109203X (10"6 M) P<0.01 P>0.05
ACTH + GF109203X (1CT7 M) vs ACTH + GF109203X (10"5 M) P<0.001 P<0.001






6 hr 24 hr
Fig 6-2-2c Western immunoblot of StAR protein in response to PMA and 4a-
PDD. Lanes 1 and 5: Zero time untreated cells; lanes 2 and 6: 6 and 24 hr
untreated cells respectively; lanes 3 and 7: PMA (10 6 M)-treated cells; lanes 4 and
8: 4a-PDD (10"6M)-treated cells. All samples (20 pg protein) were resolved on a
12.5% large SDS-PAGE gel. Sheep anti-bovine peptide antibody (1:10,000) and
donkey anti-sheep/goat antibody conjugated with HRP (1:25,000) were diluted in















Basal PMA (10 M) 4a-PDD (10 M)
Fig. 6-2-2d Effects of PMA and 4a-PDD on the levels of StAR protein. Cells
were treated with PMA (10 6 M) and 4a-PDD (10~6 M) and harvested for Western
immunoblot after 6 and 24 hr treatment. Values from a single experiment are
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Fig. 6-2-3 Changes of cAMP production in response to PMA (upper panel),
ACTH and the combined PMA and ACTH (lower panel) treatment. Cells were
treated with PMA (10"8-10 6 M), ACTH (10 8 M) and combined various concentrations
of PMA with ACTH. Values are expressed as fold increases over the basal (mean ±
SEM), n=3. Columns without the same superscript are significantly different. Letters
























GF109203X (10 7 M) +
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■>-12Fig. 6-3-1 a Effect of GF109203X on the basal and ACTH (10 M)-induced
Cortisol levels. Cells were treated with various concentrations of GF109203X for
60 min prior to the addition of ACTH. Values are expressed as fold increases over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time point data and letters
in upper case indicate 6 hr time point data. Columns with subscript "1" are multiple
comparison between various concentrations of GF109203X alone and the basal;
columns with subscript "2" are multiple comparison between ACTH and ACTH in
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Fig. 6-3-1 b Effect of GF109203X on the basal and ACTH (108 M)-induced
Cortisol levels. Cells were treated with various concentrations of GF109203X for
60 min prior to the addition of ACTH. Values are expressed as fold increases over
basal levels (mean ± SEM), n=3. Columns without the same superscript are
significantly different. Letters in lower case indicate 1 hr time point data and letters
in upper case indicate 6 hr time point data. Columns with subscript "1" are multiple
comparison between various concentrations of GF109203X alone and the basal;
columns with subscript "2" are multiple comparison between ACTH and ACTH in
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Fig. 6-3-2 Western immunoblots of StAR protein in response to ACTH and
various concentrations of GF109203X at 1 hr (upper panel) and at 6 hr (lower
panel). C: Zero time point control; D: 0.05% DMSO control; B: 1 hr or 6 hr
Untreated cells. Samples (25 pg protein) were resolved on two 12.5% large SDS-
PAGE gels. Sheep anti-bovine peptide antibody (1:10,000) and donkey anti-
sheep/goat antibody conjugated with HRP (1:25,000) were diluted in PBS/10%




Despite promoting StAR protein synthesis PMA singularly did not markedly increase
the Cortisol levels. A similar result was obtained by Clark et al who showed that PMA
stimulated StAR expression but not steroidogenesis in H295R cells (Clark et al.,
1995a). This is possibly due to a lack of Ca2+ mobilization to play a synergetic role
since PMA requires Ca2+ ionophore to open the Ca2+ channel for steroidogenesis
(Berridge et al, 2000).
PMA (10"8-106 M) inhibited ACTH-induced Cortisol secretion in a concentration-
dependent manner after 24 hr treatment. A possible reason for this is that chronic
treatment may alter expression of various steroidogenic enzymes, leading to
decrease in Cortisol production. For example, PMA (107 M) attenuated the large
increase in CYP17 induced by ACTH (10 8 M) after prolonged treatment (Bird et al.,
1993). This may be a mechanism by which PMA reduced the remarkable increase
in ACTH-induced Cortisol output although it enhanced StAR protein under the same
condition.
PMA, most likely as a PKC activator, also potentiated ACTH-induced cAMP
formation, in agreement with other reports. PMA promoted ACTH-stimulated cAMP
production on Day 0, 3, and 7 in bovine adrenocortical cells (Begeot et al., 1988)
and also in bovine ZG cells (Baukal et al., 1994). The effect of PMA on cAMP levels
was prevented by a inhibitor of protein kinase (staurosporine); PMA partially
mimicked the effect of Ang II on the ACTH-induced cAMP response (Baukal et al.,
1994). This raises the possibility of an interaction between cAMP and PKC
pathways. PKC may be located at a cross-over point of various pathways in
hormone signalling action (Nishizuka, 1984). Houslay proposed that PKC might play
a pivotal role in modulating relationships between signal transduction pathways
(Houslay, 1991). Furthermore, Jacobowitz and Iyengar concluded that the activation
of PKC by PMA resulted in phosphorylation and stimulation of AC2, a cell
membrane enzyme without binding to G-protein, providing a G-protein-independent
mode for signal transduction (Jacobowitz and Iyengar, 1994). In this present work,
PMA alone had no effect on cAMP production, consistent with the result obtained by
Culty and co-worker (Culty et al., 1984). PMA in combination with ACTH, however,
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led to further increases in ACTH-induced cAMP production, implying the influence
of PMA on cAMP production might rely on an ACTH trigger.
GF109203X reduced ACTH-stimulated Cortisol output but appeared not to alter the
levels of total StAR protein, implying that phosphorylation of pre-existing StAR
protein by PKC rather than the activation of nuclear transcription might be involved
in steroidogenesis, i.e. non-genomic regulation is also important for steroidogenic
capacity; or/and other phosphoprotein(s) might participate in steroidogenesis.
Moreover, the stimulatory effects of ACTH on StAR protein and Cortisol were also
inhibited by KN-93, a specific inhibitor of CaM kinase II, but not KN-92, an analogue
of KN-93 in bovine adrenal ZF cells. This is suggestive that the action ACTH is at
least partially regulated by a calcium/calmodulin-dependent protein kinase II in
addition of PKA and PKC (Nishikawa et al., 1997).
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CHAPTER 7 CONCLUDING REMARKS AND FUTURE
DIRECTIONS
In the past few decades extensive studies have demonstrated that the availability of
cholesterol is an important determinant of steroidogenesis in the adrenal and the
gonad. The outstanding fundamental question(s) is (are) what is (are) the regulator
(s)/mediator(s) and how does this process happen. Steroidogenic acute regulatory
(StAR) protein has been identified to play a crucial role in cholesterol transfer from
the outer to the inner mitochondrial membrane where the first step of cholesterol
conversion to steroid hormones occurs. This discovery has triggered research on
steroidogenesis in many directions at the cellular and molecular levels. The work
presented in this thesis has evaluated the role of StAR protein and its relationships to
the signalling systems of ACTH-induced steroidogenesis in primary cultures of
bovine adrenal ZF cells. The conclusion and speculation raised from this work are
summarised as below:
1. Characterisation and validation of a novel anti-bovine peptide StAR polyclonal
antibody has permitted detection of StAR protein by Western immunoblotting.
Furthermore, a newly formulated protocol based on enhanced
chemiluminescence methodology has provided an accurate approach to quantify
StAR protein using a molecular image analyser. The linearity and the reliability of
this technique have been confirmed by similar testing of an ubiquitous cell
protein, actin.
2. The observation of the level of StAR protein expression in the absence and
presence of ACTH (10"8 M) at separate times over five days of culture allowed
the determination of Day 3 as an appropriate starting time for further
investigations and treatments. Concentration response curves presented more
detailed changes in StAR protein, Cortisol and cAMP levels at acute (1 hr) and
chronic (6 hr) phases. Marked changes in StAR protein appeared at 6 hr and the
greater increases in Cortisol output were correlated with greater increases in the
levels of StAR protein. At both 1 and 6 hr, the Cortisol levels were significantly
elevated when the concentrations of ACTH were equal to or greater than 10"12 M.
While increases in cAMP were measurable at 10"11 M and higher concentrations
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of ACTH, suggesting cAMP may not be the principal second messenger at low
concentrations of ACTH (1012 M) that still elicit increased Cortisol secretion.
3. The relationships between StAR protein and Cortisol production as well as cAMP
formation were studied further through 0.5-24 hr treatment periods. The high
concentration ACTH (10 8 M) resulted in the temporal appearance of total StAR
protein changes coincidental with Cortisol production, supporting the notion of a
direct relationship between the levels of StAR protein and the steroidogenic
capacity under supraphysiological conditions. However, at low concentration
ACTH (10"12 M), there was a lack of close parallelism between StAR protein and
Cortisol levels. The difference of the action of high- and low-ACTH was also
confirmed by measurements of cAMP production which showed that the changes
of Cortisol were consistent with those of cAMP at 10~8 M ACTH. On the other hand,
the Cortisol levels were elevated without any notable increase in cAMP over the
basal level at 10"12 M ACTH, suggesting that the major signalling is possibly cAMP-
independent.
4. To identify possible second messengers, in addition to the cAMP, the role of the
PLA2-AA signalling system was evaluated. 4-BPB, a selective inhibitor of PLA2,
impaired the increases in Cortisol output induced by ACTH, suggesting that PLA2-
catalysed pathway may be a key approach for releasing AA from phospholipid.
Investigation of the downstream AA cascade demonstrated that NDGA, a
selective inhibitor of LOX, significantly reduced ACTH-elevated Cortisol levels,
suggesting that AA-LOX pathway may be major route of AA conversion to its
metabolites. INDO, a selective inhibitor of COX, slightly enhanced Cortisol output
induced by ACTH, implying that the function of separate branches (i.e. COX and
LOX) of the AA cascade may differ in mediating steroidogenesis, possibly via a
pivotal mechanism. Overall, the effects of these inhibitors were acute and more
profound at low concentrations of ACTH (10~12 M). Meanwhile, the mediation of
Cortisol secretion by the third branch of AA metabolism, cytochrome P450-
dependent monoxygenase pathway metabolites cannot be ruled out.
5. Results reported herein favour a dual signalling model, cAMP and the PLA2-AA
cascade. The roles of PLA2-AA signalling pathways are predominantly observed
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in the presence of low concentrations of ACTH. The differential activation of
second messenger systems may be dependent on the intensity of ACTH
treatment. Furthermore, NDGA and INDO that are inhibitors of AA metabolism
also affected the cAMP levels, implying an interaction between the two signalling
systems. Apart from the cAMP and PLA2-AA second messenger systems, Ca2+
may primarily or/and co-ordinately participate in activation of steroidogenesis; for
instance, the involvement of PLA2 in signal transduction may be dependent on
Ca2+. Meanwhile, ACTH-induced increases in cAMP levels may be via a Ca2+-
sensitive adenylate cyclase. Ca2+ is possibly a cross-over point between cAMP
and AA cascades. Therefore, a full spectrum scenario may be that the cAMP
pathway, AA cascades and Ca2+ are triple second messengers, which constitute
signalling networks to mediate steroidogenesis. The signal transduction is not
only via the linear correlated multiple factors, but also via the interaction of the
factors in a transient or a stable manner. Moreover, cAMP might also play other
roles such as in protein-protein interaction in addition to facilitating protein
phosphorylation as a conventional second messenger.
6. Both concentration response curves and time courses showed that Cortisol was
markedly increased acutely without significant alteration in total amount of StAR
protein, implying that the initial steroidogenesis may rely on the pre-existing StAR
protein, or may be StAR protein-independent. Furthermore, StAR protein did not
show notable quantitative variations among inhibitor-untreated and treated cells
in the presence of ACTH. This raised the possibility that, in response to, ACTH
StAR may change in phosphorylation forms rather than in net protein amount
or/and another protein may also be involved in initiating steroidogenesis.
7. PMA, a PKC activator, increased StAR protein without significantly elevating
Cortisol levels in the absence of calcium ionophore, suggesting that the
expression of StAR protein may be regulated by PKC and that Ca2+ mobilisation
is required for steroidogenesis. Chronically, PMA attenuated ACTH-induced
Cortisol secretion despite elevated StAR protein levels, implying that an inhibitory
effect of PMA on other components (e.g. CYP17) of steroidogenic pathways
likely occurred. The inhibitory effect of bisindolylmaleimide I (GF109203X), a
highly selective inhibitor of PKC, on Cortisol output provided evidence that a
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possible sequential activation of steroidogenesis might be PLA2-AA-PKC.
Overall, PKA, PKC and Ca27calmudulin-dependent kinase II may be activated
through cAMP, the PLA2-AA and Ca2+signalling pathways respectively which are
initially dependent on the concentrations of ACTH.
8. Ang II, an activator of both PKC and Ca2+, moderately enhanced StAR protein
and Cortisol levels. The effect of the combined Ang II and various concentrations
of ACTH on Cortisol output exceeded those of Ang II and ACTH alone although
the combinations did not produce additive effects on the expression of StAR
protein. The mechanism of the interaction of Ang II and ACTH remains unclear.
9. It appears that other factors may also participate in the process of initiating
and/or ongoing cholesterol translocation to achieve a flexible and comprehensive
steroid output although StAR has been identified as a key mediator in initiating
steroidogenesis. PBR and arachidonic acid-related thioesterase involved in
steroidogenesis (ARTISt) have emerged as putative candidates in concert with
StAR protein to facilitate cholesterol delivery.
Fig. 7-1 illustrates an overview of the main features of this thesis and the possible
involvement of other factors.
In summary, there are at least two fundamental mechanisms for steroidogenesis,
i.e. the activation of second messenger networks and the regulation of StAR
protein, either via rapid non-genomic response (e.g. phosphorylation) or genomic
activation (transcription).
In addition, it should be noted that this study was focused on the correlation
between the changes of Cortisol and StAR protein. However, Cortisol is the end
product of the steroidogenic pathway in adrenal ZF cells, several components of the
steroidogenic pathway also steer the nature steroid synthesis (e.g. CYP11 A, CYP17
and CYP11B steroid hydroxylase, etc), since steroidogenesis is a complex and
multifactorial process. The co-ordinate roles of those proteins must also be
considered, particularly for long term, chronic effects.
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Fig. 7-1 A summary of the main story presented in this thesis and
the possible involvement of other factors. PLA2: Phospholipase A2;
AA: Arachidonic acid; PKA: Protein kinase A; PKC: Protein kinase C;
CaM kinase II: Ca27calmodulin-dependent kinase II; PBR: Peripheral
benzodiazepine receptor; ARTISt: Arachidonic acid-related
thioesterase involved in steroidogenesis.
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This work should promote future work on several aspects:
1. Phosphorylation of StAR protein in response to hormonal treatment
StAR protein is initially synthesised as a precursor in cytosol and cleaved to mature
protein in mitochondria, and can be phosphorylated by several protein kinases.
Therefore, StAR protein exists in several forms in terms of molecular mass and
isoelectric point value. Because the measurement of total protein amount appears
not enough for evaluating the precise action of StAR protein, it would be likely to be
of much value to examine the relationship between acute steroidogenesis and
various forms of StAR protein in the absence and presence of ACTH. A more
detailed investigation would be to look at StAR protein in both mitochondrial-
enriched and cytosol fractions. Whether ACTH induces any changes in different
forms of StAR protein is now being investigated by 2-D gel electrophoresis. The
preliminary data showed that StAR protein diverted to more acidic forms in the
presence of 10~8 M ACTH.
2. Measurement of pregnenolone
Pregnenolone is the first product of steroidogenic pathways, its content therefore
more closely reflects the action of StAR protein/other proteins in facilitating
cholesterol transfer. As only low level pregnenolone accumulates in cell culture
medium, the measurement probably requires the use of inhibitor(s) for preventing
pregnenolone conversion to its products (progesterone and 17-
hydroxypregnenolone).
3. Further studies on secondary messengers and protein kinase systems
i) Examination of the role of Ca2+ in steroidogenesis and whether Ca2+ is a link
between the cAMP and PLA2-AA signalling pathways.
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ii) Evaluation of roles for PLA2-AA signalling pathways using a specific inhibitor. For
example, methyl arachidonyl fluorophosphonate (MAFP) is designed as a potent
PLA2 inhibitor in vitro.
iii) Investigation of the effect of Ca2+-CaM kinase II on phosphorylation of StAR
protein and steroidogenesis.
4. Evaluation of relationships between StAR protein and steroid output using
superfusion system
The Cortisol levels after hour(s) periods of incubation only reflect accumulated
steroid production, whereas the superfusion system is able to demonstrate more
accurately cell responses to a treatment within a few seconds/minutes. A precise
temporal relationship between StAR protein and steroid output could be determined
to understand the acute regulatory mechanism of StAR protein in steroidogenesis.
5. Identification of protein-protein interaction
During the last decade, a number of studies have demonstrated that protein-protein
interactions have emerged as a major regulatory mechanism for intracellular
networks. One of the sophisticated techniques, yeast two-hybrid system, is
designed for elucidating the role of a protein in one or another cellular process
(Pirson et al., 1999). The examination of the interactions of StAR-PBR, StAR-
ARTISt and PBR-ARTISt may provide a more comprehensive scenario of
cholesterol translocation, a key initial step for steroidogenesis.
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Appendix I
APPENDIX I MATERIALS OBTAINED FROM COMMERCIAL
SOURCES
Amersham Life Science Ltd., Amersham Place, Buckinghamshire HP7 9NA, UK
Cortisol-3-(0-carboxymethyl) oximino- (2-[1251] iodohistamine), IM 129
ECL Western blotting analysis system, RPN 2108
BDH-Merck Ltd Hunter Boulevard, Magna Park, Lutterworth LE17 4XN, UK
Acetic anhydride, Prod. 10002
Acetic acid glacial, Prod. 100018Q
Acrylamide, Prod. 44299 4J




Sodium acetate anhydrous, Prod. 10236
Sodium dihydrogen orthophosphate, Prod. 30132
Di-sodium hydrogen orthophosphate anhydrous, Prod. 10249
Trisodium citrate, Prod. 102427X
The Binding Site Ltd., P.O. BOX 4073, Birmingham B29 6AT, UK
Donkey anti-sheep/goat immunoglobulins peroxidase, AP 360
Donkey anti-rabbit immunoglobulin peroxidase, AP311
Bio-Rad Laboratories Ltd., Maylands Avenue, Hertfordshire HP2 7TD, UK
30% Acrylamide/Bis solution 37.5:1 (2.6% C), 161-0158
Kaleidoscope pre-stained standards,161-0324
Pre-stained SDS-PAGE standards (low range), 161-0305
Boehringer Mannheim UK (Diagnostics & Biochemicals) Ltd., Bell Lane, Ease
Sussex BN7 1LG, UK
Protease inhibitor cocktail tablets, 1697498
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Calbiochem-Novabiochem (U.K.) Ltd., Padge Road, Nottingham NG9 2JR, UK
Bisindolylmaleimide I (GF109203X), Cat. No. 203290
Protein kinase C inhibitor 19-27, Cat. No. 476475
Gibco BRL (Life Technologies Ltd.), 3 Fountain Drive, Paisley PA4 9RF, UK
Amphotericin B (250 pg/ml), 15290-026
Dubecco's MEM/NUT mix F-12 (Ham), 31330-038
Earle's balanced salt solution (EBSS), 14015-044
Nutrient mixture Ham's F10, 31550-023
Penicillin/Streptomycin (10,000 units/ml Penicillin and 10,000 pg/ml Streptomycin),
15140-114
Trypsin 2.5%, 25095-019
Lome Laboratories Ltd., PO Box 6, Twyford, Reading RG10 9NL, UK
Collagenase (Type 1), CLS 1
Marvel Original, Stafford ST20 OOJ, UK
Dried skimmed milk powder (99% fat free)
National Institute for Biological Standards and Control (NIBSC), Potters Bar,
Herts, UK
Angiotensin II (asp1-val5, WHO standard 64/15)
Novartis Pharma AG, CH-4332, Stein, Switzerland
Synacthen Ampoules (ACTH1.24)
Pierce & Warriner (UK) Ltd., 44 Upper Northgate Street, Chester CH1 4EF, UK
SuperBlock blocking buffer in PBS, 37515
SuperSignal West dura extended duration substrate, 34075




Scottish Antibody Production Unit (SAPU), Lanarkshine, ML8 5ES, UK
Donkey anti-rabbit serum, S 022-220
Donkey anti-sheep/goat IgG, S024-220
Normal rabbit serum, S119-205
Normal sheep serum, S031-220
Sheep anti-cortisol serum, S004-201
Sigma-Aldrich Company Ltd., Fancy Road, Poole, Dorset, BH12 4QH, UK
Arachidonic acid, A-3555
Albumin, Bovine (Fraction V, Fatty acid free), A-8806
Albumin, Bovine (Fraction V), A-9418
Ammonium persulfate, A-3678
Brilliant blue G (Coomassie brilliant blue G-250), B-0770
4-Bromophenacyl bromide, B-2006
Controlled process serum replacement-1, C-8905
Deoxycholic acid (sodium salt), D-6750
Gelatin (Type B), G-6269
Hydrocortisone, H-4001
Indomethacin, I-7378
Kodak X-OMAT film, F-5513
Kodak X-OMT LS film, F-1149
Lauryl sulfate (SDS, sodium dodecylsulfate), L-3771
Immobilon-P polyvinylidene difluoride (PVDF), P-2938
2-Mercaptoethanol, M-7154
Nordihydroguaiaretic acid, N-5023
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ABSTRACT
We have studied the effects of inhibitors of arachidonic acid (AA) metabolism,
nordihydroguaiaretic acid (NDGA), a lipoxygenase (LPX) inhibitor, and
indomethacin (1NDO), a cyclooxygenasc (COX) inhibitor, on Cortisol secretion
and StAR protein in primary cultures of bovine adrenal zona fasciculata (ZF)
cells. NDGA inhibited Cortisol secretion in response to both 10~12 M and 10 s M
ACTH. AA (1CT1 M) partially reversed the inhibition of Cortisol secretion by
NDGA at 10"12 M ACTH but not at 10"8 M ACTH. On the other hand, INDO
potentiated the Cortisol response to 10"12 M ACTH. Neither NDGA nor INDO
significantly affected StAR protein levels. These results suggest a StAR protein-
independent role for the LPX and COX pathways in acute Cortisol secretion, and
support the hypothesis that LPX products of AA metabolism are key cellular
signals when bovine ZF cells are acutely stimulated by physiological
concentrations of ACTH (10"12 M).
INTRODUCTION
Our previous results have demonstrated that the secretion and expression
profiles for Cortisol and Steroidogenic Acute Regulatory (StAR) protein differ in
response to high (10"8 M) versus low (10"'2 M) ACTH treatment of bovine ZF
cells (1). There was a strong positive correlation between Cortisol secretion and
705
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StAR protein induction in response to 104 M ACTH but not !0'12 M ACTH. The
intracellular mechanism for ACTH-stimulated steroidogenesis at high
concentrations is principally via a cAMP dependent pathway (2-4). On the other
hand, several studies strongly suggest that arachidonic acid (AA) metabolites may
be important second messengers for ACTH stimulation (5, 6). The purpose of this
study was to investigate the role of the AA pathway in the stimulatory effects of
ACTH, at both high (10"s M) and low (10"i2 M) concentrations, on Cortisol output
and StAR protein levels.
MATERIALS AND METHODS
Nutrient mixture Ham's F10 medium and antibiotics were obtained from Life
Technologies Ltd (Paisley, UK). ACTH1.24 was purchased from Alliance
Pharmaceutical Ltd (Chippenham, Wiltshire, UK). CPSR-1, bovine serum
albumin (BSA), arachidonic acid, nordihydroguaiaretic acid and indomethacin
were obtained from Sigma (Poole, Dorset, UK). After isolation, bovine ZF (1.5
x 106/35 mm well) cells were cultured in Ham's F10 containing 10% (v/v) CPSR-
1 for 48 lir prior to the medium being replaced overnight with Ham's F10
containing 0.2% (w/v) BSA (7, 8). Cells were treated with ACTH (10"12 M or 10*
8
M) after 15 min pre-incubation with NDGA or INDO. Cortisol in the medium
was measured by radioimmunoassay. StAR protein levels were quantified by
Phosphor Imaging analysis of ECL western immunoblots (8). Statistical analyses
were performed with ANOVA, followed by Student-Newman-Keuls multiple
comparison test.
RESULTS AND DISCUSSION
As shown in Fig 1 A, 5xlO*5 M NDGA inhibited 10*12 M- and 104 M ACTH-
stimulated Cortisol production and 2x10"6 M NDGA also decreased 10'12 M
ACTH-stimulated Cortisol secretion but not that at i04 M ACTH, suggesting that
NDGA was more inhibitory at the lower ACTH concentration. The addition of
10"5 M or KT1 M INDO increased 10*12 M ACTH-stimulated Cortisol secretion at
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1 hr and 10"4 M INDO enhanced 10'12 M ACTH-stimulated Cortisol secretion at 6
hr. Neither concentration of INDO significantly affected 10"8 M ACTH-
stimulated Cortisol output (Fig IB). In all treatments with inhibitors, there were
no measurable alterations in ACTH-induced StAR protein levels (data not
shown). The addition of arachidonic acid rescued the inhibitory effect of NDGA
on 10"'2 M ACTH-stimulated Cortisol output at both 1 and 6 hrs. But the Cortisol
secretion was less effectively restored at 1 hr, indicating that NDGA has a more
marked effect on Cortisol production at the early time point. AA only marginally
changed the NDGA-inhibited Cortisol output at 10"8 M ACTH (Fig 1C).
AA is released from membrane phospholipids by the action of phospholipase
A2 (9) and then can be further metabolised to other eicosanoids via two main
pathways (LPX and COX). AA and its metabolites have been demonstrated to
function as second messengers in response to trophic hormone stimulation (10-
12). Our results have shown that the inhibition ofNDGA was more notable at 10"
12 M ACTH and in the acute phase of steroidogenesis. The enhanced effect of
INDO on 10"12 M ACTH-stimulated Cortisol production suggests that the
metabolism of AA through cyclooxygenase may be prevented and redirected into
lipoxygenase metabolites, thereby leading to increased Cortisol secretion.
In conclusion, (i) arachidonic acid and its metabolites may be a key second
messenger system for steroidogenesis in response to low concentrations of ACTH
(10-12 M); (ii) high concentrations of ACTH (10'8 M) which stimulate the cAMP
signalling pathway may also activate the arachidonic acid cascade; (iii) StAR
protein levels remain unchanged after treatment with AA pathway inhibitors.
This raises the possibility that the role of AA may be independent of newly
synthesised StAR protein; or that StAR protein may co-operate with other proteins
(e.g. ARTISt, PBR) in regulating Cortisol secretion in bovine adrenal 2F cells.
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ABSTRACT
Upregulation of the steroidogenic acute regulatory
protein (StAR) is implicated in the rapid synthesis
and secretion of steroidogenic cells to produce
steroids in response to stimulation by trophic
hormones of the gonadal and stress axes. In the
present study, we have assessed the kinetics of both
StAR gene transcription and protein biosynthesis in
primary cell cultures of bovine adrenocortical and
ovarian theca cells, under conditions of acute
stimulation by corticotrophin (ACTFI) and luteiniz¬
ing hormone (LH), respectively. In both cell
systems, detectable upregulation of StAR gene
transcription occurred within 1—2 h, reaching
maxima at 4 h (theca cells) or 6 h (adrenocortical
cells). mRNA levels returned rapidly to baseline, by
12 h or 24 h, respectively. Specific StAR protein
levels were assessed by western blotting using a
novel antibody raised against a bovine StAR
peptide, and showed a similar fast upregulation,
albeit delayed by 1—2 h compared with the mRNA.
The response of the cultured theca cells was more
acute than that of the adrenocortical cells, possibly
reflecting the propensity of the LH receptor to
desensitize rapidly, unlike the ACTIT receptor. The
primary bovine theca cell cultures were also used for
fully homologous transfection studies using various
deletion promoter—reporter constructs of the bovine
StAR gene. Kinetic analysis of the results indicated
that the acute transcriptional response resides
within the proximal ( — 315 bp) promoter region,
which includes two putative responsive elements for
the steroidogenic factor-1. More distal promoter
regions may be involved in modulating the
specificity of expression by combining enhancer and
inhibitory functions.
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INTRODUCTION
In steroidogenic tissues, the rate-limiting step in the
acute hormone-dependent upregulation of steroid
biosynthesis is considered to be the transport of the
cholesterol substrate to the inner mitochondrial
membrane, where it is converted to pregnenolone
by the cytochrome P450 cholesterol side-chain
cleavage complex (reviewed in Thomson 1998).
This rate-limiting mitochondrial transport is depen¬
dent upon the de novo biosynthesis of new protein
(reviewed in Stocco & Clark 1996). An important
candidate for this role is the recently cloned
steroidogenic acute regulatory protein (StAR; Clark
et al. 1994), which is rapidly and highly upregulated
after a steroidogenic stimulus, and becomes associ¬
ated with mitochondria (Stocco & Clark 1996).
Furthermore, the apparently indispensible nature
of StAR is revealed by the severe impairment of
steroidogenesis after inactivation of the StAR
gene in mice by homologous recombination (Caron
et al. 19976), or in the naturally occurring human
deficiency disease, congenital lipoid adrenal
hyperplasia (Miller 1997).
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The cDNA and gene sequence encoding the
StAR protein have been elaborated, initially for the
mouse (Clark et al. 1994), and subsequently for
other species, including the bovine (Hartung et al.
1995). Initial experiments investigated the basal
levels of StAR mRNA in different tissues in vivo, or
in tumour cell lines, and the levels attained after
long-term stimulation. Although several studies
have looked at factors regulating the StAR gene
promoter (reviewed in Reinhardt et al. 1999b), most
of these used a prolonged (>12 h) stimulation
protocol, and so the molecular mechanisms respon¬
sible for the acute (<4 h) cAMP-dependent upregu-
lation of StAR gene transcription remain unclear.
In order to investigate this in a homologous system,
we have exploited the ability of bovine ovarian theca
cells and bovine adrenocortical cells to produce
large amounts of steroids in response to acute
stimulation by the natural adenylate cyclase-linked
secretagogues, luteinizing hormone (LH) and
adrenocorticotrophic hormone (ACTH), respect¬
ively. Using northern and western blotting for
StAR mRNA and protein, we first characterized the
time-course of the acute specific stimulation of
StAR gene transcription in these cell types by
their natural effectors. Subsequently, we used
transfection of previously characterized promoter-
deletion—reporter constructs derived from the
bovine StAR gene (Rust et al. 1998) into cultured
bovine primary ovarian theca cells to provide a
completely homologous system in which to de¬
lineate elements of the StAR promoter that are
required for the rapid LH-dependent increase in
transcription. These results show that the time- and
hormone-specificity of StAR gene transcription
reside within the proximal promoter region,
between — 315 and the transcriptional start site.
MATERIALS AND METHODS
Cell culture
Bovine theca interna cells were prepared from large
antral follicles (10—25 mm diameter) of ovaries
collected from mid- to late-cycle cows at the local
abbatoir. Cell preparation and primary culture
conditions were exactly as described by Bathgate
et al. (1999). After Percoll purification, cells were
resuspended in 1 : 1 Dulbeccos's minimal essential
medium and Ham's F-12 medium, supplemented
with 2 mM L-glutamine, 100 IU/ml penicillin,
lOOpg/ml streptomycin, 0T% BSA, 5 pg/ml trans¬
ferrin, and 5 ng/ml sodium selinite. For mRNA and
protein preparation, approximately 106 cells were
seeded into vitrogen-coated six-well plates and
cultured at 37 °C under 95% air-5% C02 for 6 days
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(with medium changed every 2 days), attaining in
that time approximately 80% confluence. For
measurements of endogenous mRNA and protein
production, after the medium change on day 6, cells
were supplemented in addition with 100 ng/ml
bovine insulin with or without 10 ng/ml bovine
luteinizing hormone (bLH; a kind gift of NIADDK
and the National Hormone and Pituitary Program,
NIH, Bethesda, MD, USA), and culture continued
for the times indicated. Primary zona fasciculata/
reticularis (ZFR) cells were isolated from sliced
bovine adrenocortical tissue as previously described
(Williams et al. 1989, Nicol et al. 1998) and were
plated at a density of 1-5 x 106 per well of a six-well
plate for both mRNA and protein studies. After
plating, cells were maintained for 48 h in Ham's
F-10 medium containing 10% v/v controlled pro¬
cessed serum replacement-1 (Sigma, Poole, Dorset,
UK), 100 IU penicillin, 100pg/ml streptomycin
and 5 pg/ml amphotericin B at 37 °C under 95%
air—5% C02, with one medium change after 24 h,
and then for a further 16 h in Ham's F-10 medium
containing 0-2% BSA and antibiotics as above,
before hormone treatment using 10 nM Synacthen
(synthetic ACTH(1—24) peptide, Novartis Pharma¬
ceuticals, Camberley, Surrey, UK) in the same
medium.
Northern hybridization
For the ovarian theca cells, total RNA was extracted
using the peqGOLD RNA-Pure (peqLab,
Erlangen, Germany) reagent and pooled from two
wells per experiment for each data point. Two
micrograms total RNA per slot were subjected to
northern hybridization using 1-3% agarose—2-2 M
formaldehyde gels in morpholinopropanesulphonic
acid running buffer (Sambrook et al. 1989). RNA
was transferred to a nylon membrane (Nytran;
Schleicher & Schiill, Dassell, Germany) by over¬
night capillary transfer and fixed by u.v. crosslink-
ing. Hybridization with a 750 bp gene-specific
probe from the 5' region of the bovine StAR cDNA
was exactly as previously described (Hartung et al.
1995). To control for even loading and transfer of
the RNA, blots were rehybridized using a radio-
labelled probe specific for the bovine SI5 ribosomal
protein (Bathgate et al. 1999). For the ZFR cells,
total RNA was isolated using the RNAzol B reagent
(Biogenesis, Poole, Dorset, UK), and 20 pg RNA
per slot was denatured with glyoxal (Thomas 1983),
resolved on a 1-2% agarose gel in 10 mM sodium
phosphate pH 7-0 buffer, capillary-transferred to
positively charged nylon membranes (Stratagene)
and fixed by u.v. crosslinking. Hybridization for
StAR mRNA was as above, but using a somewhat
www.endocrinology.org
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shorter 5' cDNA probe (accession number S79908,
nucleotides 210—608). Even loading and transfer
were confirmed by rehybridization using a P-actin
probe. All northern and western (see below)
blotting experiments were repeated at least twice for
fully independent batches of cells, and gave fully
reproducible results.
Antibody production and western blotting
Total cellular protein (ZFR cells 25 pg, theca cells
15 pg per sample), was prepared by homogenization
in PBS containing 0-1% SDS and 1% sodium
deoxycholate, resolved on a 12% acrylamide gel,
and electroblotted onto Immobilon-P membrane
(Sigma). Western analysis was carried out using, as
primary antibody, a polyclonal sheep antiserum
raised against a peptide fragment (AMQRALGIL
KDQEGWKKESRQANGDE; amino acids 82-
107; Hartung et al. 1995) from the predicted bovine
StAR protein sequence attached to a lysine-web-
based eight-branched antigen scaffold (The Binding
Site, Birmingham, UK), and a donkey anti-sheep
horseradish peroxidase-conjugated second antibody.
After preliminary optimization (data not shown),
primary and secondary antibodies were used
respectively at 1 : 10 000 and 1 : 25 000 dilutions
in PBS containing 10% blocking buffer (Pierce,
Rockford, IL, Staffs, USA) and 2% w/v non-fat
milk (Marvel Original; Premier Beverages, Stafford,
UK) for immunodetection of adrenocortical pro¬
teins, and at 1 : 7500 and 1 : 10 000 dilutions,
respectively, in PBS containing 10% blocking buffer
(Pierce) and 1% non-fat milk for theca cell proteins.
The final signal was visualized by chemilumi-
nescence (SuperSignal ULTRA kit; Pierce). The
specificity of the antibody was demonstrated first by
its ability to detect a protein in adrenocortical
protein extracts at the anticipated size of approxi¬
mately 30 kDa, the pattern of expression of which
followed closely behind that of the StAR mRNA
(see later), and, secondly, by the complete elimi¬
nation of the specific 30 kDa band as a result of the
addition of an excess (>3 ng/ml) of the peptide used
to generate the antibody (not shown).
Cell transfection and analysis
All bovine StAR promoter-reporter DNA con¬
structs, in addition to control vectors, were exactly
as previously described (Rust et al. 1998). DNA was
purified using the EndoFree Plasmid Maxi Kit
(Qiagen, Hilden, Germany) as described by the
manufacturer. For transfection experiments, 10°
bovine theca cells per well, prepared as above, were
seeded into 12-well plates, and cultured as above
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in the presence of 100 ng/ml insulin for 2 days.
Cells were then washed briefly in PBS before
the addition of OPTI-MEM (Gibco-BRL,
Deisenhofen, Germany) transfection medium.
Transfection was carried out by adding 5 pg per
well LipofectAMINE (Gibco-BRL) at a ratio of
2 : 1 with the DNA to be transfected, and
incubating for 5 h. Medium was then replaced by
the standard culture medium and incubation
continued for a further 3 days, before treatment
or not with 10 ng/ml bLH, for the times as
indicated. Cells were then washed rapidly in
PBS and immediately extracted into 40 pi reporter
lysis buffer (Luciferase Assay System; Promega,
Madison, WI, USA) before luciferase activity was
measured using the same kit. As cotransfected
control, a P-galactosidase reporter gene driven from
the cytomegalovirus (CMV) promoter was used,
measuring the resulting activity using the Galacto-
Light kit (Tropix, Bedford, MA, USA). All
transfections were performed in triplicate for any
batch of primary cells. All experiments were
repeated at least twice using independent batches of
cells, with fully reproducible results.
RESULTS
Expression of endogenous StAR mRNA and
protein in primary cultures of bovine ovarian
theca and adrenocortical (ZFR) cells
The endogenous StAR mRNA in bovine ovarian
theca and adrenocortical (ZFR) cells was expressed
as transcripts of three different sizes (Figs 1, 2), as
shown previously also for bovine corpus luteum
(Hartung et al. 1995, Pescador et al. 1996) and
predicted from the positions of alternative poly-
adenylation sites within the 3' UTR of the cloned
bovine cDNA (Hartung et al. 1995). These
migrated as two major bands at approximately
3'0 kb and 1-8 kb, and a minor band at 1-6 kb,
evident only in the theca cells. Levels in untreated
cells were very low for both cell types (Figs IB, 2B).
After treatment of theca cells with bLH or
adrenocortical cells with ACTH, there was a similar
rapid increase in the relative amounts of the two
major StAR transcripts in both cell systems. This
increase was already detectable after 1 h of
stimulation, by comparison with the untreated
controls, and reached a maximum at about 4 h
(theca cells, Fig. 1A) and 6 h (adrenocortical cells,
Fig. 2A) of treatment. At the time of maximal
induction of StAR mRNA, the shorter l-6kb
transcript became readily detectable in the theca
cell cultures (Fig. 1A). Also of significance was the
rapid decline in transcript levels at subsequent
Journal of Molecular Endocrinology (2000) 24, 109-118








figure 1. Northern hybridization of StAR mRNA in extracts of bovine theca
cells cultured for the time indicated in the presence (A) or absence (B) of
10 ng/ml LH. As control for even loading and transfer, blots were
rehybridized against a probe for the bovine ribosomal protein, SI5. The blots
in (A) and (B) are from parallel experiments using the same batch of cells.
Duplicate lanes represent RNA from independent parallel cell cultures from
within the same experiment, to indicate the extent of within-batch variation.
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figure 2. Northern hybridization of StAR mRNA in
extracts of bovine adrenocortical (zonae fascicularis and
reticularis) cells cultured for the times indicated in the
presence (A) or absence (B) of 10 nM ACTH. As
control for even loading and transfer, blots were
rehybridized against a probe for P-actin. The blots in
(A) and (B) are from parallel experiments using the
same batch of cells, with all operations being performed
in parallel.
time-points, such that, at 12 h (theca cells) or 24 h
(adrenocortical cells), StAR mRNA had returned to
basal (unstimulated) levels. The apparent and slight
long-term increase in StAR mRNA in the absence
of bLH (Fig. IB) probably reflected the differen¬
tiation of these cells in culture under the influence
of insulin only (Bathgate et al. 1999).
Total cellular protein was also prepared from
similar cultures of stimulated and unstimulated cells
and subjected to western blotting using a newly
developed anti-StAR polyclonal antibody. This
antibody was raised against a 26-mer sequence from
the predicted external surface of the bovine StAR
protein (Hartung et al. 1995) and specifically
recognized a 30 kDa protein (Fig. 3). Protein bands
of similar size were detected in adrenocortical and
luteal protein extracts using another polyclonal
antibody raised against mouse recombinant StAR
protein (Pescador et al. 1996, Ronen-Fuhrmann
et al. 1998, and data not shown). The time-course of
changes in StAR protein levels in the two cell types
was similar (Figs 3, 4), with a first detectable
increase at 2 h and maximum levels being main¬
tained through to 6 h (theca cells) or somewhat
longer (adrenocortical cells), but with a return to
near basal values by 12-24 h. Thus StAR protein
production was marginally delayed, both in appear¬
ance and disappearance, with respect to the changes
in levels of the specific mRNA. Absolute levels of
StAR protein, both basal and stimulated, appear to
be much greater in the adrenocortical cells than in
the bovine theca cells, as indicated by the control
lanes (1 and 2) in Fig. 3, in which the same amount
of total protein as in the other lanes had been
loaded.
Acute regulation of the bovine StAR gene
promoter in homologous cell culture
In a previous study (Rust et al. 1998), we have been
able to characterize the role of certain cis elements
within the upstream promoter region of the bovine
StAR gene responsible for expression in a heterolo¬
gous cell system cotransfected or not with the
transcription factor, steroidogenic factor-1 (SF-1;
Ad4 BP; Fig. 5). In this system, deletion promoter-
reporter constructs had been transfected into
non-steroidogenic cells together with appropriate
expression vectors. In order to determine whether
the SF-1-responsive elements are also involved in
endogenous StAR gene expression in primary
cultures of bovine steroidogenic cells (i.e. in a
homologous system as close to the in vivo situation
as possible), and are sufficient to account for the
acute up- and downregulation of the StAR gene, a
time-course for activation of defined promoter-
reporter constructs was determined under acute
bLFI stimulation after transfection into primary
ovarian theca cells (Fig. 6). The results show that
there was consistently detectable upregulation
in response to bLH by 3 h of stimulation. The
maximum level of luciferase activity accumulated in
the cells was reached by 4—6 h, and was not further
increased at later times. A comparable time-course
was obtained irrespective of the use of a long
promoter fragment (— 1245 bp; Fig. 6A), or a
shorter fragment (—315 bp; Fig. 6B) attached to the
luciferase reporter gene. However, it should be
noted that, in repeated experiments, the response to
LH appeared generally to be more robust, consist¬
ent, and somewhat earlier in these primary cell
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figure 3. Western blot of immunoreactive StAR protein in extracts of bovine adrenocortical cells cultured as
indicated for increasing times in the absence or presence (+) of 10 nM ACTH. The upper, more slowly migrating
band appears to be non-specific and its intensity does not alter with time or incubation conditions. The specific,
approximately 30 kDa StAR protein appears as a doublet with a more rapidly moving isoform increasing in
intensity, in parallel with the principal StAR protein band. In all lanes, 25 pg protein were loaded.
cultures, for the shorter —315 bp construct (cf.
Fig. 7).
Experiments using different promoter—deletion
constructs transfected into theca cells optimally
stimulated by bLH for 4h indicated that the acute
stimulation of the bovine StAR gene requires only
the minimal promoter up to -315 bp (Fig. 7), which
includes the first two proximal SF-1 binding motifs
(Rust et al. 1998). Indeed, even shorter constructs
comprising only one (— 203) or none (— 101) of the
proximal SF-1 sites, also appear to be responsive to
LFI. Longer promoter constructs, however, do not
increase the level of luciferase activity obtained. As
already indicated in Fig. 7, these appear to have
reduced activity by comparison with the shorter
constructs. This would suggest that the region
upstream of the —315 construct may include a
negative factor that could modulate the activity of
the proximal promoter.
DISCUSSION
The acute response of steroidogenic cells to the
anterior pituitary hormones, LFI or ACTH, is an
essential part of the regulatory mechanisms promot¬
ing steroid biosynthesis. Both peptide hormones are
released in short pulses or trains of pulses, and elicit
both immediate and sustained effects. Amongst the
immediate effects are those influencing steroid
secretion (reviewed in Thomson 1998). In addition
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to such very acute events, there is also an effect at
the transcriptional level. This effect was quite rapid,
newly transcribed StAR mRNA being detectable
in both adrenocortical and ovarian thecal cells after
about 1 h of stimulation. Equally important,
however, is the observation, also for both cell types,
that levels of mRNA peaked at about 4—6 h and then
declined to basal values by, maximally, 12—24 h.
This shows that the stimulatory effect upon
transcription is short-lived, and that mechanisms
are present in these steroidogenic cells for the rapid
degradation of the newly synthesized StAR mRNA.
It is important to note that the primary cell cultures
were exposed continuously, through the treatment
period, to the effectors LII or ACTH. It is known
that the LH receptor is rapidly downregulated
(desensitized, internalized) within the first few
minutes of hormone exposure (e.g. for bovine luteal
cells; Budnik & Mukhopadhyay 1987), thus all
subsequent LH-dependent events will be receptor-
independent consequences of this initial stimu¬
lation. For the effect of ACTH on adrenocortical
cells, the situation appears to be different. Instead of
being desensitized, the cognate receptor appears
rather to be upregulated (Penhoat et al. 1989). This
could explain the more sustained transcriptional
response of the StAR gene to ACTH treatment
evident in the adrenocortical cell cultures.
By transfecting different promoter—reporter con¬
structs into ovarian theca cells, under a treatment
paradigm similar to that above in which we have
www.endocrinology.org













cultured bovine theca cells
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figure 4. Western blot of immunoreactive StAR protein in extracts of bovine theca cells cultured as indicated for
increasing times in the absence or presence (+) of 10 ng/ml bovine LH. It should be noted that the absolute levels of
the StAR protein are considerably less than in the adrenocortical cells (lanes 1 and 2), and there is thus an increased
non-specific background. As for the adrenocortical cells, the StAR protein appears to be represented as a doublet. In
all lanes, 1 5 pg protein were loaded.
shown acute upregulation of the endogenous StAR
gene, we were also able to show that luciferase
activity (i.e. expression of active protein) follows the
same time-course of induction as the native StAR
protein. Increased luciferase activity was evident
first at 2—3 h, just like the endogenous StAR protein
seen in the western blots, suggesting that both StAR
and luciferase mRNAs are translated in a compar¬
able manner. The induction of reporter activity
was, as expected, slightly delayed by comparison
with the induction of transcription. The disappear¬













figure 5. Schematic representation of the bovine StAR gene and its
promoter, indicating putative transcription factor binding elements.
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figure 6. Primary cultures of bovine theca cells
transfected with luciferase reporter constructs linked
with either the — 1245 (full-length, A) or the
—315 (short, B) bovine StAR gene promoters. Three
days after the transient transfection, cells were
stimulated or not as indicated by addition of 10 ng/ml
bovine LH. The amount of luciferase protein
synthesized is estimated from its enzymatic activity
expressed in relative light units (RLU; relative to the
cotransfected CMV-pi-galactosidase constitutive
construct) as a percentage of the level attained with the
strong constitutive promoter of the pGL3-C construct
(C2) in the absence of LH. CI, luciferase activity of the
empty reporter vector, pGL3-B. Data are expressed as
means ± s.e.m from parallel triplicate experiments using
the same batch of primary cells.
time-course different from that for the endogenous
protein, as this will depend on the function of
substrate-specific proteases. Nevertheless, it is
evident that there is a plateau in luciferase
expression at 4—6 h, with no further increase after
this, reflecting precisely the short phase of tran¬
scriptional induction. This experiment showed that
the promoter information required for this acute
pGL3-B pGL3-C -101 -203 -315 -1009 -1245
figure 7. Primary cultures of bovine theca cells
transfected with luciferase reporter constructs linked
with different deletion fragments of the bovine StAR
gene promoters. The promoter fragments correspond to
DNA sequences extending upstream from the
transcription start site to the restriction sites for BanI
(-101), Hpall (-203), PstI (-315), Kpnl (- 1009)
and BamHI ( — 1245), respectively. Results are
expressed in relative light units (RLU) as a percentage
of the luciferase activity obtained using the strong
constitutive promoter construct, pGL3-C, in the
absence of LH.
upregulation of transcription resides within the first
1200 bp upstream of the transcription start site, and
probably within the first 315 bp of this. Use of
promoter—deletion constructs confirmed what we
have previously shown for this gene using a
heterologous transfection system (Rust et al. 1998),
namely that LH-induced, cAMP-dependent gene
activation is maximal where the first two SF-1-
responsive elements, which reside within the
—315 bp immediate upstream region of the pro¬
moter, are present. It should be noted, though, that
a marked LPI-dependent stimulation was also
evident for the very short —101 construct (Fig. 7),
which does not include an SF-1 binding element,
suggesting that SF-1 may not be absolutely
required to mediate the stimulatory effect of LFI.
Other genes have also been described in the same or
related cell types, for example, P450scc in luteal
cells (Liu & Simpson 1997) or oxytocin in granulosa
cells (Wehrenberg et al. 1994), which also depend
upon SF-1 interaction, and respond to LH
stimulation. These responses, however, have a quite
different time kinetic and cell specificity. Thus
other factors must act in conjunction with SF-1 to
encode the cellular and temporal specificity ob¬
served for the StAR gene. One candidate in the
case of the mouse StAR gene is the transcription
factor, CCAATT/enhanced binding protein P
(C/EBPP) (Reinhardt et al. 1999a, Silverman
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et al. 1999). Support for this view is provided by
a comparison of the present transfection results,
using cells endogenously expressing the StAR
gene, with the heterologous system used previously.
In the previous study, the transcriptional activity
induced by SF-1 attained maximally only 2% of the
level reached by the same constitutively active
control plasmid (pGL3-C) as that used here; this
compares with greater than 50% in the present
homologous system. Similarly, a constitutively
active protein kinase A subunit was able to increase
the SF-1-dependent transcriptional activation by
only about 50% in the previous study whereas,
in the homologous system, LH induced up to a
10-fold increase in reporter gene activity. The
molecular mechanisms by which SF-1 could be
involved in cAMP-dependent signal transduction
are not yet understood. In a recent study, a
potential serine acceptor site for protein kinase A
(PKA) phosphorylation, and the C-terminal acti¬
vation domain were both implicated in the transcrip¬
tional upregulation of the high-density lipoprotein
receptor gene in rat luteal cells via SF-1 (Lopez et al.
1999). Also, possible mitogen-activated protein
kinase phosphorylation of SF-1 has been suggested
in the context of cofactor recruitment (Hammer et al.
1999).
The requirement for other factors to act with SF-1
in mediating cAMP-regulated signal transduction
would also offer an explanation for the anomalous
findings regarding specific nuclear protein-binding
to the bovine StAR promoter (Rust et al. 1998). Of
the three putative SF-1 binding motifs evident in the
bovine StAR promoter (Fig. 5), only the distal
element bound purified SF-1 with high affinity. The
second proximal element bound SF-1 only weakly,
and the most proximal element failed to show any
binding activity (Rust et al. 1998). Yet it is the
proximal promoter containing the first SF-1 motifs
which, in this and other studies, appeared to mediate
SF-1-dependent activation of the StAR gene by
adenylate cyclase in (for example) humans
(Sugawara et al. 1996), mouse (Caron et al. 1997a),
rat (Sandhoff et al. 1998) and pig (LaVoie et al.
1999). Findings of a recent study using the mouse
StAR gene promoter even suggested that an inter¬
action of SF-1 in the proximal promoter may not
be essential, and that adenylate cyclase-induced acti¬
vation can be mediated by a combination of the
transcription factors C/EBPP and GATA-4 only
(Silverman et al. 1999). This opinion is supported by
findings of the present study, in which the —101
construct of the bovine StAR gene was able to
transduce LH-stimulation to the reporter gene. This
fragment does include an inverse GATA motif at
position —65 (Rust et al. 1998).
www.endocrinology.org
Other regions of the promoter may be involved in
the definition of expression specificity. There is
evidence, from the transfection studies, for a mildly
inhibitory element in the region upstream of
nucleotide —315. There is also, in this region,
marked nuclear protein binding unrelated to SF-1
(Rust et al. 1998). Furthermore, although not
apparently contributing to gene activation, a very
good binding site for SF-1 exists in the upstream
region of the promoter at —1100 (Rust et al.
1998). Concerning the rapid switching off of the
StAR gene, this might involve the activation of the
negative transcription factor, DAX-1, which has
been shown to interact with the mouse StAR
gene promoter, possibly interfering directly with
SF-1 binding in the proximal promoter region
(Zazopoulos et al. 1997, Reinhardt et al. 1999b,
Sandhoff & McLean 1999).
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THE EXPRESSION OF STEROIDOGENIC ACUTE REGULATORY PROTEIN
(StAR) IN BOVINE ADRENOCORTICAL CELLS
M.R. Nicol, H. Wang, R. Ivell*, S.D. Morley, S.W. Walker, and J.I. Mason
University Dept. of Clinical Biochemistry, RIE, Edinburgh, EH3 9YW, U.K.
*Institute for Hormone and Fertility Research, D-22529 Hamburg, Germany.
ABSTRACT
StAR protein may facilitate rapid transfer of cholesterol from the outer to the inner
mitochondrial membrane, the site at which cholesterol is converted to pregnenolone by
the cholesterol side chain cleavage complex. We have studied the effect of ACTH
treatment on StAR mRNA and protein levels in bovine adrenocortical cells in primary
culture. Cells were initially cultured for 3 days after isolation, and then treated with
ACTH (10"SM) for various times up to 24 hours. Northern analysis of total BAC mRNA,
using a [a32P]-labelled cDNA probe encoding a 5' region of bovine StAR mRNA,
revealed two principal hybridising species of 1.6 and 3.0 kb. Western immunoblot
analysis revealed a principal band at 30 kDa. Levels of both StAR mRNA and protein
showed an increase at 1 hour, reached a maximum at around 6 hours and declined to
basal levels at 24 hours. Cortisol secretion (measured by RIA) showed a similar change
over the same period. From these results it appears that StAR mRNA and protein levels
in BAC are acutely regulated in concert with ACTH-stimulated Cortisol secretion.
INTRODUCTION
The first enzymatic step in steroidogenesis is the conversion of cholesterol to
pregnenolone .catalysed by the cytochrome P450 side chain cleavage (P450scc) enzyme
which resides on the inner mitochondrial membrane. The rate-limiting step in this
process is the translocation of cholesterol from the outer to the inner mitochondrial
membrane, which requires a rapidly synthesised regulatory protein. StAR protein was
initially described in rat and bovine adrenal cells by using two-dimensional gel
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electrophoresis to identify a family of mitochondrial proteins synthesised in response to
ACTH-stimulation. StAR protein has also been found in other steroidogenic tissues (1,2)
and StAR cDNA was first cloned and sequenced from mouse MA-10 Leydig tumour
cells (3). MA-10 and COS-1 cells transfection with StAR cDNA, in conjunction with the
P450scc system, resulted in steroidogenesis in the absence of trophic hormone
stimulation (4,5). Demonstration that the inherited defect, lipoid congenital adrenal
hyperplasia, is due to mutations in the StAR gene further emphasises the its role in
steroidogenesis (6). StAR cDNAs have now been cloned from a variety of tissues and
species including bovine luteal cells where the corresponding mRNA was found to be
transcribed as 3 kb and 1.6 kb transcripts (7). In this study, we have examined the
regulation of StAR mRNA and protein levels in bovine adrenocortical (BAC) cells in
response to trophic hormone treatment.
METHODS
BAC cells were isolated and cultured as previously described (8). Cells were plated
at a density of 5 x 106 per 25 cm2 flask for mRNA studies and 1.5 x 106 per well of a 6-
well plate for protein studies. Total RNA (25 fig) was analysed by northern blot and
StAR mRNA was detected using a [a32P]-labelled cDNA probe encoding a 5' region of
the bovine StAR (GenBank acc.# S79908, position 210-608). Total cellular protein (25
}j.g) was analysed by western blot using a primary polyclonal sheep antiserum raised
against a peptide fragment (amino acids 82—107) of the bovine StAR protein and a
donkey anti-sheep second antibody coupled to a HRP-conjugate (The Binding Site,
Birmingham, UK). The final signal was detected by chemiluminescence (SuperSignal
ULTRA kit, Pierce, Rockford, USA). Cortisol contents of media were quantified using a
double antibody radioimmumoassay.
RESULTS AND DISCUSSION
This study demonstrates the presence, in BAC cells, of two principal StAR mRNA
transcripts of 1.6 and 3.0 kb and principal and minor protein species of 30 and 40 kDa,
similar to other studies on StAR mRNA (9) and protein (10) in BAC cells. Distinctly in
the present study, western blot analysis shows that freshly isolated BAC cells contain
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BAC cells isolated at time 0 were cultured for 24, 48, 72 or 96 hours and then treated
with/without ACTH (10"s M) for a further 6 and 24 hours. Quantification of Western blot
analysis (30 kDa band) was made using an image analyser.
high levels of StAR protein, while these levels decrease over 3 days of culture. ACTH
treatment for 6 hours following 24, 48, 72 or 96 hours of culture increases the StAR
protein levels; however, when ACTH treatment is prolonged for 24 hours, the StAR
protein levels return to untreated levels (Figure 1). Western blotting and northern
analysis show that StAR gene expression appears to be most responsive to ACTH
stimulation following 48 and 72 hours of culture (Figures 1 and 2). We therefore chose
to use cells cultured for 72 hours for subsequent experiments.
Following ACTH treatment StAR mRNA levels and Cortisol secretion were increased
after I hour (Figures 2B and 3), whereas StAR protein levels were not increased above
that in untreated cells until 6 hours of treatment (Figure 2A). This suggests that the
initial steroidogenic response is not primarily dependent on the presence of high levels of
newly synthesised StAR protein, although participation of a small sub-pool of new
protein cannot be excluded. Instead, mechanisms, such as post-translational modification
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FIGURE 2
BAC cells were cultured for 72 hours after isolation, then incubated with/without ACTH
(10"8 M) for 1, 2, 4, 6, and 24 hours. (A) Quantification of Western blot analysis (30 kDa
band) and (B) Quantification of northern blot analysis (3 kb band) was made using an
image analyser.
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response, while newly synthesised StAR is needed to maintain steroidogenesis over a
period of hours. Consistent with this hypothesis, the decreased rate of Cortisol secretion
observed after prolonged (24 hour) ACTH treatment is associated with decreased StAR
mRNA and protein levels (Figure 3). The discordance between StAR protein and
mRNA levels, and the production of Cortisol at the early time-points merits further
investigation.
REFERENCES
1. Alberta JA, Epstein LF, Pon LA, Orme-Johnson NR 1989 J Biol Chem
264:2368-2372.
2. Krueger RJ, Orme-Johnson NR 1983 J Biol Chem 258:10159-10167.
3. Clark BJ, Wells J, King SR, Stocco DM 1995 J Biol Chem 269:28314-28322.
4. Clark BJ, Soo SC, Caron KM., Ikeda Y, Parker KL, Stocco DM 1995 Mol
Endocrinol 9:1346-1355.
5. Sugawara T, Holt JA, Driscoll D, Strauss JF, Lin D, Miller WL, Patterson D,
Clancy KP, Hart IM, Clark BJ, Stocco DM 1995 Proc Natl Acad Sci USA
92:4778-4782.
6. Lin D, Sugawara T, Strauss JF, Clark BJ, Stocco DM, Saenger P, Rogol A,
MillerWL. 1995 Science 267:1828-1831.
7. Hartung S, Rust W, Balvers M, Ivell R 1995 Biochem Biophys Res Comm
215:646-653.
8. Williams BC, Lightly ERT, Ross AP, Bird IM, Walker SW 1989 J Endocrinol
121:317-324.
9. Brand C, Cherradi N, Defaye G, Chinn A, Chambaz EM, Feige JJ, Bailly, S 1998
J Biol Chem 273:6410-6416.
10. Nishikawa T, Sasano H, Omura M, Suematsu S 1996 Biochem. Biophys. Res.
Comm 223:12-18.
P95 REGULATION OF StAR PROTEIN DURING HIGH & LOW CONCENTRATION ACTI-I-STIMULATED
STEROIDOGENESIS IN PRIMARY BOVINE ADRENAL ZONA FASCICULATA CELLS
II Wang1, M Nicol1, SW Walker1. JI Mason1, SD Morley1, BC Williams2.
'Department of Reproductive & Developmental Sciences (Clinical Biochemistry), University of Edinburgh,
Royal Infirmary, Lauriston Place, Edinburgh EH3 9YW, UK; 2Department of Medical Sciences, University of
Edinburgh, Western General Hospital, Crewe Road, Edinburgh EII4 2XU, UK
Cyclic 3'-5" AMP (cAMP)-mediated steroidogenesis is accompanied by concomitant up-regulation of Steroid
Acute Regulatory Protein (StAR). Whilst studies utilising supra-physiological levels of ACTFI do indeed lead
to cAMP-mediated up-regulation of StAR protein levels, the response of StAR protein to physiological
concentrations of ACTH which do not stimulate cAMP (Yanazaki T. el al., 1996 Endocrinology 137:2670-75)
is less clear. Therefore, the purpose of this study was to examine the correlation between Cortisol secretion and
StAR protein induction, in response to high (10~8M) and low (10"12M) ACTH concentrations in bovine adrenal
zona fasciculata (ZF) primary cell cultures. Following a 0.5-24h time-course treatment of ZF cells with either
10"8M or 10"l2M ACTH, Cortisol in the medium and StAR protein in cell lysates were determined respectively
by RIA or western blotting using a polyclonal sheep antiserum raised against a peptide fragment (amino acids
82-107) of the bovine StAR protein sequence (Hartung S. et al., 1995 BBRC 215:646-53). ACTH (10~SM)
treatment resulted in a strongly correlated induction of Cortisol secretion and StAR protein levels (R=0.92),
with maximal increases occurring after 4h (Cortisol 144-fold; StAR protein levels 4-fold). In contrast, treatment
with 10"i2M ACTH resulted in a maximum 24-fold increase in Cortisol levels at 2h, which preceded any change
in StAR protein levels, and no correlation between Cortisol secretion and SlAR protein induction (R<0.1).
These results suggest that Cortisol secretion in response to 10"12M ACTH may be independent of induction of
StAR protein synthesis and that steroidogenesis in response to physiological concentrations of ACTH may be
mediated by intracellular signalling systems distinct from those regulating SlAR nrotein induction
P98 ACUTE REGULATION OF THE BOVINE GENE FOR THE STEROIDOGENIC ACUTE REGULATORY
(StAR) PROTEIN IN OVARIAN THECA AND ADRENOCORTICAL CELLS.
R [veil1, G Tillmann1, H Wang2, M. Nicol2, I'M Stewart3, B Banlick1. N Walther1, JJ. Mason2, SD Morley2.
1 Institute for Hormone and Fertility Research, University of Hamburg, Grandweg 64, 22529 Hamburg,
Germany; department of Reproductive and Developmental Sciences (Clinical Biochemistry), University of
Edinburgh, Royal Infirmary, Lauriston Place, Edinburgh, EI 13 9YW. UK;3Department of Medicine, University
ofBirmingham Queen Elizabeth Hospital, Edgbaston, Birmingham. B15 2TH, UK.
Up-regulation of the steroidogenic acute regulatory protein (StAR) is implicated in the rapid synthesis and
secretion of steroids by the ovary and adrenal cortex, in response to stimulation by trophic hormones of the
gonadal and stress axes. In the present study we have assessed the kinetics ofboth StAR gene transcription and
protein biosynthesis in primary cci! cultures of bovine ovarian thcca (OT) and adrenocortical (BAC) cells, under
conditions of acute stimulation by luteinizing hormone (LH) and corticotrophin (ACTH), respectively. In both
cell systems detectable up-regulation ofStAR gene transcription occurs within 1 -2h. reaching maxima at 4h (OT
cells) or 6h (BAC cells), and returns to baseline by 12h or 24h, respectively. Specific StAR protein levels were
assessed by western blotting, using a polyclonal sheep antiserum raised against a peptide fragment (aa 82-107)
of the bovine StAR protein sequence (Hartung S. et al., 1995 BBRC 215:646-53), and showed a similar fast up-
and down-regulation, albeit delayed by l-2h compared to the niRNA, The response of OT cells was altogether
more acute than that of BAC cells, possibly reflecting the propensity of die LH receptor to rapidly desensitise,
unlike the ACTH receptor. Primary OT cell cultures were also used for fully homologous transfection studies
using various deletion promoter-reporter constructs of the bovine StAR gene. Kinetic analysis of the results
indicated that the acute transcriptional response resides within the proximal (-315 bp) promoter region which
includes two putative responsive elements for the steroidogenic factor-1 (SF-1). More distal promoter regions
may be involved in delineation of cell-type specificity by combining enhancer and inhibitory functions.
